

THE UNIVERSITY OF BRITISH COLUMBIA

Curriculum Vitae for Faculty Members

Date: August 14, 2023

Initials: LDL

1. **SURNAME:** Lynd

FIRST NAME: Larry

MIDDLE NAME(S): David

2. **DEPARTMENT/SCHOOL:** Pharmaceutical Sciences

3. **FACULTY:** Pharmaceutical Sciences

4. **PRESENT RANK:** Professor **SINCE:** July 2014

5. **POST-SECONDARY EDUCATION**

University or Institution	Degree/ Diploma	Subject Area	Dates
Centre for Teaching and Academic Growth, University of British Columbia, Vancouver, BC	Certificate	Teaching and Learning on Higher Education	2005 - 2006
Centre for Evaluation of Medicines, McMaster University & St. Joseph's Hospital, Hamilton, ON, Canada	Post- doctoral Fellow ¹	Health Economics	2002 - 2004
University of British Columbia, Vancouver, BC, Canada	Ph.D. ²	Health Care & Epidemiology	1997 - 2002
St. Paul's Hospital, Vancouver, BC, Canada	Residency Certificate	Hospital Pharmacy Residency	1986 - 1987
University of Saskatchewan, Saskatoon, SK, Canada	BSP	Pharmacy	1982 - 1986

¹Courses: Principles of Health Economics, Advanced Economic Methods, Advanced Economic Modeling.

²Courses: Health Economics, Microeconomics, Health Services Research, Demography, Basic Statistics, Advanced Statistics/Multivariate Analysis, Longitudinal/Repeated Measures Analysis, Clinical Epidemiology, Population Health, Pharmacoepidemiology 1, 2, 3 and 4 (McGill University).

Title of Dissertation and Name of Supervisor

Title: An evaluation of the determinants of asthma management and asthma control: a study of British Columbia asthmatics.

Supervisor: Aslam Anis

Special Professional Qualifications

Licensure – BC College of Pharmacists

Certified Specialist – Poison Information and Toxicology, American Association of Poison Control Centers

Member of Register of Pharmacists of the Pharmacy Examining Board of Canada (RPEBC)

6. EMPLOYMENT RECORD

(a) *Prior to coming to UBC*

University, Company or Organization	Rank or Title	Dates
Centre for Evaluation of Medicines, McMaster University/ St. Joseph's Hospital, Hamilton, ON	Post-doctoral Fellow	2002 - 2004
BC Regional Adverse Drug Reaction Reporting Program, BC Drug and Poison Information Centre & Health Canada, Drugs Directorate, Therapeutic Products Program	Program Coordinator	1995 - 1997
BC Drug and Poison Information Centre	Drug and Poison Information Specialist	1990 - 2002
Royal University Hospital, Saskatoon, SK.	Staff Pharmacist	1987 - 1990

(b) *At UBC*

Rank or Title	Dates
Dean <i>pro tem</i>	August 2023 – September 2024
Associate Dean, Research	April 2019 – July 2023
Director, Collaboration for Outcomes Research and Evaluation	July 2014 -
Professor (with Tenure), Pharmaceutical Sciences	July 2014 -
Associate Professor (with Tenure), Pharmaceutical Sciences	2009 – June 2014
Associate Director, Collaboration for Outcomes Research and Evaluation	2004 – June 2014
Scientist, Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute	2004 - 2007; 2010 - present
Scientist, Centre for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute	2007 - present
Associate, School of Population and Public Health, Faculty of Medicine, University of British Columbia	2004 - present
Assistant Professor (Tenure Track), Pharmaceutical Sciences	2004 - 2009
Associate Head, Health Economics Program, Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute	2004 - 2007
Clinical Instructor	1990 - 2002

(c) *Date of Granting Tenure at UBC: **July 2009***

(d) *Other Academic Affiliations*

Scholar, Peter Wall Institute for Advanced Studies, UBC (September 1, 2011 - ongoing)
Adjunct Professor, Dept. of Epidemiology and Biostatistics, Erasmus University Rotterdam, The Netherlands

7. LEAVES OF ABSENCE

July 1, 2014 to December 31, 2014 – Sabbatical
July 1, 2022 to December 31, 2022 - Sabbatical

8. TEACHING

(a) *Areas of Special Interest and Accomplishments*

I was a Michael Smith Foundation for Health Research Scholar and a Canadian Institutes for Health Research New Investigator during the first five years of my academic appointment at UBC. The intention of these peer-reviewed, competitive salary awards is to facilitate and promote my research career. As such, both awards stipulated limitations

to the amount of time that can be committed to teaching so that I could focus on developing my research program. Despite these restrictions on my teaching, I continued to teach as much as these awards permit. In doing so, I developed two new courses in the faculty, and continue to teach at both the graduate and undergraduate levels.

Relevant Education and Teaching Approach

Over the course of my post-graduate career, I have been involved in numerous courses related to instructional and lecture skills and techniques. As a clinical faculty member in Faculty of Pharmaceutical Sciences and mentor for PharmD students and hospital pharmacy residents, I have participated in a number of workshops designed for the development of preceptors directly involved in the mentorship of these students. During my post-graduate and post-doctoral training, I was also involved in seminars and symposia on instructional methods aimed at enhancing instructional skills and was mentored by two excellent teachers, Dr. Aslam Anis and Dr. Bernie O'Brien. My exposure to these mentors has helped me to develop my own personal approach to teaching and higher education that involves developing a connection with the students, identifying their needs and goals, and motivating them to strive to meet or exceed their own personal expectations.

Outside of academia, I am a certified intermediate-level hockey coach, a program that involves instruction on teaching techniques, mentorship, communication skills, and conflict resolution methods. Having now coached hockey at many levels for many years, I have applied and developed many different instructional techniques (e.g. building on components of certain skills over time) and motivational approaches that are also applicable to the university classroom or one-to-one mentorship of trainees.

Context of University Teaching

I have been involved in various facets of university teaching, including didactic instruction at both the undergraduate and graduate levels, one-to-one mentorship of undergraduate directed studies students, hospital pharmacy and medical residents, and PharmD students. I have also been involved in the continuing education of pharmacy and medical professionals in workshops and conferences.

In the undergraduate curriculum, I am involved in teaching courses within the Pharmaceutical Sciences curriculum in which I have taught in classes of approximately 160 students in the area of health outcomes assessment and pharmacoeconomics. I also developed, and am currently teaching a 4th year undergraduate elective course in pharmacoeconomics which has now been offered since the winter term of 2006.

At the graduate level, I lead the development of a new 6 credit course in the Doctor of Pharmacy Program (PHAR506). Since the inception of the PharmD program at UBC, PharmD students were enrolled in HCEP400 (Basic Biostatistics) and HCEP 502 (Clinical Trials). Having taken both of the courses, I was aware that the content and objectives of these courses did not meet the learning needs of Doctor of Pharmacy Students. Therefore, in collaboration with Dr. Carlo Marra, I undertook a review of the current courses, and an environmental scan of curricula from PharmD programs throughout North America, and developed a new 6-credit course encompassing biostatistics, epidemiology, and health economics –PHAR506 Critical Appraisal of Pharmacotherapy Literature. This course was run for two years as a directed studies course, after which we applied for, and received UBC Senate approval as an official course in the PharmD curriculum.

Finally, I have led discussions in economic evaluation and quantitative benefit-risk analysis in the Department of Health Care and Epidemiology in the Faculty of Medicine (approximately 15 students). Outside of the core courses within the Faculty, the students enrolled in the course often come from health care backgrounds prior to entering pharmacy, and have specific interests in health economics, epidemiology, and outcomes research. Exposing students to these concepts has been a valuable approach to attracting directed studies and summer research program students as well.

Approach to Teaching & Learning

Philosophy of teaching

I believe that any educational process must involve the participation of both the teacher and the student, and that the balance between a learner-centred and a teaching-centred teaching approach must be adopted, depending on the

learning situation. In addition to teaching some larger classes, I have been fortunate to be involved in a lot of one-to-one mentorships with hospital pharmacy residents, Pharm.D. students, and graduate students, as well as teaching in smaller classes (of 15 – 25 students) and thus, have always had the opportunity to actively engage the students in the learning process using a learning-centred approach. Thus, when mentoring one-to-one, my teaching philosophy entails actively engaging the student in the learning progress rather than merely using didactic methods, and to involve students in active discussion and dialogue which facilitates the development and fostering of the students critical thinking skills. I also try to integrate this philosophy into the classroom environment as well.

Beliefs

Dedicated to being a life-long learner, my philosophy of teaching embraces the concept that learning is an active process that encompasses both the educator and the student. The learning environment (whether in the classroom or in an experiential setting) that I try to create encourages students to pursue their goals and express their individual ideas through intellectual discussion. Students are encouraged to take responsibility for their education and to work with me to enrich their educational experiences.

My goal is to work with students through interactions in and outside of class to explain the course materials, untangle the confusion, and guide students to meet their goals. My responsibility is to help my students learn – I do this by building on course materials and texts, integrating recent scientific findings into my teaching, encouraging the use of external resources, and trying to impart the skills of critical thinking in my students. As the scope of my professional and research interests has increased to include areas that are not traditionally part of the pharmacy curriculum, the challenge of presenting this material to both undergraduate and Doctor of Pharmacy students has increased. However, I find that, with my clinical background, I have the ability to put the issues and concepts that I am teaching into perspective such that students with a health sciences background can easily comprehend.

As a quantitative person with skills and training in this area, my overall teaching philosophy is firmly grounded within the philosophical domains of apprenticeship and development, with some components of nurturing. I find that my teaching mostly focuses on these aspects with little emphasis on trying to implement social reform through my teaching. This void is one area that I would like to fill as I move forward with my teaching within the university. Social reform is vital in the profession of pharmacy as the profession is moving towards assuming more responsibility for the primary care of patients, and is particularly germane to one of my specific areas of research interest, specifically policy development for orphan drugs. Part of this process will be to educate and motivate students to be the vehicle to implement change once they graduate. As young practitioners, many are filled with idealism and dreams that may not necessarily be feasible in practice. I feel that part of my role as an educator is to illustrate the current state of affairs with respect to the profession, establish feasible and realistic goals that students can hope to achieve within the short and long term, and to identify the challenges that the profession is faced with.

Actions

When lecturing to large classes in the undergraduate curriculum, I am often introducing new concepts and ideas that many students have not encountered. As such, these lectures are often teaching-centred such that a structured presentation is delivered. However, one of the goals of these lectures is to invigorate students and pique their interest in the content such that they will either further investigate on their own, enroll in elective courses in higher levels, or pursue directed studies or summer studentships. Therefore, I strive to give practical examples (actual topical situations that exist in the Canadian and other countries' health care systems) and assign problems (i.e. evaluate an article from the lay media about "health hype") that help them realize the importance of the material to the profession of pharmacy. Whether in a didactic setting or a situation of one-to-one mentorship, my general approach entails "teaching through example". More specifically, I use textbooks and course materials that I have developed to illustrate specific concepts, and then integrate scientific findings and specific real-world examples of where the concepts have been demonstrated.

I strongly believe that students may have different objectives for taking the courses that they choose. Therefore, when possible I engage the student to establish specific goals and objectives for their individual learning experience. Then, as a teacher, I strive to ensure that the student realizes his or her own specific goals. Specifically, for senior undergraduate, Pharm.D, and other graduate students where I am more closely involved with the students, I adopt a discussion group approach where students are assigned one or two short pre-readings on the content area and instructed to come prepared to discuss the material. Examples are given which illustrate the practical application of the content of the pre-readings and case-studies are completed during the session to help them develop critical thinking and problem-solving skills. As such, I try to keep these sessions as "learner-centered" as possible.

(b) Courses Taught at UBC*

Session	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs/IAs	Other
2020 (W)	SPPH 541	3	12	3			
2020 (W)	PHRM 100	2	224	2			
2019 (W)	PHRM 100	2	224	2			
2019 (W)	PHAR 450B	39	1				39
2018 (W)	PHRM 312		224			12	
2018 (W)	PHRM 312 (Tox)	26	224	2		12	
2018 (W)	PHAR 456	39	16	3			
2018 (W)	PHRM 131	24	224	14			
2018 (W)	PHRM 100	24	224	2			
2017 (W)	PHRM 312		224	2		12	
2017 (W)	PHAR 456	49	16	3			
2017 (W)	PHRM 312 (Tox)		224	2		12	
2017 (W)	PHRM 131	24	224	14			
2017 (W)	PHRM 100	24	224	2	11		
2016 (W)	PHRM 100	21	224	11			
2016 (W)	PHAR 506	78	6	45			
2015 (W)	PHRM 100	21	224	11	9		
2015 (W)	PHAR506	78	8	45			
2015 (W)	PHAR456	39	3	14			
2015 (W)	SPPH 514	39	13	3			
2014 (W)	PHAR 456	39	12	23			
2014 (W)	PHAR 506	78	8	37			
2014(W)	PHAR201	39	224	3			
2013 (W)	PHAR 456	39	12	24	6		
2013 (W)	PHAR 506	39	8	30			
2012 (W)	PHAR 456	39	14	30			
2012 (W)	PHAR 506	78	8	48	6		
2012 (W)	ECON 384	39	60	2			
2011 (W)	PHAR 506	78	8	40			
2011 (W)	PHAR 456	39	23	16	8		
2010 (W)	PHAR 506	78	8	40			
2010 (W)	PHAR 456	39	23	16	8		
2009 (W)	HCEP 541	39	12	3			
2009 (W)	HCEP 580B	39	6	3			
2009 (W)	DPAS 410	1.5	160	1.5			
2009 (W)	PHAR 506	39	8	25.5			
2009 (W)	PHAR 456	39	28	16	8		
2008 (W)	PHAR 405B	39	8	4			
2008 (W)	PHAR 535B	39	15	4			
2008 (W)	PHAR 450B	39	21	15	6		
2007 (W)	PHAR 201	39	160	3			
2007 (W)	PHAR 450B	39	17	14	6		
2007 (W)	PHAR 453	39	1				15
2007 (W)	PHAR 399	39	152	1			
2007 (W)	PHAR 590	39	17	3			
2007 (W)	PHAR 535B	39	7	4			

Session	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs/IAs	Other
2007 (W)	DPAS 410	1.5	160	1.5			
2007 (W)	HCEP 580	39	10	3			
2007 (W)	HCEP 541	39	13	3			
2006 (W)	PHAR 450B	39	13	14	6		
2006 (W)	PHAR 201	39	120	2			
2006 (W)	PHAR 590	39	10	4			
2006 (W)	DPAS 410	39	160	1.5			
2006 (W)	HCEP 580B	39	5	1			
2005 (W)	HCEP 580B	39	8	1			
2005 (W)	DPAS 410	39	280	1			
2005 (W) Term 2	PHAR 450B	39	17	14	6	----	----
2005 (W) Term 1	PHAR 450B	39	3	14	6	----	----
2005 (W)	Pharm 201	39	120	3	----	----	----
2004	HRM789 (Mac)	3	16	3			
2003	Phm435 (UofT)	2	140	2			
2001 (W)	PHAR 535B	6	6	6	----	-----	-----
2000 (W)	PHAR 535B	6	6	6	----	-----	-----
1999 (W)	PHAR 535B	6	6	6	----	-----	-----
1994 (W)	PHAR 200	12	24	----	-----	12	-----
1994 (W)	PHAR 400	12	8	----	12	----	----
1993 (W)	PHAR 200	15	24	----	-----	15	-----
1993 (W)	PHAR 406	12	8	----	12	----	----

*No courses taught W2013 due to study leave July 1 - Dec 31, 2013.

Courses currently taught: PHAR 456 – Introduction to Health Technology Assessment and Pharmacoeconomics, PHAR 506 – Critical Appraisal of Pharmacotherapy Literature, HCEP 541 – Health Services Research and Economic Evaluation, HCEP 580 – Pharmacoepidemiology.

(c) *Graduate Students Supervised*

M.Sc. and Ph.D. Graduate Students Supervised

Student Name	Program Type	Year		Supervisory Role (supervisor, co-supervisor, committee member)
		Start	Finish	
Tamara Mihic	PhD, Pharmaceutical Sciences	09/2023		Co-Supervisor
Kennedy Borle	Ph.D., Interdisciplinary Studies	09/2021		Co-Supervisor
Safa Ahmadian	M.Sc., Faculty of Pharmaceutical Sciences	09/2019		Committee Member
Shahzad Salmasi, M.Sc.	Ph.D., Faculty of Pharmaceutical Sciences	09/2018	10/2021	Committee Member
Hinda Ruton, M.Sc.	Ph.D. UBC School of Population and Public Health	09/2018		Committee Member
Celestin Hategakimana, MD	Ph.D., UBC School of Population and Public	09/2016	03/2020	Co-Supervisor

Student Name	Program Type	Year		Supervisory Role (supervisor, co-supervisor, committee member)
		Start	Finish	
	Health			
Shahrzad Salmasi, Bachelor of Pharmacy	M.Sc., Faculty of Pharmaceutical Sciences	09/2016	04/2018	Co-Supervisor
Kate Johnson	M.Sc., Faculty of Pharmaceutical Sciences	09/2016	03/2020	Committee Member
James Hicklin , BSc (CS)	M.Sc., Faculty of Pharmaceutical Sciences	01/2016	04/2018	Co-Supervisor
Nicole Tsao, MSc ¹⁰	Ph.D., Faculty of Pharmaceutical Sciences	09/2014	08/2018	Co-Supervisor
Anik Patel, MHA, BSc (Pharm)	Ph.D., Faculty of Medicine	09/2014	05/2017	Co-Supervisor
Katelyn Verstraten	M.A., School of Journalism	11/2013	05/2014	Co-Supervisor
Celestin Hategakimana, MD ¹	M.Sc., School of Public and Population Health	09/2013	08/2015	Supervisor
Pardis Lakzadeh, BSc ²	M.Sc., School of Public and Population Health	06/2013	04/2016	Supervisor
Zachary Daly, BSc	M.Sc., Faculty of Land and Food Systems	09/2012	05/2014	Committee Member
Samantha Pollard, MSc	Ph.D., Population and Public Health	09/2012	06/2017	Committee Member
Kyly Whitfield, MSc	Ph.D., Faculty of Food and Nutrition Sciences	09/2012	02/2016	Committee Member
Wenjia Chen, MSc	Ph.D., Faculty of Pharmaceutical Sciences	05/2014	09/2016	Co-Supervisor
Vashti Verbowski	MSc, Faculty of Land and Food Systems	09/2013	10/2015	Committee Member
Zafar Zafari, MSc	Ph.D., Faculty of Pharmaceutical Sciences	05/2012	09/2016	Committee Member
Natalie McCormick, MSc	Ph.D., Faculty of Pharmaceutical Sciences	09/2012	04/2018	Committee Member
Alberto Mendoza-Galina, BSc	M.A., School of Journalism	09/2011	09/2013	Co-Supervisor
Keith Rozendal, PhD ³	M.A., School of Journalism	09/2011	10/2013	Co-Supervisor
Adam Raymakers, MA	Ph.D., Faculty of Pharmaceutical Sciences	09/2011	07/2017	Supervisor
Shirin Rizzardo, BSc(Pharm) ⁴	M.Sc., Faculty of Pharmaceutical Sciences	09/2011	04/2014	Supervisor
Mehran Najibnia, BSc(Pharm)	M.Sc., Faculty of Pharmaceutical Sciences	09/2011	04/2015	Committee Member
Kirby Smith	M.Sc., Faculty of Pharmaceutical Sciences	09/2012	05/2017	Supervisor
Ryan Maltais, BSc (Pharm)	M.Sc., Faculty of Pharmaceutical Sciences	01/2011	Withdrew 01/2013	Committee Member
Negar Omidakhsh, BSc	M.Sc., Faculty of Land and Food Systems	09/2010	03/2013	Committee Member
Natalie McCormick, BSc	M.Sc., Faculty of Pharmaceutical Sciences	09/2009	06/2012	Committee Member
Lilla Roy, BSN	M.Sc., Faculty of Pharmaceutical Sciences	09/2010	09/2013	Supervisor
I Fan Kuo, PharmD ⁵	M.Sc. Faculty of Pharmaceutical Sciences	09/2010	04/2014	Supervisor
Mohsen Sadatsafavi, MD ⁶	Ph.D., Faculty of Pharmaceutical Sciences	09/2008	01/2012	Committee Member
Bridgette Oteng, BA	M.Sc., Faculty of Pharmaceutical Sciences	09/2007	09/2009	Committee Member

Student Name	Program Type	Year		Supervisory Role (supervisor, co-supervisor, committee member)
		Start	Finish	
Katie Sweeney, BSc	M.Sc. Faculty of Pharmaceutical Sciences	09/2007	10/2010	Supervisor
Belinda Chen, BSc	M.Sc., Faculty of Pharmaceutical Sciences	09/2007	12/2010	Supervisor
Mehdi Najafzadeh, MA	Ph.D., Faculty of Pharmaceutical Sciences	09/2007	03/2012	Committee Member
Vivian Leung, PharmD	Ph.D., Faculty of Pharmaceutical Sciences	09/2007	09/2012	Committee Member
Camilla Guimaraes, MSc ⁷	Ph.D., Faculty of Pharmaceutical Sciences, University of Sal Paulo, Brazil	09/2005	04/2009	Co-supervisor (Primary Canadian Supervisor)
Kelly Grindrod, PharmD ⁸	M.Sc., Faculty of Pharmaceutical Sciences	05/2007	09/2009	Co-Supervisor
John Woolcott, MA ²	Ph.D. Faculty of Pharmaceutical Sciences	09/2005	12/2011	Committee Member
Helen McTaggart-Cowan ⁹	M.Sc., School of Population and Public Health	09/2004	09/2006	Co-Supervisor
Pauline Leung	Ph.D.	01/2007	w/d for health reasons 06/2007	Co-Supervisor

¹Master training scholarship – CIDA/UWO/NUR/CIDA Maternal, Newborn, and Child Health Training Program

²Pfizer Studentship – Health Outcomes Research

³CIHR Graduate Fellowship

⁴Pharmaceutical Policy Research Collaboration Fellowship and Merck Canada Postgraduate Fellowship

⁵Heart and Stroke Foundation of Canada/CIHR Postdoctoral Fellowship

⁶CIHR Banting and Best Doctoral Award and MSFHR Senior Trainee Award

⁷Graduate exchange student from Brazil. Completed all course work in Brazil, received scholarship to undertake research component of degree abroad. Sought out my research program to undertake her research project, under my supervision. Completed her PhD dissertation under my sole supervision in Canada.

⁸Michael Smith Foundation for Health Research doctoral award and a CIHR doctoral award

⁹Michael Smith Foundation for Health Research trainee award

¹⁰CIHR Frederick Banting and Charles Best Graduate Scholarship

Post-doctoral Fellows Supervised

Fellow Name	Program Type	Year		Supervisory Role (supervisor, co-supervisor, committee member)
		Start	Finish	
Sara Kassani	Postdoctoral Fellow, Faculty of Pharmaceutical Sciences	03/2021	01/2022	Supervisor
Elisabet Rodriguez-Llorian	Postdoctoral Fellow, Faculty of Pharmaceutical Sciences	04/2020	11/2022	Supervisor
Rachel Magarinos-Torres, PhD	Honorary Postdoctoral Fellow, Faculty of Pharmaceutical Sciences	03/2015	08/2017	Supervisor
Daphne Ling, PhD ⁴	Postdoctoral Fellow, Centre for Health Evaluation and Outcome Sciences (CHEOS)	01/2015	07/2016	Co-Supervisor

Fellow Name	Program Type	Year		Supervisory Role (supervisor, co-supervisor, committee member)
		Start	Finish	
Nick Dragojlovic, PhD ¹	Postdoctoral Fellow, Faculty of Pharmaceutical Sciences	09/2013	08/2015	Supervisor
Conor Douglas, PhD	Postdoctoral Fellow, Faculty of Pharmaceutical Sciences	07/2013	08/2015	Supervisor
Pierrick Bedouch, PhD ²	Postdoctoral Fellow, Faculty of Pharmaceutical Sciences	08/2010	08/2011	Supervisor
Nick Bansback, PhD ³	Postdoctoral Fellow, School of Pop. and Public Health	01/2010	01/2011	Co-Supervisor

¹CIHR/Pfizer Post-doctoral Fellowship for Rare Diseases, Michael Smith Foundation for Health Research (MSFHR) Post-Doctoral Fellow Trainee Award

²Sanofi-Aventis award and funding from Grenoble University Hospital

³Canadian Arthritis Network Postdoctoral Fellowship

⁴MSFHR 2015 Research Trainee – Post-Doctoral Fellowship Award

Graduated Student/PDF Supervised: Current Positions

Adam Raymakers – PDF, BC Cancer Agency; previously PDF, University of Galway HTA assessment unit.

Daphne Ling – Sports Medicine Epidemiologist, Hospital for Special Surgery, Columbia University, New York, NY

Conor Douglas, PhD – Assistant Professor, Maastricht University, Maastricht, the Netherlands.

Shirin Rizzardo, MSc – Pharmacist, Medical Beneficiary & Pharmaceutical Services Division, BC Ministry of Health

I fan Kuo, PharmD, MSc – Assistant Professor, School of Pharmacy, Faculty of Health Sciences, University of Manitoba

Lilla Roy, MSc – Assistant Professor, School of Professional Studies, Cape Breton University

Nick Bansback, PhD - Assistant Professor, School of Population and Public Health, UBC

Pierrick Bedouch, PhD – Head, Clinical Pharmacy Unit – Pharmacy Department, Grenoble University Hospital, Grenoble, France

Kelly Grindrod, Pharm.D, MSc – Assistant Professor, School of Pharmacy, University of Waterloo

Camila Guimaraes, PhD – Professor, Department of Clinical, Toxicological and Bromatological Analysis, University of São Paulo, Brazil

Helen McTaggart-Cowan, PhD – Health Economist, BC Cancer Agency

Graduate Student Supervisory Committees Chair/ Examinations

Student Name	Program Type	Date	Role
Joseph Ho	M.Sc.	04/2023	External Examiner
Arwa Nemir	M.Sc.	09/2019 – 08/2021	Thesis Committee Chair
Rakhee Raghunandan	Ph.D. (U of Otago)	05/2021	External examiner
Tarique Benbow	Ph.D.	09/2018- 10/2021	Thesis Committee Chair
Ariana Saachi	Ph.D.	09/2017 04/2023	Thesis Committee Chair
Chris Chen	M.Sc.(UofA)	06/2016	External Examiner
Wasem Alsaggaghi	Ph.D.(UofS)	2015	External Examiner
Jiemin Zhu	M.Sc.	2014 - 2018	Thesis Committee Chair
Vongai Nyamandi	Ph.D.	2014 - 2019	Thesis Committee Chair
Mohamed Wehbe	Ph.D.	2014 - 2019	Thesis Committee Chair
Jailin Xu	M.Sc.	2012 - 2014	Thesis Committee Chair
Jennifer Rose St. Onge	Ph.D.	12/2011	Thesis Committee Chair, Oral Exam Chair
Jayakumar Surendradoss	M.Sc.	2008 - 2012	Thesis Committee Chair
Alexis Twiddy	M.Sc.	2009 - 2013	Thesis committee chair
Marion Pearson	M.Sc.	09/2008	University examiner – thesis defense
Samantha Bowker	Ph.D. (U of A)	11/2007	External examiner – comprehensive exam
Magnolia Pak	Ph.D.	09/07 - 2012	Thesis Committee Chair
Karen Long	M.Sc.	09/2004 - 08/2006	Thesis Committee Chair

Pharm.D. Students Supervised

Student Name	Date	Project
Kyle Collins	04/2016	Demonstrating the value of observational vs RCT studies
Jason Tan	05/2016	Evaluating decision-making for drugs for rare diseases.
Melanie Sunderland*	03/2014	Newborn screening for tyrosinemia
Queeny Ip (U of Arizona)	5/2012	Drug prices for expensive drugs for rare diseases
Arden Barry	5/2009	PharmD Rotation
Ruth Tsang*	03/2007	Type II error in adverse event analysis in randomized controlled trials (published)
Sean Spina	02/2007	Utilities and quality of life in Irritable Bowel Syndrome
Adil Virani	03/1997	Quinine-induced thrombocytopenia
Christine Hughes	02/1997	Venlafaxine related hypertension
Wendy Gordon	01/ 1997	Low molecular weight heparin-induced thrombocytopenia
Patricia Gerber*	12/1996	SSRI-induce dystonic reactions (published)
David Gardner*	11/1996	Sumatriptan and the risk of serotonin syndrome (published)
Ema Ferreira	10/1996	Risk of thromboembolism related to 3 rd generation progestins
Allan Low	10/1995	Drug information rotation
Suzanne Malfair	04/1995	Drug information rotation
Carlo Marra*	03/1995	Drug information and toxicology resources on the Internet (Published)
Donna Buna	02/1995	Drug information rotation
John Forrester-Coulle	11/1994	Drug information rotation
John Mcready	10/1994	Drug information rotation
Linda Sulz	05/1995	Drug information rotation
Brenda Johannesson	03/1994	Drug information rotation
Margaret Ackman	02/1994	Drug information rotation
Jane Delemos	01/1994	Drug information rotation
Fawziah Lalji	10/1993	Drug information rotation
Shallen Letwin	01/1993	Drug information rotation

* = published a paper during rotation under my supervision

Undergraduate Summer (SSRP), Directed Studies (DS) Students, Graduate/Undergraduate Research Assistants (RA) Supervised

Student Name	Program Type	Year		Principal Supervisor	Co-Supervisor(s)
		Start	Finish		
Kodee Bao	SSRP	May/2022	Aug/2022	Larry Lynd	Nick Dragojlovic
Joseph Ho	DS	Sep/2019	Dec/2019	Larry Lynd	Nick Dragojlovic
Joseph Ho	SSRP	June/2019	Aug/2019	Larry Lynd	Nick Dragojlovic
Manrubby Dhillon	SSRP	Apr/2019	Aug/2019	Larry Lynd	Nick Dragojlovic
Rachel Tandun	SSRP	June 2018	Aug/2018	Larry Lynd	Nick Dragojlovic
Ellen Kim	SSRP	June/2016	Aug/2016	Larry Lynd	Nick Dragojlovic
Dimitra Panagiotoglou	GRA	July/2014	Aug/2016	Larry Lynd	
Michelle Lee	SSRP	June/2013	Aug/2013	Larry Lynd	
Justin Scaini	URA	May/2012	Aug/2012	Larry Lynd	
Alana Isakovic	RA	July/2009	Oct/2009	Larry Lynd	Carlo Marra
Alicia Lin	RA	July/2009	Oct/2009	Larry Lynd	Carlo Marra
Omid Zargaran	RA	July/2009	Oct/2009	Larry Lynd	Carlo Marra
Ahmad Abouzant	RA	July/2009	Oct/2009	Larry Lynd	Carlo Marra
Diana Lam	RA	July/2009	Oct/2009	Larry Lynd	Carlo Marra
Allan Lee	DS	Sept/2007	Apr/2008	Larry Lynd	Carlo Marra
Wendy Li	SSRP	June/2007	Aug/2007	Larry Lynd	Carlo Marra
Eric Poulin	SSRP	May/2005	Aug./2005	Larry Lynd	Carlo Marra
Victorine Ssozi	DS	May/2005	Aug/2005	Larry Lynd	Carlo Marra
Jackie Siu	DS	May/2005	Aug/2005	Carlo Marra	Larry Lynd

(d) *Continuing Education Activities*

Course	Institution/Location	Date
Modeling decision making and discrete choice behaviour	Statistical Innovations, Boston, MA	Oct. 21 - 22, 2010
Certificate in Teaching and Learning in Higher Education	University of British Columbia, Vancouver, BC	2005 - 2006
Using discrete choice experiments in health economics	University of Calgary, University of Aberdeen. Lake Louise, AB	Sept. 29 - Oct. 1, 2004
Using Bayesian methods for cost effectiveness analysis	Society for Medical Decision Making Short Course. Chicago, IL.	Oct. 19, 2003
Reducing Bias in observational studies: Propensity Methods	Society for Medical Decision Making Short Course. Chicago, IL.	Oct. 19, 2003
Advance modeling methods for economic evaluation	Centre for Health Economics, York and Oxford Universities. Oxford, UK	Sept. 2003
HRM 737-Economic analysis for the evaluation of health services	Faculty of Health Sciences, McMaster University, Hamilton, ON	Jan. - Apr. 2003
Designing and Implementing Economic Evaluations of Medicines	Centre for Evaluations of Medicines, McMaster University, Hamilton, ON	2003
Advanced methods in economic evaluation	Centre for Evaluation of Medicines / McMaster University, Hamilton, ON	2003

(e) *Other*

Activity	Institution/Company	Dates
Instructor – BC Pharmacy Residents, Evidence Based Medicine Rotation	BC Interior Health Authority	July 14, 2014
Instructor – Hospital Pharmacy Residents	BC Drug and Poison Information Centre/Faculty of Pharmaceutical Sciences, UBC	1990 - 1997
Coordinator – Hospital Pharmacy Residents Drug and Poison Information rotation	BC Drug and Poison Information Centre/Faculty of Pharmaceutical Sciences, UBC	1992 - 1994
Instructor – PharmD students Drug Information	BC Drug and Poison Information Centre/Faculty of Pharmaceutical Sciences, UBC	1994 - 1997
Coordinator – PharmD students Drug Information and Toxicology rotation	BC Drug and Poison Information Centre/Faculty of Pharmaceutical Sciences, UBC	1995 - 1997

9. SCHOLARLY AND PROFESSIONAL ACTIVITIES

(a) *Research or equivalent grants (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC))*

Granting Agency	Subject	COMP	\$ Per Year (Total)	Year	Principal Investigator	Co-Investigator(s)
CIHR	Strengthening the Healthcare Workforce: Enhancing Genetic Counselling Access and Efficiency	C	\$250,000 (\$750,000)	2024-2027	Dr. A. Elliot (NPA); Dr. L. Lynd (PA)	J. Nuk Dr. N. Michaels Dr. J. Austin Dr. J. Friedman Et al.
CIHR	Rare disease administrative data research (RADAR) team: putting the health system impact of rare disease on the radar	C	\$400,000 (\$1.6M)	2024-2028	Dr. D. Marshal	Dr. L. Lynd Dr. K. Boycott Dr. E. Potter Dr. A. Lehman Dr. G. Saunders et al.

NanoMedicine s Innovation Network (NMIN) Strategic Initiatives- Commercialization Support Program	Early health technology assessment of novel companion diagnostics for the HER2 biomarker in breast cancer	C	50000	2023-2025	Dr. Larry Lynd	Dr. Michel Meunier
NanoMedicine s Innovation Network (NMIN) Strategic Initiatives- Commercialization Support Program	Early health technology assessment (eHTA) of PORPHYOSOME-enabled Therapeutic Products for Pancreatic Cancer in the US Market	NC	50000 (45000 Zheng lab, 5000 Lynd lab)	2023-2025	Dr. Gang Zheng	Dr. Larry Lynd
NanoMedicine s Innovation Network (NMIN) Strategic Initiatives- Commercialization Support Program	Early health technology assessment of potential retinal disease indications for targeted delivery of therapeutic RNA using a photoreactive lipid nanoparticle system	C	\$50,000	2023-2025	Dr. L.D. Lynd	Dr. Michel Meunier
NanoMedicine s Innovation Network (NMIN) Strategic Initiatives- Commercialization Support Program	Early health technology assessment for long-acting nanomedicine-based treatment for inherited bleeding disorders	C	\$50,000	2023-2024	Dr. L.D. Lynd	Dr. D. Lillicrap
Genome Canada, Genome British Columbia, BC Provincial Health Services Authority, BC Children's Hospital Foundation, BC Women's Hospital Foundation	RapidOmics 2.0: Long-read Genome Sequencing for Urgent Genetic Disease Diagnosis	C	(\$3,583,291)	2023-2026	Dr. J.M. Friedman, Dr. C. Ivany	Dr. A. Elliott, Dr. W. Gibson, Dr. S. Jones, Dr. L.D. Lynd, Dr. L. Prentice

NanoMedicine s Innovation Network (NMIN) Strategic Initiatives- Commercialization Support Program	Early health technology assessment of novel companion diagnostics for PD-L1	C	\$50,000	2023-2024	Dr. L.D. Lynd	Dr. M. Meunier
Pfizer Canada	Lost productivity among Canadians with atopic dermatitis, alopecia areata, and migraines.	C	\$326,270	2023 - 2024		Dr. L.D. Lynd, Dr. W. Zhang, Dr. L. Trenamann
NanoMedicine s Innovation Network (NMIN) Strategic Initiatives	An early Health Technology Assessment (eHTA) platform to inform nanomedicine development decisions and improve commercialization success	C	\$240,000	2021-2024	Dr. L.D. Lynd	
Canadian Institutes of Health Research	Predictive modeling in multiple sclerosis: using real world data to inform practice, policy, and research	C	(\$470,475)	2021-2025	Dr. J. Cragg, Dr. L.D. Lynd	Dr. R. Tam, Dr. A. Traboulsee, Dr. M. Sadatsafavi, Dr. M. De Vera, Dr. A. Conklin, Dr. J. Oh, Dr. R. Ann Marrie, Dr. S. Patten

Canadian Institutes of Health Research	IMplementing Predictive Analytics towards efficient COPD Treatments (IMPACT)	C	\$1,986,406	2021 - 2025	21	Dr. M. De Vera Dr. D. Sin Dr. N. Bansback Dr. J. Bottorff Dr. S. Bryan Dr. C. Carlsten Dr. A. Conklin Dr. J. Fitzgerald Dr. A. Gershon Dr. S. Gupta Dr. P. Gustafson Dr. J. Leung Dr. L.D. Lynd Dr. A. Safari Dr. L. Struik Ms. J. Sutherland Mr. B. Simmers Mr. A. Smith
TD Ready Challenge	UBC's Remote Communities Drone Transportation Initiative	C	\$750,000	2020-2021	Dr. M. Allard	Dr. L.D. Lynd Dr. N. Caron Dr. N. Humber D. Kang J. Mah Dr. S. McDonald Dr. G. Ogilvie Dr. J. Pawlovich Dr. R. Petrella Dr. P. Zed
Gyconet NCE	Economic evaluation of a novel prostate cancer glycan-based diagnostic tool	C	\$78,000 (\$157,500)	2020 - 2021	Dr. A. Conklin	Dr. L.D. Lynd Dr. K. Williams Dr. W. Zhang Dr. S. Lui
Genome Canada	Implementation of diagnostic genome sequencing for rare diseases in British Columbia	C	\$2.9M (\$8.1M)	2020 - 2023	Dr. A. Lehman Pam Ramsey	Dr. L.D. Lynd Dr. N. Dragojlovic D. Wilson Dr. D. McFadden Dr. S. Nikkel Dr. T. Nelson

Trans-Atlantic Platform: Social Sciences and Humanities	Social Pharmaceutical Innovation for Unmet Medical Need (SPIN)	C	(\$750,000)	2019 - 2022	Dr. C. Douglas Dr. E. Moors Dr. F. Aith Dr. V. Rabeharisoa	Dr. L.D. Lynd Dr. C. Cordovil-Oliveira Dr. L. Doganova Dr. A. Mallard Dr. W. Boon Dr. J. Hoekman Dr. R. Hagendijk
CIHR BC SPOR Economics Methods Cluster	Using natural language processing to explore patients preferences using social listening	C	\$50,000	2019 - 2020	Dr. L. Lynd	Dr. N. Dragojlovic Dr. R. Ng Dr. G. Carini
Genome British Columbia	Quantifying the value of genomics-driven healthcare for children with rare diseases: a multi-country economic analysis (GeneSOLVE)	C	\$250,000 (\$500,000)	2019- 2021	Dr. D. Regier	Dr. L.D. Lynd Dr. J. Buchanan Dr. S. Wordsworth Dr. N. Dragojlovic Dr. J. Friedman Dr. C. van Karnebeek Dr. A. Elliott Dr. M. Harrison
MS Society of Canada	The Canadian Prospective Cohort Study of Progression in Patients with Multiple Sclerosis (CanProCo)	C	\$1,718,000(\$8.59M)	2018- 2023	Dr. J. Oh	Dr. L.D. Lynd Dr. A. Traboulsee Dr. S. Patten Dr. R. Tam Dr. S. Kolind Dr. A. Pratt
Genome British Columbia (administrative lead), G�enome Qu�ebec	GenCOUNSEL: Optimization of Genetic Counseling for Clinical Implementation of Genome-Wide Sequencing	C	\$1,050,000 (\$4.2M)	2018 - 2022	Dr. A. Elliot Dr. B. Knoppers Dr. L.D. Lynd Dr. J. Austin	Dr. J. Friedman Dr. M. Zawati Dr. P. Birch Dr. D. Lambert Dr. S. Adam Dr. C. du Souich Dr. N. Dragojlovic Dr. N. Bansback Dr. D. Pullman Dr. L. Clarke Dr. W. Wasserman Dr. N. Monafred Dr. A. Virami

Vice-President Research & Innovation – UBC Grants for Catalyzing Research Clusters Competition	Orphan Drugs and Rare Disease Policy Cluster	C	\$100,000	2017	Dr. L.D. Lynd	Dr. P. Klein Dr. W. McKillan Dr. J. Friedman Dr. L. Clarke Dr. M. Patel Dr. S. Sirrs Dr. C. Mitton Dr. S. Bryan Dr. A. Anis Dr. M. Burgess Dr. M. Law
MS Society of Canada	Planning Grant – MS Progressive Cohort Project	C	\$250,000	2017	Dr. J. Oh Dr L.D. Lynd (Pillar Lead) Dr. S. Platten Dr. A. Traboulsee Dr. A. Pratt Dr. R. Tam Dr. S. Kolind	
Canadian Institutes of Health - Project Grant	The pricing of generic drugs and its impact on market structure, competitiveness and security of supply	C	\$80,325 (\$240,975)	2016 - 2019	Dr. A. Anis	Dr. P. Grootendorst Dr. A. Hollis Dr. C. Ingram Dr L.D. Lynd Dr. W. Zhang
Canadian Institutes of Health Research - Operating Grant	Perinatal Use of Immunosuppressant Therapies and Risk of Infections in Mothers and Babies	C	\$74,443	2016	Dr. M. De Vera	G. Hanley N. Tsao Dr. L.D. Lynd
BC Personalized Medicine Initiative	Diabetes Interdisciplinary research on Epidemiology, Costs, and Treatment to Optimize Patient Outcomes and Inform Policy (DIRECT)	NC	\$149,282 (\$298,564)	2015 - 2017	Dr L.D. Lynd	Dr. A. Anis Dr. M. Harrison
Foreign Affairs, Trade and Development Canada (DFATD)	Training, Support and Access Model for Maternal, Newborn, and Child Health in Rwanda and Burundi	C	\$1.78M (\$8.9 M)	2015 - 2020	Dr. D. Cechetto	Dr. L.D. Lynd and others
Canadian Institutes of Health Research/Institute Community Support Award	The influence of socioeconomic inequity on the long-term health care costs of asthma under university health	C	\$1,200	2015	Dr. L.D. Lynd	W. Chen

International Development Research Centre	Scale up of homestead food production for improved household food security	C	\$1,566,666 (\$4.7M)	2015 - 2018	Co-PIs Dr. T. Green and Dr. Z. Talukdar	Dr. L.D. Lynd 8 others
Canadian Institutes of Health Research	TREC Phar: Translating Research in E-health into Community Pharmacies	C	\$9,419	2015	Dr. L.D. Lynd	N. Tsao Dr. M. De Vera Dr. C. Douglas Dr. C. Marra
Canada Foundation for Innovation	CFI Infrastructure Operating Fund	C	\$7,419 (\$37,095)	2014 - 2019	Dr. L.D. Lynd	
CIHR-MSFHR Partnerships for Health System Improvement	Informing Future Orphan Drug Coverage with Scenario Studies (iFOCUSS)	C	\$117,900 (\$235,801)	2014 - 2016	Co-PIs Dr. L.D. Lynd and Dr. T. Clifford	Dr. C. Douglas
College of Pharmacists of British Columbia	EmPhAsIS: Empowering pharmacists in asthma management through interactive SMS	NC	\$62,500 (\$250,000)	2014 - 2018	Dr. M. De Vera	Dr. C. Marra Dr. L.D. Lynd Dr. M. Sadatsafavi
AstraZeneca Canada	Evaluating pharmacist prescribing of single inhaler therapy in uncontrolled asthma – A pilot study	NC	\$29,965 (\$59,931)	2014 - 2015	Dr. L.D. Lynd	
UBC Faculty of Pharmaceutical Sciences Research Innovation Fund	Collaborative, Coordinated, Research, and Evidence-Based Medication Adherence Platform (CoREMAP)	C	\$4,000	2014	Dr. M. De Vera	Dr. C.A. Marra Dr. L.D. Lynd
Canadian Foundation for Innovation	Outcomes research in community pharmacy practice: Innovation using eHealth	C	\$38,463	2014	Dr. L.D. Lynd	Dr. C.A. Marra Dr. P. Zed
IDRC	Integration of Small-Scale Aquaculture with Homestead Food Production for Improved Household Food Security and Nutrition in Rural Cambodia	NC	\$16,082 (\$32,164)	2013 - 2015	Dr. L.D. Lynd	
CIDA/Univ of Western Ontario	Maternal, Newborn & Child Health in Rwanda	NC	\$21,144 (\$42,289)	2013 - 2015	Dr. L.D. Lynd	

Canadian Institutes of Health Research	COPD as a systemic disease: Mapping the clinical research agenda to improve patient and societal outcomes	C	\$11,578 (\$23,156)	2013 - 2014	Dr. M. Sadatsafavi	Dr. J. Avina-Zubieta Dr. S. Bryan Dr. J.M. FitzGerald Dr. W. Leslie Dr. L.D. Lynd Dr. G. Mancini Dr. C. Marra Dr. D. Sin Dr. W. Tan Dr. S. Viran
Canadian Foundation for Pharmacy	PhinDMORE: Pharmacist Innovative Drug Therapy Management Outcomes, Resource use and Economics	C	\$35,000	2013	Dr. C. Marra	Dr. L.D. Lynd J. Shaske
Irish Aid and Unicef Zambia	MNP Pilot Study for the Development of a Home Fortification Programme for Young Children in Zambia	C	\$99,000 (\$198,000) US total	2012 - 2014	Dr. J. McLean (Co-PI) Dr. L.D. Lynd (Co-PI)	
Unicef Cameroon	Formative Research for Development of a Home Fortification Program for Young Children in Cameroon	C	\$87,000US	2013	Dr. J. McLean (Co-PI) Dr. L.D. Lynd (Co-PI)	
Unicef Rwanda	The Implementation of In-Home Fortification and Nutrition Education to Combat Anaemia and Micronutrient Deficiencies among Children 6-23 months in Rwanda	C	\$76,000		Dr. J. McLean (Co-PI) Dr. L.D. Lynd (Co-PI)	
Canadian Institutes of Health Research	Improving adherence to treatments through behavioural economics: Testing an enhanced decision aid in patients with obstructive sleep apnea	C	\$100,000	2013	Dr. N. Bansback	Dr. F. Almeida Dr. N. Ayas Dr. P. Brasher Dr. L.D. Lynd Dr. C. Marra Dr. D. Stacey
AllerGen NCE	Platform for Outcomes Research and Translation in Asthma and aLlergy (PORTAL) – Renewal	C	\$37,500 (\$150,000)	2012 - 2016	Dr. L.D. Lynd	Dr. W. Unger Dr. C. Marra Dr. S. Dell Dr. S. Elliott Dr. A. Clarke Dr. J.M. FitzGerald
International Development Research Centre	Integration of small-scale aquaculture with Homestead Food Production for improved household food security and nutrition in rural Cambodia	C	\$1,45M (\$2.9M)	2012 - 2014	Dr. T. Green	Dr. J. McLean Dr. L.D. Lynd Dr. A. Talukder

Canadian Institutes of Health Research	Developing a Canadian Framework for Evaluation and Decision-Making for Expensive Drugs for Rare Diseases Through Innovation, Value, and Priority Setting	C	\$293,203 (\$1.47M)	2012 - 2017	Dr. L.D. Lynd	Dr. S. Bryan Dr. L. Clarke Dr. T. Clifford Dr. D. Coyle Dr. J. Friedman Dr. Y. Joly Dr. B. Jones Dr. P. Klein Dr. B. Knoppers Dr. E. Lun Dr. C. Marra Dr. F. Miller Dr. C. Mitton R. Nakagawa Dr. V. Ozdemir Dr. S. Sirrs
Canadian Institute of Health Research	Planning Meeting for Developing a Canadian Framework for Reimbursement Decision-Making for Expensive Drugs for Rare Diseases	C	\$24,666	2012	Dr. L.D. Lynd	+ 16 others
Canadian International Development Agency	Muskoka Initiative Partnership Program for Maternal, Newborn, and Child Health in Rwanda	C	\$600,000 (\$1.8 M)	2011 - 2014	Dr. D. Cechetto	Dr. L.D. Lynd + 10 others
Canadian Institute for Health Research	The impact of price-caps on the generic pharmaceutical industry and provincial drug plan costs in Canada	C	\$55,892 (\$115,284)	2012 - 2014	Dr. A. Anis (Co-PI) Dr. C. Marra (Co-PI)	Dr. L.D. Lynd Dr. B. Wilmer
Canadian Institute for Health Research	Understanding persistent antipsychotic polypharmacy: a prevalent practice without evidence	C	\$113,765 (\$341,294)	2010 - 2013	Dr. R. Procyhyn (Co-PI) Dr. A. Barr (Co-PI)	Dr. W. Honer Dr. J. Johnson Dr. L.D. Lynd
Canadian Institute for Health Research	A randomized controlled trial evaluation of brief, telephone supported CBT self-help in primary care patients with mild to moderate depression	C	\$73,378 (\$220,135)	2010 - 2013	Dr. M. Lau	Dr. S. Hollon Dr. L.D. Lynd
Canadian Institute for Health Research	The Feasibility of Using Community Pharmacists in Focused Surveillance for Drug Safety and Effectiveness: A Case Study of Anti-Hypertensives in Pregnancy	C	\$98,847	2010	Dr. L.D. Lynd (Co-PI) Dr. C. Marra (Co-PI)	Dr. E. Ferreira Dr. L. Magee Dr. P. Von Dadelnszen
Canadian Institute for Health Research	Effects of Prescription Adaptation and Renewal by Pharmacists	C	\$103,157 (\$309,472)	2010 - 2013	Dr. M.Law	Dr. L.D. Lynd Dr. SR Majumdar Dr. C. Marra Dr. S. Morgan

AllerGen NCE	Platform for Outcomes Research and Translation in Asthma and aLlergy (PORTAL)	C	\$100,000 (\$300,000)	2009 - 2012	Dr. L.D. Lynd	Dr. W. Ungar Dr. C. Marra Dr. S. Dell Dr. S. Elliott Dr. A. Clarke Dr. J.M. FitzGerald
AllerGen NCE	Consumer Preferences for Allergen Food Labeling	C	\$46,892	2009	Dr. L.D. Lynd Dr. C. Marra	
Canadian Institute for Health Research	Mindfulness-Based Cognitive Therapy to prevent the relapse of depression in the workplace	C	\$75,000	2009	Dr. M. Lau	Dr. L.D. Lynd Dr. P. McGrath Dr. Z. Segal Dr. P. Coleridge Dr. S. Ogrodniczuk
Canadian Institute for Health Research	Evaluating the association between inhaled corticosteroid and statin use on lung cancer in COPD: a BC linked health database study	C	\$62,930 (\$125,576)	2008 - 2010	Dr. L.D. Lynd	Dr. J.M. FitzGerald Dr. S. Lam Dr. C. Marra Dr. D. Sin
Canadian Institute for Health Research	Study of understanding patients' preferences on remuneration and transition towards pharmacists' provision of chronic disease management	C	\$53,430 (\$106,861)	2008 - 2010	Dr. L.D. Lynd	Dr. W. Mail Dr. C. Marra Dr. J. Taylor Dr. R. Tsuyuki
Canadian Institute for Health Research	Pharmacy-based Immunization in Rural Communities Strategy (PhICS)	C	\$50,000 (\$150,000)	2008 - 2011	Dr. J. Kaczorowski	Dr. P. Kendall Dr. C. Marra Dr. F. Marra Dr. R. Brunham Dr. L.D. Lynd
National Sanitarium Association	Respiratory Evaluation Sciences Programme	C	\$200,000 (\$1M)	2007 - 2012	Dr. C. Marra Dr. J.M. Fitzgerald	Dr. L.D. Lynd Dr. A. Anis Dr. B. Carleton
Canadian Institute for Health Research	Antidepressants and risk of suicide or self-harm in Canadian youth: A national population-based study	C	\$120,987 (\$241,975)	2008 - 2010	Dr. Y. Moride	Dr. M. Abrahamowicz Dr. R. Battista Dr. G. Galabud du Fort Dr. B. Greenfield Dr. A. Kozyrskyj Dr. J. Leloirier Dr. L.D. Lynd Dr. C. Metge Dr. S. Perreault

Canadian Foundation for Pharmacy	Compensation for pharmacists clinical care services – development of a sustainable, scalable and economically viable solution.	C	\$50,000 (\$100,000)	2007 - 2009	Dr. R. Tsuyuki	Dr. L.D. Lynd Dr. C. Marra Dr. M. Makowsky
BC Knowledge Development Funds	Developing a Laboratory for Therapeutic Risk-Benefit Assessment	C	\$10,000 (\$40,000)	2006 - 2010	Dr. L.D. Lynd	
Canadian Foundation for Innovation	Developing a Laboratory for Therapeutic Risk-Benefit Assessment	C	\$10,000 (\$40,000)	2006 - 2010	Dr. L.D. Lynd	
MSFHR	Calculating health care costs related to asthma in British Columbia	C	\$50,000 (\$100,000)	2006 - 2008	Dr. J. Mark Fitzgerald	Dr. L.D. Lynd Dr. C. Marra Dr. B. Carleton
MSFHR (Team Planning Grant)	CORRECT Groups: Collaborative Resources for Research on Counseling and Therapy	C	\$25,000 (\$50,000)	2006 - 2007	Dr. J. Ogrodniczuk	Dr. L.D. Lynd
MSFHR (Team Planning Grant)	Increasing consumer access to cognitive behaviour therapy (CBT) in British Columbia: Applying a knowledge exchange framework to CBT dissemination	C	\$25,000 (\$50,000)	2007 - 2008	Dr. M. Lau	Dr. L.D. Lynd Dr. J. Ogrodniczuk Dr. Sagar Parikh Dr. Steven Hollon Dr. Dan Bilsker
MSFHR	The role of pharmacists in prescribing medications – seed funding to develop research proposal for CIHR	C	\$5000	2006	Dr. L.D. Lynd	
Pfizer Canada	Evaluating care gaps in the management of rheumatoid arthritis in British Columbia: a population based analysis	NC	\$110,219	2006	Dr. L.D. Lynd (Co-PI) Dr. C.A. Marra (Co-PI)	Dr. D. Fielding Dr. J. Soon Dr. M. Levine
Canadian Institute for Health Research	Evaluating socioeconomic status differences in patient preferences for asthma therapy using discrete choice experimentation	C	\$58,500 (\$292,500)	2006 - 2011	Dr. L.D. Lynd	
Canadian Institute for Health Research	Population-based comparison of two regimens for emergency contraception	C	\$36,982 (\$110,946)	2005 - 2008	Dr. M. Levine (Co-PI) Dr. J. Soon (co-PI)	Dr. M. Ensom Dr. D. Fielding Dr. L.D. Lynd Dr. C. Marra
MSFHR	Establishment Grant Evaluating socioeconomic differences in patient's preferences for asthma therapy	C	\$62,500 (\$125,000)	2005 - 2007	Dr. L.D. Lynd	

AllergenNCE	Investigating asthma among British Columbia workers: a pilot surveillance project	C	\$62,300 (\$124,600)	2005 - 2007	Dr. M. Kiehoorn	Dr. L.D. Lynd Dr. S. Kennedy Dr. J. Beach Dr. P. Demers
BC Lung Association	Antibiotic use during the first year of life and subsequent development of childhood asthma: a population-based study	C	\$30,000 (\$60,000)	2005 - 2007	Dr. F. Marra	Dr. L.D. Lynd Dr. C. Marra Dr. J.M. FitzGerald
Glaxo Smith Kline	Evaluating GINA guidelines for asthma control	NC	\$37,500 (\$75,000)	2005 - 2007	Dr. L.D. Lynd	Dr. J.M. FitzGerald
University of British Columbia	Start up Funds	NC	\$116,666 (\$350,000)	2004 - 2007	Dr. L.D. Lynd	
Vancouver Coastal Health Authority	Start up Funds	NC	\$8,333 (\$25,000)	2004 - 2007	Dr. L.D. Lynd	
BC Lung Association	Evaluating health-related quality of life and patients' preferences for treatment in asthma	C	\$45,000	2005	Dr. L.D. Lynd	Dr. C. Marra Dr. G. Currie Dr. A. Anis Dr. Tony Bai Dr. J.M. FitzGerald
Pfizer Canada Ltd.	Bayesian vs. frequent presentation of clinical trial results: impact on treatment decisions in anticoagulant therapy	C	\$25,500	2005	Dr. L.D. Lynd	
Canadian Coordinating Office for Health Technology Assessment	Development of an undergraduate level course and workshop on the principles of health economics and HTA	C	\$68,165	2005	Dr. L.D. Lynd	Dr. C. Marra Dr. A. Anis Dr. D. Fielding Dr. E. Balka Mr. R. Goeree
Glaxo Smith Kline	A framework for evaluating risks and benefits of drug therapy: identification, evaluation, and development	C	\$96,000 (\$250,000)	2004	Dr. L.D. Lynd	Dr. A. Willan Dr. M. Sculphur
Providence Health Care	An evaluation of factors influencing the safety and efficacy of warfarin anticoagulation	C	\$15,000	2001	Dr. S. Shalansky Dr. L.D. Lynd	
Providence Health Care	A pilot study of camouflage recruiting	C	\$6,000	2000	Dr. A. Anis	Dr. P. Paré Dr. L.D. Lynd
BC Lung Association	Socioeconomic determinants of short-acting beta- agonist use.	C	\$24,400 (\$48,800)	1998 - 2000	Dr. A. Anis	Dr. P. Paré Dr. T. Bai Dr. J.M. FitzGerald

Pharm. Manufacturers Assoc. of Canada (PMAC)	A provincial pharmacist education program on adverse drug reactions and post-marketing surveillance	NC	\$6,500	1996	Dr. L.D. Lynd	Dr. D. Daws
--	---	----	---------	------	---------------	-------------

(b) *Research or equivalent contracts (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC)).*

Granting Agency	Subject	COMP	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
Pfizer Canada	Lost productivity among Canadians with atopic dermatitis, alopecia areata, and migraines	NC	\$326,270	2023-2024	Dr. L. Trenamann Dr. W. Zhang Dr. L. D. Lynd	
AstraZeneca Canada	Pattern and outcomes associated with inappropriate use of short-acting beta-agonists in asthma	NC	\$350,140	2015 - 2017	Dr. M. Sadatsafavi	Dr. L.D. Lynd Dr. J.M. Fitzgerald
BC Pharmacy Association	BC Medication Management Project (BCMMP) Qualitative Evaluation	NC	\$131,500 (\$263,000)	2012 - 2013	Dr. C.A. Marra	Dr. L.D. Lynd
College of Pharmacists of BC	Evaluating pharmacists working conditions in BC: replicating the Oregon experience	NC	33,550	2013	Dr. C.A. Marra Dr. L.D. Lynd	
Sanofi-Aventis/Genzyme	Evaluating treatment preferences in MS: a stated choice study	NC	\$232,470	2012	Dr. L.D. Lynd	Dr. C.A. Marra Dr. N. Mittman Dr. C. Evans
Astra Zeneca	Evaluating pharmacist prescribing in uncontrolled asthma	NC	\$65,000	2010	Dr. L.D. Lynd	
BC Pharmacy Association	Evaluation of Pharmacy Adaptation Services in British Columbia	NC	\$291,954	2009	Dr. L.D. Lynd (Co-PI) Dr. C.A. Marra (Co-PI)	Dr. K. Grindrod
PROOF	The potential economic impact of new strategies	NC	\$12,000	2009	Dr. C.A. Marra	Dr. L.D. Lynd
PROOF	Cost-effectiveness of new biomarker for rejection in heart transplant	NC	\$5,000 (\$10,000)	2009 - 2010	Dr. C.A. Marra	Dr. L.D. Lynd
Pharmaglyph	Randomized Controlled Trial: Pharmaglyph-Enhanced Counselling in HIV and Transplantation	NC	\$65,982	2009	Dr. L.D. Lynd	Dr. C.A. Marra

(c) *Invited Presentations*

1. Rare genetic disorders: policy and reimbursement challenges and opportunities. 2023 ISPOR New Zealand Annual General Meeting and Annual Scientific Meeting. Virtual. May 2, 2023.
2. The economic burden of multiple sclerosis. Benefits Canada 2023 Chronic Disease at Work. Feb. 2, 2023. Virtual Conference.
3. Diagnosis and treatment of rare diseases: the need to innovate to enable access. The joint meeting of 8th annual Canadian Human and Statistical Genetics Meeting and CIHR Institute of Genetics Canadian GE3LS* and Health Services Policy Meeting. June 16 - 19, 2019. Montreal, QC.
4. When zebras run with horses: the impact of treatment for rare disease on mainstream medicine. Canadian Society of Nephrology Annual General Meeting and Renal Pharmacists Network Joint Session. May 4, 2019. Montreal, QC.
5. Orphan Drugs for Rare Diseases: the need to innovate to enable access. Telus Health Annual Conference. April 10, 2019. Vancouver, BC.
6. Orphan Drugs for Rare Diseases: the need to innovate to enable access. Telus Health Annual Conference. April 2, 2019. Toronto, ON.
7. Orphan Drugs for Rare Diseases: the need to innovate to enable access. Canadian Institutes for Health Research Socioeconomic Burden of Rare Diseases Workshop. March 21, 2019. Ottawa, ON.
8. The need for innovation to enable access to diagnosis and treatment of rare diseases. Life Sciences BC Access to Innovation 2019. January 30, 2019. Vancouver, BC.
9. Expensive drugs for rare disease – challenges in evaluation and access. Provincial Renal Grand Rounds. Vancouver General Hospital. April 6, 2018. Vancouver, BC.
10. Using big data to inform practice, policy, and research – a Canadian experience. 2017 Drug Utilization Research Conference. September 2017. Rio de Janeiro, Brazil.
11. Prescription to over-the-counter: potential unintended consequences. Healthy Canada Conference 2017: Access to Affordable Medicines. April 26, 2017. Toronto, ON.
12. Evaluating provincial challenges and opportunities around orphan drugs. 15th Annual Market Access Summit. November 16, 2016. Toronto, ON.
13. Developing a Canadian framework for evaluation and decision-making for rare diseases. Delivering Innovation: a Moon Shot for Rare Disorders and Beyond. November 6-7, 2017. Toronto, ON.
14. Using big data to inform practice, policy, and research. International Summit Forum on Prevention and Precision Medicine of Infectious Diseases. October 13, 2016. Shenzhen, China.
15. The Canadian orphan drug framework in context – implications for patients, practice, and society. Garrod Symposium. May 21, 2016. Halifax, NS.
16. Exploring Contemporary Pressures on Pharmaceutical Reimbursement in an Era of Orphan Drugs and Personalized Medicine. 2016 CADTH Symposium. April 12, 2016. Ottawa, ON.
17. Using big data to inform practice, policy, and research. The Data Effect meeting. March 11, 2016. Vancouver, BC.
18. Exploring a new paradigm of drug discovery and development: what are the implications? College of Pharmacy, University of Saskatchewan. September 21, 2015. Saskatoon, SK.
19. Clinical Research in Drug Approval. 2nd Annual International Summer Program in Medicine. UBC Faculty of Medicine. July 24, 2015. Vancouver, BC.
20. Can we move from sick-care to health-care? LSI Public Talks, Personalized Medicine: Your Life, Your Genes, Your Health and Happiness. February 4, 2015. Vancouver, BC.
21. Evaluating the implications of orphan drugs and rare diseases in Canada: A reimbursement/health care sustainability perspective. Providence Health Care Research Institute Work in Progress Seminar Series. October 22, 2014. Vancouver, BC.
22. Evaluating the implications of orphan drugs and rare diseases in Canada – a reimbursement/health care sustainability perspective. UBC Faculty of Pharmaceutical Sciences Seminar Series. October 8, 2014. Vancouver, BC.
23. Pharmacists' Working Conditions in British Columbia. College of Pharmacists of British Columbia Board Meeting. September 25, 2014. Vancouver, BC.
24. Providing professional pharmacy services in British Columbia – implementation, evaluation, and reimbursement. 15th Annual Congress of the Society Francaise de Pharmacie Clinique (SFPC). February 7, 2014. Grenoble, France.
25. Using state choice methods in health services research and evaluation. Université Joseph Fournier. February 5, 2014. Grenoble, France.
26. Decision making for pharmaceuticals – focus on orphan drug policy in Canada. Centre for Genomics and Policy, McGill University. December 5, 2013. Montreal, QC.

27. Personalized medicine, orphan disease drugs, and the future of health economics. Panelist and Speaker. The 9th World Congress on Health Economics. July 10, 2013, Sydney, Australia.
28. Where do we stand in the economics of asthma and asthma care? Asthma Symposium, in conjunction with the 9th World Congress on Health Economics. July 6, 2013. Sydney, Australia.
29. Positive patient outcomes through partnerships and collaborations – government, industry, and academia. Social and Administrative Pharmacy Educators of Canada Annual Meeting. October 9-10, 2012, Montreal, QC.
30. Developing a Canadian Framework for Evaluation and Decision-Making for Expensive Drugs for Rare Diseases through Innovation, Value, and Priority Setting. 2012 Rare Disease Day Conference February 20 – March 1, 2012. Ottawa, ON.
31. The economics of asthma: it's about more than the dollars (Keynote). 1st International Symposium on the Economics of Asthma and Asthma Care, in conjunction with the 8th World Congress on Health Economics. July 9, 2011. Toronto, ON.
32. Evaluating patients' preference for pharmacist provision of chronic disease management using a discrete choice experiment. Canadian Pharmacists Association National Conference May 28-31, 2011, Montreal, QC.
33. Integrating benefit and risk data into decision-making. 32nd Annual Society of Clinical Trials Meeting. May 16, 2011. Vancouver, BC.
34. Exploring the international landscape of new methods for benefit-risk assessment. Canadian Association of Population Therapeutics Annual Conference. April 19, 2011. Ottawa, ON.
35. Economic evaluation and cost effectiveness analysis – the 4th hurdle in drug development. Centre for Drug Research and Development Seminar. March 21, 2011. Vancouver, BC.
36. Risk benefit analysis: combination LABA+ICS vs ICS alone for the treatment of asthma. 3rd Annual UBC Centre for Lung Health Research and Policy Day. March 26, 2010. Vancouver, BC.
37. Incremental net benefit case studies. US FDA/DIA: Assessing benefits and risks of medicinal products in regulatory decisions. November 4, 2009. Bethesda, MD.
38. Incremental net benefit for quantifying benefit-risk tradeoffs. US FDA/DIA: Assessing benefits and risks of medicinal products in regulatory decisions. November 3, 2009. Bethesda, MD.
39. Applications of incremental net benefit to quantitative risk benefit analysis. The future of drug safety research: an interdisciplinary environment. Erasmus University. October 31, 2008. Rotterdam, The Netherlands.
40. Applications of pharmacoeconomics to re-imburement of expensive drugs for rare diseases. BC Ministry of Health Expensive Drugs for Rare Disease Advisory Committee. October 7, 2008. Vancouver, BC.
41. The economics of drug coverage in Canada. UBC Dept. of Medicine Internal Medicine Residents Whistler Conference. Advocacy in Action. March 6, 2008. Whistler, BC.
42. Case studies using incremental net benefit for risk-benefit analysis. At: Joint FDA, PhRMA, BIO working conference: Assessing drug benefits and risks in regulatory decisions: framed the need, evaluating the tools, and deciding next steps. November 7-8, 2007. Washington, DC.
43. An introduction to pharmacoepidemiology: an overview and examples. Pfizer Canada, Inc. Vancouver, BC. July 11, 2007.
44. Using incremental net-benefit for quantitative risk-benefit analysis. Presented at: Drug Information Association 43rd Annual Meeting. June 18, 2007. Atlanta, GA.
45. Quantitative methods for therapeutic benefit risk assessment. FDA/Regenstrief Institute joint meeting on Benefits and Risks of Pharmaceuticals: Frameworks, Methods and Policies. March 15-15, 2007, Washington, DC. (Presenter and Panelist)
46. Methods in quantitative risk benefit analysis. In: Advance Topics in Pharmacoepidemiology. 22nd International Conference on Pharmacoepidemiology and Therapeutic Risk Assessment. August 24, 2006. Lisbon, Portugal.
47. Quantitative methods for therapeutic risk-benefit analysis. International Society of Pharmacoeconomics and Outcomes Research Annual meeting. May 22, 2006. Philadelphia, PA. (Presenter and Panelist)
48. Methodologic approaches to risk-benefit analysis. 3rd Canadian Therapeutic Congress. Hilton Toronto. May 10, 2006. Toronto, ON.
49. FDA round-table discussion on benefit-risk assessment of pharmaceuticals. PhRMA/FDA joint meeting. May 2, 2006. Washington, DC. (Presenter and Panelist)
50. Metrics for benefit-risk assessment. International Society for Pharmacoepidemiology 2006 Midyear Meeting. April 24, 2006. Washington, DC.
51. A systematic review and evaluation of methods for risk-benefit analysis; the results of Phase I. GlaxoSmithKline Global Health Outcomes Annual Meeting. April 20, 2005. Fiuggi, Italy.
52. Quantitative methods for risk benefit analysis. GlaxoSmithKline Global Clinical Scientific and Pharmacovigilance Group. March 24, 2004. Philadelphia, PA.
53. Risk-benefit analysis: the past, the present, and paving the way of the future. Grand rounds. Dept. of Health Care and Epidemiology, Faculty of Medicine, University of British Columbia. January 21, 2004. Vancouver, BC.

54. Taking calculated risks: an innovative approach to risk assessment. Plenary speaker. Canadian College of Clinical Pharmacy Annual Meeting. June 3, 2004. Winnipeg, MB.
55. Asthma control in British Columbia: is it a problem, and what is causing the problem. University of British Columbia Faculty of Pharmaceutical Sciences Research Seminar. February 26, 2002. Vancouver, BC.
56. Tackling the difficult patient – case challenges in asthma. Clearing the Air on Asthma conference. November 4, 2001. Burnaby, BC.
57. Using the Pharmacare database to assess the appropriateness of asthma medication use. University of British Columbia Respiratory Division Research Seminar Series, 2000-2001. St. Paul's Hospital. October 24, 2001. Vancouver, BC.
58. Setting the stage: asthma management in British Columbia. BC Asthma Educators 4th Annual Retreat. October 12-13, 2001. Vancouver, BC.
59. Exploring the relationship between socioeconomic status and short-acting beta-agonist use in British Columbian asthmatics. Research In Progress rounds. St. Paul's Hospital. September 24, 2001. Vancouver, BC.
60. Double trouble: inappropriate asthma medication use linked to increased use of health care resources. Vancouver and area Respiriologists Quarterly Journal Club. August 8, 2001. Vancouver, BC.
61. Beta-agonist utilization patterns in British Columbia: analysis of BC Pharmacare data. Glaxo-Wellcome expert advisory committee meeting. October 8, 2000. Vancouver, BC.
62. Confounding in clinical research. Doctor of Pharmacy Seminar. Faculty of Pharmaceutical Sciences, University of British Columbia. March, 2000. Vancouver, BC.
63. A longitudinal analysis of β -agonist use in British Columbia. Research in Progress rounds. St. Paul's Hospital. March 2000. Vancouver, BC.
64. Bias in clinical research. Doctor of Pharmacy Seminar. Faculty of Pharmaceutical Sciences, University of British Columbia. February, 2000. Vancouver, BC.
65. The "How To" of detecting bias and confounding in clinical trials. BC Drug and Poison Information Centre drug information rounds. St. Paul's Hospital. October 17, 1999. Vancouver, BC.
66. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. May 1997. Kelowna, BC.
67. Adverse drug reactions – the role of the physician in post-marketing surveillance. Medical Grand Rounds. Kelowna General Hospital. May, 1997. Kelowna, BC.
68. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. May 1997. Terrace, BC.
69. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. March, 1997. Trail, BC.
70. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. March, 1997. Penticton, BC.
71. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. February, 1997. Abbotsford, BC.
72. Adverse drug reactions and post-marketing surveillance - how pharmacists can contribute to drug safety. Canadian Society of Hospital Pharmacists – BC Branch February Program. February 26, 1997. Vancouver, BC.
73. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. January, 1997. Sechelt, BC.
74. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. December, 1996. Salmon Arm, BC.
75. Adverse drug reactions in the long term care population. New Ideas for Old Friends - BC's Long Term Care Pharmacy Conference. May 1996. Vancouver, BC.
76. Adverse drug reactions and interactions - a focus on ACE Inhibitors and herbal drugs. Pharmacy Evening Continuing Education Lecture Series. November, 1996. Victoria, BC.
77. Adverse drug reactions and interactions - identification and management. A focus on calcium channel blockers. Pharmacy Evening Continuing Education Lecture Series, March, 1996. Victoria, BC.

(d) *Other Presentations*

Panel Participant/Presentations

1. Moderator and Panelist. Career Pathways in Pharmaceutical Sciences: The Future of Pharmaceutical Sciences: Research, Development, and Policy. March 9, 2019. Vancouver BC.

2. Lau M, Williams C, Hollon S, Lynd LD. Transporting CBT from the research clinics to the providers and consumers who want and need them: what we have done, and what we still need to do. 45th Annual Convention of the Association of Behavioural Cognitive Therapists. Nov. 10, 2011. Toronto, ON (peer reviewed)
3. Van Staa, TP, Lynd LD, Leufkens HGM, Raine J, Petri, H. Benefit-harm modeling: What is this and what can it contribute to pharmacovigilance? 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Copenhagen, Denmark, August 17 – 20, 2008. (peer reviewed)
4. Invited participant. Next-steps working group on FDA benefit-risk assessment. Washington, DC. March 14, 2008.
5. Ogrodniczuk JS, Lynd LD, Richardson K. Day treatment for personality disorder: Predicting premature termination. Panel Presentation. Society for Psychotherapy Research. Thirty-seventh Annual Meeting, Edinburgh, Scotland, June 24, 2006. (Peer reviewed)
6. Health outcomes approaches to risk-benefit analysis: How ready are they. Issues Panel. International Society for Pharmacoeconomics and Outcomes Research, 11th Annual International Meeting. Philadelphia, PA. May 23, 2006. (Peer reviewed)
7. Stakeholder roundtable: optimizing benefit risk assessment. Invited participant. Scientific and Regulatory Executive Committee of the Pharmaceutical Research Manufacturers of America (PhRMA) and US Food and Drug Administration. Washington, DC. May 2, 2006. (Invited)

(e) *Other*

Workshops Presented

1. Critical evaluation of randomized controlled trials. Canadian Agency for Drugs and Technologies in Health. Ottawa, ON. September 29 & 30, 2015. (with Drs. Carlo Marra and Joel Singer).
2. Interpretation of the rheumatology literature. Vancouver Island Rheumatologists' Journal Club. Victoria, BC. October 25, 2015.
3. Reflecting on the findings of a pharmaceutical value framework workshop. Canadian Association of Population Therapeutics 2013 Annual Conference. November 17, 2013. Toronto, ON.
4. Evaluation of outcomes associated with a continuing professional development program in maternal and child health in Rwanda. Inter-professional collaborative teamwork and clinical teaching workshop on Maternal, Newborn and Child Health. October 16-17, 2012. Kigali, Rwanda.
5. Outcomes evaluation of the UWO/KHI/NUR/MOH Continuing Medical Education program in Maternal, Newborn, and Child Health in the Eastern District of Rwanda. October 16-17, 2012. Kigali, Rwanda.
6. Vancouver short course on health economics and health care coverage decision-making. Vancouver, BC, November 24-25, 2011.
7. Health Economic Evaluation and Coverage Decision Making. November 24 – 25, 2010. Vancouver, BC.
8. Platform for Outcomes Research and Translation in Asthma and Allergy. Allergen Network Wide Research Workshop. Toronto, ON. Dec 18, 2009.
9. Applications of quantitative risk benefit analysis to regulatory decision making. October 30, 2008. Erasmus University, Rotterdam, Netherlands.
10. Collaboration for Outcomes Research and Evaluation Inter-professional Health Economics Workshop. October 2 – 3, 2008. Vancouver, BC, Canada.
11. Using incremental net benefit for quantitative benefit-risk analysis – case studies of Vioxx® and Lotronex®. At: Office of Health Economics/ European Medicines Evaluation Agency Workshop: “How can regulatory agencies improve the risk-benefit assessment of pharmaceuticals? Does an economic perspective help? London, England. October 24, 2007.
12. Introduction to economic evaluations in health. Half-day workshop. Vancouver Coastal Health Research Institute. Vancouver General Hospital, May 2007.
13. Pharmaceutical reimbursement policies for drug therapy for children with asthma in British Columbia, in: Public Health, Policy and Society Workshop on Improving Drug Benefits for Children with Asthma: Building a Research Agenda. March 27 – 28, 2007. Toronto, ON. (Presenter and Panelist).
14. Pharmacoeconomics and drug policy decision-making: a primer for pharmacists. Sheraton Wall Centre, February 3, 2007. Vancouver, BC.
15. Quantitative methods for therapeutic risk-benefit analysis – focus on rofecoxib. For: Merck Frosst, Inc. November 17, 2006. Philadelphia, PA.
16. Facilitator: Advanced modeling methods for health economic evaluation. Toronto Renaissance Skydome. Toronto, ON. June 21-23, 2006

17. Drugs, devices and procedures: Getting what you need – the assessment of technology in health. Regina Qu'Appelle Regional Health District. Regina, SK. June 8, 2006.
18. Introduction to economic evaluation for clinicians. For: Vancouver Coastal Health and Vancouver General Hospital. April 11, 2006.
19. Evidence-based medicine workshop: avoiding harm, explaining harm. Canadian College of Clinical Pharmacy Annual Meeting. Winnipeg, MB. June 3, 2004.
20. Workshop Coordinator. Using administrative databases for health outcomes research. Centre for Health Evaluation and Outcome Sciences Workshop. St. Paul's Hospital. Vancouver, BC, Canada. June 21, 1999.

Continuing Education Events Developed and Presented

1. Lynd LD, FitzGerald JM. Patients' preferences for the effective control of asthma. October 10, 2006, Vancouver, BC. 1.5 CEUs. (14 attendees)
2. Lynd LD, FitzGerald JM. Patients' preferences for the effective control of asthma. October 23, 2006, Kamloops, BC. 1.5 CEUs. (13 attendees)
3. Lynd LD, FitzGerald JM. Patients' preferences for the effective control of asthma. October 24, 2006, Kelowna, BC. 1.5 CEUs. (18 attendees)

(f) *Conference Participation (Organizer, Keynote Speaker, etc.)*

Member, Canadian Society of Pharmaceutical Sciences Planning Committee, UBC, Faculty of Pharmaceutical Sciences, 2015-2016.

Member, Organizing Committee, Asthma Symposium 2011, 1st International AllerGen Symposium on Asthma and Economics, iHEA Congress, Toronto, Canada.

Chair, Scientific Evaluation Committee, Canadian Association of Population Therapeutics, 2004-2005, 2009-2010.

Member, Scientific Program Committee, Canadian Association of Population Therapeutics, 2004-2005.

Member, Annual Conference Scientific Program Committee, Canadian Association of Population Therapeutics, 2003-2004.

Co-Chair, Scientific Evaluation Committee, Canadian Association of Population Therapeutics, 2003-2004.

10. SERVICE TO THE UNIVERSITY

(a) *Memberships on committees, including offices held and dates*

Committee	Faculty/Dept	Dates
Member – UBC-V Senate		2023 - ongoing
Member – UBC Senate Academic Policy Committee		2023 - ongoing
Member – UBC Health		2023 - ongoing
Member – UBC Information Technology Advisory Committee		2023 - ongoing
Member – Nanomedicines/Chemical Biology Assistant Professor Search Committee	Faculty of Pharmaceutical Sciences	2023-24
Member – Assistant Professor of Teaching Search Committee – BPSc Program	Faculty of Pharmaceutical Sciences	2023-24
Member – Search Committee – Professor – Translational Medicine	School of Population and Public Health – Faculty of Medicine	2023-24

Member – Search Committee – Associate Dean Practice Innovation	Faculty of Pharmaceutical Sciences	2021 - 2023
Member – UBC Health Advisory Committee	UBC	2020 - 2023
Co-Chair – Search Committee – Assistant Professor, Respiratory Outcomes	Faculty of Pharmaceutical Sciences	2020-2021
Chair – Search Committee – Assistant Professor/CRC Tier 2 Nanomedicines/Chemical Biology/MSP	Faculty of Pharmaceutical Sciences	2020 - 2021
Member – Impact of COVID on Career Trajectory	Vice President Research Office, UBC	2020
Member – Search Committee – Assistant Professor, Pharmacokinetics	UBC, Faculty of Pharmaceutical Sciences	2020
Member – Bachelor of Pharmaceutical Sciences Screening Committee	UBC, Faculty of Pharmaceutical Sciences	2020- 2022
Member – Bachelor of Pharmaceutical Sciences Program Committee	UBC, Faculty of Pharmaceutical Sciences	2020- 2023
Member – Search Committee – Greg Moore Professorship in Cardiovascular Health Outcomes	UBC, Faculty of Pharmaceutical Sciences	2019-2020
Chair – Search Committee – CRC in Nanomedicines and Molecular and Systems Pharmacology	UBC, Faculty of Pharmaceutical Sciences	2019-2020
Dean’s Advisory Committee on Promotion and Tenure	UBC, Faculty of Pharmaceutical Sciences	2017 - 2019
Faculty Research Advisory Committee	UBC, Faculty of Pharmaceutical Sciences, Office of Associate Dean Research	2016 – ongoing
Associate Member Committee	UBC, School of Population and Public Health, Faculty of Medicine	2016 – ongoing
Chair – Search Committee – Assistant/Associate Professor, Health Outcomes Research	UBC, Faculty of Pharmaceutical Sciences	2015
Member – Mentorship Committee	UBC, Faculty of Pharmaceutical Sciences	2015 – ongoing
Co-Lead – Foundations for Pharmacy Epidemiology and Critical Evaluation	UBC, Faculty of Pharmaceutical Sciences	2014-2015
Member, CHEOS Internal Executive Committee	UBC & Providence Health Care Research Institute	2014 - ongoing
Member – Selection Committee – FoPS-LMFS Partner position	UBC, Faculty of Pharmaceutical Sciences	2014
Member – Selection Committee – FoPS-FH Partner Position	UBC, Faculty of Pharmaceutical Sciences	2014
Member – Search Committee – Associate Dean, Academic	UBC, Faculty of Pharmaceutical Sciences	2014-2015
Member – Selection Committee – FoPS-NH Partner position with Northern Health – Research & Development Pharmacists, Primary Care	UBC, Faculty of Pharmaceutical Sciences	2014

Member – Search Committee – Nutritional Epidemiologist	UBC, Faculty of Land and Food Systems	2013-14
Chair – Search Committee – Professorship in Health Care Sustainability	UBC, Faculty of Pharmaceutical Sciences	2012- 2013
Member – Pharmacist Clinic RFP Evaluation Committee	UBC, Faculty of Pharmaceutical Sciences	2012
Member – Professionalism Committee	UBC, Faculty of Pharmaceutical Sciences	2012 - 2015
Member – Early Career Scholar Adjudication Committee	UBC, Peter Wall Institute for Advanced Studies	2012
Member – CRC Search Committee	UBC, Faculty of Pharmaceutical Sciences	2011-2012
Member – Faculty Executive Committee	UBC, Faculty of Pharmaceutical Sciences	2010 - 2015
Member, Graduate Scholarship Selection Committee	UBC, Faculty of Pharmaceutical Sciences	2009 - 2015
Member - Merit Committee	UBC, Faculty of Pharmaceutical Sciences	2009 - 2015
Member, Research Committee	UBC, Faculty of Pharmaceutical Sciences	2005 - 2016
Chair (2009-2011), Bernie Riedel Golf Tournament Committee	UBC, Faculty of Pharmaceutical Sciences	2006 - 2015
Member, New Building Committee	UBC, Faculty of Pharmaceutical Sciences	2007 - 2010
Interviewer – Undergraduate Student Entrance Interviews	UBC, Faculty of Pharmaceutical Sciences	2006 – 2010

(b) *Other service, including dates*

1. Network Investigator, Allergen NCE (National Centre of Excellence), 2008 - ongoing
2. Affiliate, Centre for Health Care Management (UBC), 2007 - ongoing
3. MSc/PhD Student-Faculty Representative (appointed), Dept. of Health Care and Epidemiology, UBC 1998 - 2000
4. Graduate Education Committee Student Representative (appointed), Faculty of Medicine, UBC 1998 - 2002

11. SERVICE TO THE COMMUNITY

(a) *Memberships on scholarly societies, including offices held and dates*

Member – CIHR Institute of Genetics Advisory Committee – 2019 - ongoing
Member, Scientific Advisory Committee, CIHR GE3LS/Health Services and Policy Research Conference, 2014 - 2015
Member of the Board (elected), Canadian Association of Population Therapeutics, 2002 - 2007
Chair, Scientific Evaluation Committee, Canadian Association of Population Therapeutics, 2004 - 2005, 2009 -2010
Member, Scientific Program Committee, Canadian Association of Population Therapeutics, 2004 - 2005
Member, Annual Conference Scientific Program Committee, Canadian Association of Population Therapeutics, 2003 - 2004
Co-Chair, Scientific Evaluation Committee, Canadian Association of Population Therapeutics, 2003 - 2004
Member, American Thoracic Society
Member, Society for Medical Decision Making
Member, International Society for Outcomes Research

Member, International Society for Pharmacoepidemiology

Member, Canadian Pharmacists' Association

(b) *Memberships on other societies, including offices held and dates*

(c) *Memberships on scholarly committees, including offices held and dates*

Member, Pharmacy Examining Board of Canada Panel of Examiners, 2009 - 2016

Reviewer, Allied Health Researcher Fellowship Review Committee, Canadian Institutes for Health Research, 2006 - 2014

Member, MSFHR Population Health Research Fellowship Review Committee, Michael Smith Foundation for Health Research, 2006 - 2014

Member, Strategic Planning Committee, Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, 2004 - 2007

(d) *Memberships on other committees, including offices held and dates*

Provincial

Member, BC Health Authorities Provincial Pharmacy & Therapeutics Appeals Committee, 2011 - ongoing

Member, BC Health Authorities Provincial Pharmacy & Therapeutics Committee, 2009 - 2011

Member, BC Ministry of Health Expensive Drugs for Rare Diseases Committee (appointment); 2008 - ongoing

Member, Member BC College of Pharmacists PharmaNet Data Access Committee (appointment), 2007- 2012

National

Witness, The House of Commons' Standing Committee on Health, Development of a National Pharmacare program, December 2016

Member, Expert Advisory Committee on the Vigilance of Health Products, Health Products and Food Branch, Health Canada, 2012 - ongoing (appointed)

Chair, Health Canada Scientific Advisory Committee on Nonprescription Drugs (SAC-NPD), 2011 - 2015

Member, Expert Advisory Committee to Health Canada – Respiratory and Allergy Medicines, 2006 - ongoing

Member, National Drug Scheduling Advisory Committee member (appointment), National Association of Pharmacy Regulatory Authorities, 2001 - 2009

International

Next Steps working group on FDA benefit-risk assessment (Invited), 2007 – ongoing

Member, Executive Council, the Friends of Rwanda Forum, March 2013 - 2019

(e) *Editorships (list journal and dates)*

(f) *Reviewer (journal, agency, etc. including dates)*

Medical Decision Making	2005 – ongoing
Pharmacoepidemiology and Drug Safety	2004 - ongoing
Canadian Journal of Hospital Pharmacy	2000 - ongoing
Health Policy	2010
The Canadian Medical Association Journal	2006 - 2010
The Annals of Pharmacotherapy	2005- ongoing
The Canadian Journal of Public Health	2008
Canadian Journal of Emergency Medicine	2009
Canadian Medical Association Journal	2009 - 2011
Value in Health	2006 – ongoing

(g) *External examiner (indicate universities and dates)*

Student Name	Program Type	Date	University/Role
--------------	--------------	------	-----------------

Rakhee Raghundandan	Ph.D.	03/2021	University of Otago, Dunedin, New Zealand
Jennifer Donnon	Ph. D.	06/2019	Memorial University, Faculty of Pharmacy, External Examiner
Amynah Janmohamed	Ph.D.	11/2015	UBC, Faculty of Land and Food Systems/University External Examiner
Wasem Alsabbagh	Ph.D.	01/2015	University of Saskatchewan, College of Pharmacy/External Examiner
Meghan Gregg	M.Sc.	2012	McMaster/External Examiner
Gillian Hanley	Ph.D.	2011	UBC/ University External examiner
Marion Pearson	M.Sc.	2008	UBC/ University External examiner
Samantha Bowker	Ph.D. (UofA)	11/07	U of A/ External examiner – comprehensive exam
Jennifer Rose St. Onge	Ph.D.	12/2011	Thesis Committee chair, Oral Exam chair

(h) *Consultant (indicate organization and dates)*

1. Consultant, Sanofi-Aventis Canada, 2011 – ongoing
2. Consultant, BC Pharmacy Association (re: pharmacists' remuneration strategies), 2009–2011
3. Consultant, Pfizer Canada, Inc., 2009 – ongoing
4. Consultant, BC Provincial Health Services Authority (re: cost benefit analysis of providing cognitive behavior therapy), 2008 - 2011
5. Consultant, Therapeutic Products Directorate, Health Canada, 2005-2006
6. Consultant Glaxo Smith Kline, Novartis, 2004-2005, 2009-2010
7. Consultant, Office of Drug Safety, US Food and Drugs Administration, 2005 - ongoing
8. Consultant, Advertising Standards Canada, 2004 - ongoing
9. Consultant, Effectiveness/Cost effectiveness of anti-rejection drug therapy, BC Transplant Society, 2001-2002
10. Consultant/ Expert Witness British Columbia Coroner's Office, 1994-2001

(i) *Other service to the community*

Promotion Review. Dr. Byung.Kwang Yoo. UC Davis. November 2016.
 Tenure and Promotion Review – Dr. Todd Lee, University of Illinois, Chicago. Sept 2015.
 Tenure and Promotion Review – Dr. Daria O'Reilly, McMaster University, July 2012.

12. AWARDS AND DISTINCTIONS

(a) *Awards for Teaching (indicate name of award, awarding organizations, date)*

Teaching Scholarship, Faculty Certificate Program in Advanced and Higher Education, UBC, 2005
 Program Instructor Award, Faculty of Pharmaceutical Sciences Doctor of Pharmacy (PharmD), UBC, 2013

(b) *Awards for Scholarship (indicate name of award, awarding organizations, date)*

Name of Award	Organization	Date
John McNeill Excellence in Health Research Mentorship Award	University of British Columbia	2022
Fellow	Canadian Academy of Health Sciences	2018
Doctor of Pharmacy (PharmD) Program Instructor Award	Faculty of Pharmaceutical Sciences	2014-2015

Doctor of Pharmacy (PharmD) Program Instructor Award	Faculty of Pharmaceutical Sciences	2013
Publication Award – Research Article	Canadian Society of Hospital Pharmacists – BC Branch	2012
Early Career Scholar	Peter Wall Institute for Advanced Studies	2011
Specialties in Pharmacy Practice Award	Canadian Society of Hospital Pharmacists	2008
New Investigator Award	Canadian Institutes of Health Research	2006
Career Scholar Award (\$80,000/yr x 5 years)	Michael Smith Foundation for Health Research	2005
Post-Doctoral Fellowship (\$47,500/yr salary support, \$3,500/yr research allowance – 2 years. (Ranked No.1)	Canadian Institutes for Health Research (Peer Reviewed)	2003
Doctoral Trainee Award (\$16,000 / year – 1 year)	Michael Smith Foundation for Health Research (Peer Reviewed)	2002
Doctoral Fellowship Award (\$45,000/year salary support, \$3,500/year research allowance – 2 years)	Canadian Institutes for Health Research (Peer Reviewed)	2000
George R.F Elliot Fellowship in Community Health - \$7,500.	Dept. of Health Care and Epidemiology. University of British Columbia/ BC Medical Service Foundation (Peer-reviewed)	1999
Health Care and Epidemiology Alumni Association Scholarship - \$850. (<i>Scholarship for PhD students with First Class Standing in first 2 years of course work</i>)	Dept. of Health Care and Epidemiology Alumni Association	1999
John Snow Prize \$100 (<i>Highest standing in Epidemiology course HCEP 502</i>)	Dept. of Health Care and Epidemiology, University of British Columbia	1998
University Graduate Fellowship (<i>Awarded to top 10% of students in Graduate studies applying – \$16,000/yr x 2yrs.</i>)	University of British Columbia (peer reviewed)	1998 (Declined)
Medical Research Council of Canada/Canadian Drug Manufacturers Association Studentship (\$16,500/yr -4 years.	Medical Research Council of Canada/ Canadian Drug Manufacturers Association (peer-reviewed)	1997
Canadian Foundation for Pharmacy Past President's Award - \$750 (<i>Awarded to student in Pharmacy at a Canadian University selected for outstanding academic achievement and deemed most likely to succeed and contribute to the profession of pharmacy over their career</i>)	Canadian Foundation for Pharmacy	1986

(c) Awards for Service (indicate name of award, awarding organizations, date)

(d) Other Awards

BC Journalism Award for Science, Technology, Health & Environment, Milliondollarmeds Rare Diseases in Canada, Jack Webster Awards, 2016

Edward R. Murrow Award for Best Website (International Region), Milliondollarmeds Rare Diseases in Canada, Radio Television Digital News Association, 2016
Centennial Alumni of Influence Award, University of Saskatchewan College of Pharmacy and Nutrition, 2014
Best Paper Award, Canadian Pharmacists Journal, 2012

13. **OTHER RELEVANT INFORMATION** (Maximum One Page)

THE UNIVERSITY OF BRITISH COLUMBIA
Publications Record

SURNAME: Lynd

FIRST NAME: Larry

Initials: LDL

MIDDLE NAME(S): David

Date: October 2020

1. REFEREED PUBLICATIONS

Underlined designates student or trainee: Students and trainees are have been underlined in the following list of publications. In order to facilitate their career development, it has always been my philosophy to support and assist students in the development of their publication record. In this regard, where ever possible, I allow my students and trainees to be first authors on any publications where they participated significantly in the conceptualization, design, and manuscript preparation. In each instance, I have assumed either the second or anchor author position and am the senior and corresponding author.

Journal	Thompson-Reuters SciCitInx Impact Factor
Annals of Pharmacotherapy	2.45
Arthritis Care and Research	4.851
BioMedCentral Health Services Research	1.66
BioMedCentral Pulmonary Medicine	2.04
BMC Neurology	2.474
Canadian Journal of Psychiatry	2.5
Canadian Medical Association Journal	7.27
Canadian Respiratory Journal	1.556
Chest	5.25
Clinical and Applied Thrombosis/Hemostasis	1.332
Diabetes Technology and Therapeutics	1.931
Drug Development and Industrial Pharmacy	1.494
European Journal of Epidemiology	4.713
European Journal of Human Genetics	4.246
European Respiratory Journal	12.2
Genetic Medicine	4.762
Health Economics	2.123
Health Policy	2.980
Heart Rhythm	4.045
International Journal of Technology Assessment in Health Care	1.79
J Arthroplasty	2.11
J Asthma Allergy and Clinical Immunology	12.05
Journal of Asthma	1.37
Journal of Cardiovascular Electrophysiology	3.064
Journal of Clinical Epidemiology	4.271
Journal of Rheumatology	3.695
Journal of the American College of Cardiology	24.094
Journal of Telemedicine and Telecare	6.184
Molecular Genetics & Genomic Medicine	2.183
Multiple Sclerosis	5.855
Pediatrics	5.437
Pharmacoeconomics	2.663
Pharmacoepidemiology and Drug Safety	2.528
Pharmacotherapy	2.631

PLOS One	4.411
Psychotherapy and Psychosomatics	5.37
Quality of Life Research	2.3
Respiratory Research	3.36
Technological Forecasting and Social Change	8.593
Rheumatology	4.058
Value in Health	2.191

(a) *Journals*

1. Tam AC, Niak H, Trenaman L, **Lynd LD**, Wei Zhang. Health-related quality of life among women and men living with migraine: a Canada-wide cross-sectional study. *J Headache Pain*. 2024; 25. doi:10.1186/s10194-024-01882-4
2. Oh J, Arbour N, Giuliani F, Guenette M, Kolind S, **Lynd LD**, Ruth AM, Metz LM, Patten SB, Prat A, Schabas A, Smyth P, Tam R, Traboulee A, Wee Yong V. The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristics. *Therapeutic Advances in Neurological Disorders*. 2024;17. doi:10.1177/17562864241273045
3. Regier DA, Loewen R, Chan B, Ehman, M, Pollard S, Friedman JM, Stockler-Ipsiroglu S, van Karnebeek C, Race S, Elliott AM, Dragojlovic N, **Lynd LD**, Weymann D. Real-world diagnostic outcomes and cost-effectiveness of genome-wide sequencing for developmental and seizure disorders: evidence from Canada. *Gen Med* 2024; 26 (4): 101069. doi.org/10.1016/j.gim.2024.101069
4. Amegadzie JE, Lee TY, Sadatsafavi M, **Lynd LD**, Sin DD, Johnson KM. Trends in hospital admissions for chronic obstructive pulmonary disease over 16 years in Canada. *Can Med Assoc J*. 2023; 195(35):E1172-E1179. doi.org/10.1503/cmaj.221051
5. Salmasi S, Safari A, De Vera M, Hogg T, **Lynd LD**, Koehoorn M, Barry AR, Andrade JG, Deyell M, Rush KL, Zhao Y, Loewen P. Adherence to direct or vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a long-term observational study. *J Thrombosis Thrombolysis* 2024; 57: 437-44.
6. **Borle K**, Kopac N, Dragojlovic N, Rodriguez Llorian ER, **Lynd LD**, GenCOUNSEL Study. Defining need amid exponential change: conceptual challenges in workforce planning for clinical genetic services. *Clin Ther*. 2023; 45 (8): 695-701. doi: 10.1016/j.clinthera.2023.07.005.
7. **Ahmadian S**, Johnson KM, Ho JK, Sin DD, **Lynd LD**, Harrison M, Sadatsafavi M. A cost-effectiveness analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease. *Ann Am Thor Soc* 2023;20 (12): online.
8. Mohammadi T, Guh DP, Tam ACT, Pataky R, Black PC, So A, Lynd LD, Zhang W, Conklin AI. Economic evaluation of prostate cancer risk assessment methods: a cost-effectiveness analysis using population data. *Cancer Med* 2023; 12 (19): 20106 – 20118.
9. Greenfield J, Metz LM, Khakban A, Rodriguez-Llorian E, Michaux KD, Traboulee A, Oh J, Smyth P, Lynd LD, Bulloch AGM, Williams JVA, Patten SB. Cancer risk, disease-modifying therapy, and age in multiple sclerosis: a retrospective population-based cohort study. *Mult Scler Relat Disord* 2023; 80: 105091. DOI: 10.1016/j.msard.2023.105091
10. Dragojlovic N, **Borle K**, Kopac N, Nisselle A, Nuk J, Jevon M, Friedman JM, Elliot AM, **Lynd LD**. Workforce implications of increased referrals to hereditary cancer services in Canada: a scenario-based analysis. *Curr Oncol* 2023; 30: 7241 – 51. doi.org/10.3390/curroncol30080525
11. **Rodriguez-Llorian E**, Zhang W, Khakban A, Michaux K, Patten S, Traboulee A, Oh J, Shannon K, Prat A, Tam R, **Lynd LD**. Employment status, productivity loss, and associated factors among people with multiple sclerosis. *Mult Scler*. 2023; 29(7): 866-74. doi: 10.1177/13524585231164295

12. [Rodriguez-Llorian E](#), Waliji L, Dragojlovic N, Michaux K, Nagase F, **Lynd LD**. Frameworks for health technology assessments at an early stage of product development: a review and roadmap to guide applications. *Value Health* 2023; 26(8): 1258-69. doi: [10.1016/j.jval.2023.03.009](https://doi.org/10.1016/j.jval.2023.03.009)
13. [Rodriguez Llorian E](#), Kopac N, Waliji L, Borle K, Dragojlovic N, Elliot AM, **Lynd LD**. A rapid review on the value of biobanks containing genetic information. *Value Health* 2023; S1098-3015(23)00098-0. doi: [10.1016/j.jval.2023.02.017](https://doi.org/10.1016/j.jval.2023.02.017). PMID: 36921900 ePub ahead of print.
14. Zhang W, Guh DP, Mohammadi T, Pataky RE, Tam ACT, **Lynd LD**, Conklin AI. Health care costs attributable to prostate cancer in British Columbia, Canada: A population-based cohort study. *Curr Oncol.* 2023; 30(3):3176-3188. doi: [10.3390/curroncol30030240](https://doi.org/10.3390/curroncol30030240). PMID: 36975453.
15. Sirrs S, Anderson H, Jiwani B, **Lynd LD**, Lun E, Nakagawa B, Regier D, Rizzardo S, McFarlane A. Expensive drugs for rare diseases in Canada: What value and at what cost? *Healthc Pap.* 2023; 21(1): 10-26. doi: [10.12927/hcpap.2023.27000](https://doi.org/10.12927/hcpap.2023.27000)
16. Lam JS, **Lynd LD**, Marra CA. Pharmacists' satisfaction with work and working conditions in New Zealand—an updated survey and a comparison to Canada. *Pharmacy.* 2023, 11(1), 21; DOI: [10.3390/pharmacy11010021](https://doi.org/10.3390/pharmacy11010021).
17. [Grant P](#), Cook CB, Langlois S, Nuk J, Mung S, Zhang Q, GenCOUNSEL Study, **Lynd LD**, Austin J, Elliott AM. Evaluation of out-of-pocket pay genetic testing in a publicly funded healthcare system. *Clin Genet.* 2022; 1032(4): 424-33. doi: [10.1111/cge.14276](https://doi.org/10.1111/cge.14276). PMID: 36504324
18. Khakban A, [Rodriguez Llorian E](#), Michaux KD, Patten SB, Traboulee A, Oh J, **Lynd LD**. Direct healthcare costs associated with Multiple Sclerosis: A population-based cohort study from 2001-2020 in British Columbia, Canada. *Neurol.* 2022; 100 (9): e899 – e910. doi: [10.1212/WNL.0000000000201645](https://doi.org/10.1212/WNL.0000000000201645). PMID: 36450607
19. [Rodriguez Llorian E](#), Zhang W, Khakban A, Patten S, Traboulee A, Oh J, Kolind S, Prat A, Tam R, **Lynd LD**. Productivity loss among people with early multiple sclerosis: A Canadian study. *Mult Scler.* 2022 Aug;28(9):1414-1423.. PMID: 35137613. DOI: [10.1177/13524585211069070](https://doi.org/10.1177/13524585211069070)
20. [Rodriguez Llorian E](#), Dragojlovic N, Campbell T, Friedman J, Osiovich H., RAPIDOMICS Study, Elliott AM, **Lynd LD**. The impact of rapid exome sequencing on downstream healthcare utilization for infants with suspected genetic disorders in an intensive care unit. *Genet Med.* 2022; 24(8): 1675-83. PMID: 35622065 DOI: [10.1016/j.gim.2022.04.014](https://doi.org/10.1016/j.gim.2022.04.014).
21. Salmasi S, Hogg T, Safari A, De Vera M, **Lynd LD**, Moehorn M, Barry AR, Andrade JG, Loewen P. The random-effects warfarin days' supply (REWarDS) model: development and validation of a novel method for estimating exposure to warfarin using administrative data. *Am J Epidemiol.* 2022; 191(6): 1116-24. PMID: 35015808 DOI: [10.1093/aje/kwab295](https://doi.org/10.1093/aje/kwab295)
22. [Hategeka C](#), **Lynd LD**, Kenyon C, Tuyisenge L, Law MR. Impact of a multifaceted intervention to improve emergency care on newborn and child health outcomes in Rwanda. *Health Policy Plan.* 2022; 37(1): 12-21. PMID: 34459893 DOI: [10.1093/heapol/czab109](https://doi.org/10.1093/heapol/czab109)
23. Zhang W, Sun H, Guh DP, **Lynd LD**, Hollis A, Grootendorst P, Anis A. The impact of tiered pricing framework on generic entry in Canada. *Int J Health Policy Manag.* 2022; 11(6): 768-76. doi: [10.34172/ijhpm.2020.215](https://doi.org/10.34172/ijhpm.2020.215). PMID: 33233033
24. Salmasi S, de Vera MA, Safari A, **Lynd LD**, Koehoorn M, Barry AR, Andrade JG, Deyell MW, Rush K, Zhao Y, Loewen P. Longitudinal oral anticoagulant adherence trajectories in patients with atrial fibrillation. *J Am Coll Cardiol* 2021; 78 (24) 2395–2404. PMID: 34886959. DOI: <https://www.jacc.org/doi/full/10.1016/j.jacc.2021.09.1370>

25. Cook CB, Dragojlovic N, Siemens A, Adam S, du Souich C, van Karnebeek C, Lehman A, Nelson TN, Friedman J, **Lynd LD**, Elliott AM. Integration of genetic counsellors in genomic testing triage: Outcomes of a genomic consultation service in British Columbia, Canada. *Eur J Med Genet.* 2021;64(7): 104024. doi: 10.1016/j.ejmg.2020.104024. PMID: 32798762
26. Borle K, Kopac N, Dragojlovic N, Rodriguez-Llorian E, Friedman JM, GenCOUNSEL Study, Elliot AM, **Lynd LD**. Where is genetic medicine headed? Exploring the perspectives of Canadian genetic professionals on future trends using the Delphi method. *Eur J Hum Genetics* 2021; 30:496-504. PMID: 35031678 DOI: <https://doi.org/10.1038/s41431-021-01017-2>
27. Douglas CMW, Panagiotoglou D, Dragojlovic N, **Lynd LD**. Methodology for constructing scenarios for health policy research: The case of coverage decision-making for drugs for rare diseases in Canada. *Technol Forecast Soc Change* 2021; 171 (120960): <https://doi.org/10.1016/j.techfore.2021.120960>
28. Oh J, Arbour N, Giuliani F, Guenette M, Kolind S, **Lynd LD**, Ruth AM, Metz LM, Patten SB, Prat A, Schabas, A, Smyth P, Tam, R, Traboulsee A, Wee Yong V. The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design. *BMC Neurol* 2021; 21 (418): PMID: 34706670 PMCID: PMC8549411 DOI: <https://doi.org/10.1186/s12883-021-02447-7>
29. Enns E, Wainstein T, Dragojlovic N, Kopac N, GenCOUNSEL Study, **Lynd LD**, Elliot AM. Far and wide: exploring provider utilization of remote service provision for genome-wide sequencing in Canada: a substudy of GenCOUNSEL study. *Mol Genet Genomic Med.* 2021 Oct;9(10):e1784. PMID: 34532994 PMCID: PMC8580085 DOI: <https://doi.org/10.1002/mgg3.1784>
30. Bansback N, Chiu JA, Metcalfe R, Lapointe E, Schabas A, Lenzen M, Traboulsee A, **Lynd LD**, Carruthers R. Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis. *Mult Scler J Exp Transl Clin.* 2021 Jul 15;7(3):20552173211029966. doi: 10.1177/20552173211029966. eCollection Jul-Sep 2021. PMID: 34350027 DOI: [10.1177/20552173211029966](https://doi.org/10.1177/20552173211029966)
31. Ho JK, Borle K, Dragojlovic N, Dhillon M, Kitchin V, Kopac N, Ross C, **Lynd LD**. Economic evidence of potential curative gene therapy products: a systematic literature review. *PharmacoEconomics* 2021; 39(9): 995-1019. PMID: 34156648 DOI: doi.org/10.1007/s40273-021-01051-4.
32. Grant P, Langlois S, **Lynd LD**, GenCOUNSEL Study, Austin JC, Elliott AM. Out of pocket and private pay in clinical genetic testing: a scoping review. *Clin Genet.* 2021 Nov;100(5):504-521. doi: 10.1111/cge.14006. PMID: 34080181
33. Dragojlovic N, Kopac N, Borle K, Tandun R, Salmasi S, Ellis U, Birch P, Adan S, Friedman J, Elliot AM, **Lynd LD**. Utilization and uptake of clinical genetics services in high income countries: a scoping review. *Health Policy.* 2021 Jul;125(7):877-887. doi: 10.1016/j.healthpol.2021.04.010. PMID: 33962789
34. Sadatsafavi M, Khakban A, Tavakoli H, Ehteshami-Afshar S, **Lynd LD**, FitzGerald JM. Trends in oral corticosteroid use in severe asthma: a 14-year population-based study. *Respir Res.* 2021;22(1):103. doi: 10.1186/s12931-021-01696-x. PMID: 33836765
35. Pollard S, Weyman D, Dunne J, Mayanloo F, Buckell J, Buchanan J, Wordsworth S, Friedman JM, Stockler-Ipsiroglu S, Dragojlovic N, Elliot AM, Harrison M, **Lynd LD**, Regier DA. Toward the diagnosis of rare childhood genetic diseases: what to patients value most. *Eur J Hum Genet.* 2021;29(10):1491-1501. PMID: 33903739. DOI: [10.1038/s41431-021-00882-1](https://doi.org/10.1038/s41431-021-00882-1)
36. Elliott AM, Dragojlovic N, Campbell T, Adam S, du Souich C, Fryer M, Lehmann A, van Karnebeek C, **Lynd LD**, Frieman J. Utilization of telehealth in pediatric genome-wide sequencing: healthier services implementation issues in the CAUSES study. *J Telemed Telehealth.* 2021; 29 (4): 318-327. PMID: 33470133 DOI: [10.1177/1357633X20982737](https://doi.org/10.1177/1357633X20982737)

37. Yamoah L, Dragojlovic N, Smith, A, **Lynd LD**, Marra C. Evaluating New Zealanders' values for drug coverage decision-making: tradeoffs between treatments for rare and common conditions. *PharmacoEconomics*. 2020; 39 (1): 109-19. doi: 10.1007/s40273-020-00974-8. PMID: 33150565
38. Hategeka C, Ruton H, Karamouzian M, **Lynd LD**, Law MR. Use of interrupted time series methods in the evaluation of health system quality improvement interventions: a methodologic systematic review. *BMJ Global Health* 2020;5:e003567. PMID: 33055094 PMCID: PMC7559052 DOI: 10.1136/bmjgh-2020-003567
39. Johnson KM, Sadatsafavi M, Adibi A, **Lynd LD**, Harrison M, Tavakoli H, Sin DD, Bryan S. Cost-effectiveness of case detection strategies for the early detection of COPD. *App Health Econ Health Policy*. 2020; 19:203-15. PMID: 33135094 DOI: 10.1007/s40258-020-00616-2
40. Sadatsafavi M, McCormack J, Petkau J, **Lynd LD**, Lee TY, Sin DD. Should the number of acute exacerbations in the previous year be used to guide treatments in COPD? *Eur Respir J*. 2021 Feb 11;57(2):2002122. PMID: 32855228 PMCID: PMC7876420 DOI: 10.1183/13993003.02122-2020
41. Chen W, Sadatsafavi M, FitzGerald JM, **Lynd LD**, Sin DD. Gender modifies the effect of body mass index on lung function decline in mild to moderate COPD patients: a pooled analysis. *Resp Res* 2021; 22 (59). <https://doi.org/10.1186/s12931-021-01656-5>
42. Dragojlovic N, Borle K, Kopac N, Ellis U, Birch P, Adam S, Friedman JM, Nisselle A, GenCOUNSEL Study, Elliott AM, **Lynd LD**. The composition and capacity of the clinical genetics workforce in high-income countries: a scoping review. *Genet Med* 2020; 22: 1437-49. PMID: 32576987 DOI: 10.1038/s41436-020-0825-2
43. Tsao, NW, Salmasi S, Li K, Nakagawa B, **Lynd LD**, Marra CA. Pharmacists' perceptions of their working conditions and the factors influencing this: Results from 5 Canadian provinces. *Canadian Pharmacists Journal / Revue Des Pharmaciens Du Canada*. 2020; 153(3), 161–169. PMID: 32528600 PMCID: PMC7265587 DOI: 10.1177/1715163520915230
44. Tsao NW, Rebic N, **Lynd LD**, De Vera MA. Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: A systematic review and meta-analysis of observational studies. *Rheumatology (Oxford)* 2020; 59 (8): 1808-17. PMID: 32118278
45. Dragojlovic N, Michaux KD, Moumin N, Li KH, Talukder A, Hou K, Mundy G, Stormer A, Ngik R, Green TJ, **Lynd LD**. Economic evaluation of an enhanced homestead food production intervention for undernutrition in women and children in rural Cambodia. *Global Food Security*. 2020; 24: 100335. doi: 10.1016/j.gfs.2019.100335.
46. Zhang W, Li KH, Gobis, B, Zed PJ, **Lynd LD**. Work productivity losses and associated risk factors among university employees in the CAMMPUS wellness program. *J Occup Environ Med*. 2020 Jan; 62 (1), 25-29. doi: 10.1097/JOM.0000000000001734. PMID: 31651600
47. Dragojlovic N, van Karnebeek C, Ghani A, Genereaux D, Kim E, Birch P, Elliott AM, Friedman JM, **Lynd LD**. The cost trajectory of the diagnostic care pathway for children with suspected genetic disorders. *Genet Med*. 2020; 22 (2), 292-300. doi: 10.1038/s41436-019-0635-6. PMID: 31462755
48. Michaux KD, Hou K, Karakochuk CD, Whitfield KC, Ly S, Verbowski V, Stormer A, Porter K, Li KH, Houghton LA, **Lynd LD**, Talukder A, McLean J, Green TJ. Effect of enhanced homestead food production on anemia among Cambodian women and children: A cluster randomized controlled trial. *Matern Child Nutr*. 2019; 15(S3) :e12757. . doi: 10.1111/mcn.12757. PMID: 31148398
49. Salmasi S, Tsao NW, Li K, Shaske J, Marra CA *, **Lynd LD** * (*shared correspondence). Characterization of pharmacist-based medication management services in a community pharmacy. *Res Soc Adm Pharm*. 2020 Feb; 16 (2): 178-82. doi: 10.1016/j.sapharm.2019.04.051. PMID: 31060791

50. Tsao NW, Hanley GE, **Lynd LD**, Amiri N, de Vera MA. Risk of congenital anomalies in infants born to women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. *Clin Exp Rheum* 2019; [37](#) (6): 976-82. PMID: 30943142
51. Raymakers AJN, Sadatsafavi M, Sin DD, FitzGerald JM, Marra CA, **Lynd LD**. Inhaled corticosteroids and the risk of lung cancer in chronic obstructive pulmonary disease (COPD): a population-based cohort study. *Eur Resp J*. 2019 Jun 5;53(6). pii: 1801257. doi: 10.1183/13993003.01257-2018. PMID: 30956205
52. Salmasi S, de Vera MA, Barry A, Bansback N, Harrison M, **Lynd LD**, Loewen PS. Assessment of condition and medication knowledge gaps among atrial fibrillation patients: a systematic review. *Ann Pharmacother*. 2019. 53(8): 773-785. doi: 10.1177/1060028019835845. PMID: 30835335
53. Loewen P, Bansback N, Hicklin J, Andrade JG, Kapanen AI, Kwan L, **Lynd LD**, McClean A, MacGillivray J, Salmasi S. Evaluating the effect of a patient decision aid for atrial fibrillation stroke prevention therapy. *Ann Pharmacother*. 2019; 53(7): 665-674. doi: 10.1177/1060028019828420. PMID: 30724102
54. Rizzardo S, Bansback N, Dragojlovic N, Douglas C, Mitton C, Marra, C, Blanis L, **Lynd LD**. Evaluating Canadians' values for drug coverage decision-making. *Value Health*. 2019 Mar;22(3):362-369. doi: 10.1016/j.jval.2018.08.008. Epub 2018 Nov 27. PMID: 30832975
55. Tsao NW, **Lynd LD**, Sayre EC, Sadatsafavi M, Hanley G, De Vera MA. Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based study. *BMJ Open*. 2019 Feb 20;9(2):e023714. doi: 10.1136/bmjopen-2018-023714. PMID: 30787081
56. Hannah-Shmouni F, Stratakis CA, Sechi A, Langeveld M, Hiwot TG, Tchan MC, Mochel F, Lynd LD, Sirrs S. Subspecialty training in adult inherited metabolic diseases: a call to action for unmet needs. *Lancet Diabetes Endocrinol*. 2019 Feb;7(2):82-84. doi: 10.1016/S2213-8587(18)30369-3. PMID: 30683215
57. Bansback N, Chiu JA, Carruthers R, Metcalfe R, Lapointe E, Schabas A, Lenzen M, **Lynd LD**, Traboulee A. Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients. *BMC Neurol*. 2019 Jul 20;19(1):173. doi: 10.1186/s12883-019-1382-7. PMID: 31325961
58. Ehteshami-Afshar S, Zafari Z, Hamidi N, FitzGerald JM, **Lynd LD**, Sadatsafavi M. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions. *Value Health*. 2019 Sep;22(9):1070-1082. doi: 10.1016/j.jval.2019.03.016. PMID: 31511184
59. Khakban, A, Fitzgerald, JM, Tavakoli, H, **Lynd LD**, Ehteshami-Afshar S, Sadatsafavi M. Extent, trends, and determinants of controller/reliever balance in mild asthma: a 14-year population-based study. *Respir Res*. 2019 Feb 28;20(1):44. doi: 10.1186/s12931-019-1007-0. PMID: 30819154
60. Khakban A, Mohammadi T, **Lynd LD**, Mabbott DJ, Bouffet E, Gastonguay L, Zafari Z, Malkin D, Taylor MD, Marra CA. How do parents and providers trade-off between disability and survival? Preferences in the treatment of pediatric medulloblastoma. *Patient Prefer Adherence*. 2018 Oct 10;12:2103-2110. doi: 10.2147/PPA.S168739. PMID: 30349204
61. Ling D, **Lynd LD**, Harrison M, Anis AH, Bansback N. Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies. *J Comp Eff Res*. 2019 Jan;8(1):7-19. doi: 10.2217/ceer-2018-0033. PMID: 30525982
62. Gobis B, Kapanen AI, Reardon J, Min J, Li KH, **Lynd LD**, Zed PJ. Cardiovascular risk-reduction in the workplace with CAMMPUS (Cardiovascular Assessment and Medication Management by Pharmacists at the UBC Site). *Ann Pharmacother* 2019 Jun;53(6):574-580. doi: 10.1177/1060028018823330. PMID: 30638031
63. Salmasi S, Kwan L, MacGillivray J, Bansback N, de Vera M, Barry AR, Harrison MJ, Andrade J, **Lynd LD**, Loewen P. Assessment of atrial fibrillation patients' education needs from patient and clinician perspectives: a qualitative study. *Throm Res* 2019; 173:109-116. doi: 10.1016/j.thromres.2018.11.015. PMID: 30502679

64. Chen W, FitzGerald JM, **Lynd LD**, Sin DD, Sadatsafavi M. Long-term trajectories of mild asthma in adulthood and risk factors of progression. *Int J Allergy Clin Immunol: In Practice*. 2018 Nov-Dec;6(6): 2024-2032.e5. doi: 10.1016/j.jaip.2018.04.027. PMID: 29746917
65. Dragojlovic N, Elliott AM, Adam S, Van Karnebeek C, Lehman A, Mwenifumbo JC, Nelson TN, Du Souich C, Friedman JM, **Lynd LD**. The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study. *Genet Med*. 2018; 20(9): 1013 – 1021. PMID: 29300375
66. **Lynd LD**, Henrich NJ, Hategeka C, Marra CA, Mittmann N, Evans C, Traboulsee T. Perspectives of patients with multiple sclerosis on drug treatment: a qualitative study. *Int J MS Care*. 2018; 20 (6): 269-77doi: 10.7224/1537-2073.2017-109. PMID: 30568564
67. Hategeka C, Taboulee AL, McMullen K, **Lynd LD**. Association of unemployment and informal care with stigma in multiple sclerosis: evidence from the survey on living with neurological conditions in Canada. *Int J MS Care*. 2019 Sep-Oct, 21(5):214-225. doi: 10.7224/1537-2073.2017-108. PMID: 31680783.
68. Elliott AM, du Souich C, Adam S, Dragojlovic N, van Karnebeek C, Nelson TN, Lehman A, **Lynd LD**, Friedman JM. The Genomic Consultation Service: A clinical service designed to improve patient selection for genome-wide sequencing in British Columbia. *Mol Genet Genomic Med*. 2018 May;6(4):592-600 DOI: 10.1002/mgg3.410. PMID: 29851296
69. Najafzadeh, M, Ungar WJ, Hadioonsadeh A, Tsao N, **Lynd LD**. Comparing different experimental designs for best-worst scaling choice experiments: the case of asthma control. *Int J Health Pref Res* 2018 May;1:3-16 doi: 10.21965/IJHPR.2018.001.
70. Dragojlovic N, Kim E, Elliott A, Friedman J, **Lynd LD**. Evaluating the use of parental reports to estimate healthcare resource utilization in children with suspected genetic disorders. *J Eval Clin Pract*. 2018 Apr;24(2):416-422. doi: 10.1111/jep.12876. PMID: 29603523
71. Tavakoli H, FitzGerald JM, **Lynd LD**, Sadatsafavi M. Predictors of inappropriate and excessive use of reliever medications in asthma: a 16 year population based- study. *BMC Pulm Med*. 2018 Feb 12;18(1):33. doi: 10.1186/s12890-018-0598-4. PMID: 29433489
72. Tsao NW, Sayre EC, Hanley G, Sadatsafavi M, **Lynd LD**, Marra CA, De Vera MA. Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. *Ann Rheum Dis*. 2018; 77(6): 869-74. . doi: 10.1136/annrheumdis-2018-213023. PMID: 29496718
73. Verbowski V, Talukder Z, Hou K, Sok Hoing, L, Michaux K, Anderson V, Gibson R, Li K, **Lynd LD**, McLean J, Green, TJ, Barr S. Effect of enhanced homestead food production and aquaculture on dietary intakes of women and children in rural Cambodia: a cluster randomized controlled trial. *Matern Child Nutr*. 2018 Jul; 14(3):e12581. doi: 10.1111/mcn.12581. PMID: 29314705
74. Moumin NA, Hou K, Michaux KD, Stormer A, Mundy G, Porter K, Li H, **Lynd LD**, Talukder Z, Green T. Impact of enhanced homestead food production program on household food production and dietary intake of women aged 15-49 year and children aged 6-59 months: a pragmatic, delayed cluster randomized controlled trial protocol. *Int J Clin Trials*. 2017;4(4):157-165. doi: 10.18203/2349-3259.ijct20174863
75. Tsao NW, **Lynd LD**, Sadatsafavi M, Hanley G, De Vera MA. Patterns of biologics utilization and discontinuation before and during pregnancy in women with autoimmune diseases: A population-based cohort study. *Arthritis Care Res (Hoboken)*. 2018; 70(7): 979-986. doi: 10.1002/acr.23434. PMID: 28973840
76. Fitzgerald JM, Tavakoli H, **Lynd LD**, Al Efraij K, Sadatsafavi M. The impact of inappropriate use of short acting beta agonists in asthma. *Respir Med*, 2017 Oct; 131:135 - 140. doi: 10.1016/j.rmed.2017.08.014. PMID: 28947020

77. Patel AR, Lester RT, Marra CA, van der Kop ML, Ritvo P, Engel L, Karanja S, **Lynd LD**. The validity of the SF-12 and SF-6D instruments in people living with HIV/AIDS in Kenya. *Health Qual Life Outcomes*. 2017 Jul 17;15(1):143. doi: 10.1186/s12955-017-0708-7. PMID: 28716065
78. Mohammadi T, Bansback N, Marra F, Khakban A, Campbell JR, FitzGerald JM, **Lynd LD**, Marra CA. Testing the external validity of a discrete choice experiment method: an application to latent tuberculosis infection treatment. *Value Health*. 2017 July. 20(7): 969-975. doi.org/10.1016/j.jval.2017.04.007. PMID: 28712627
79. Polisen J, Burgess M, Mitton C, **Lynd LD**. Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey. *BMC Health Serv Res*. 2017 May 26;17(1):372. doi: 10.1186/s12913-017-2310-4. PMID: 28549479
80. Magarinos-Torres R, **Lynd LD**, Luz TCB, Marques PEPC, Osorio-de-Castro CGS. Essential medicines list implementation dynamics: a case study using Brazilian federal medicines expenditures. *Basic Clin Pharmacol Toxicol*. 2017 Sep;121(3):181-188. doi: 10.1111/bcpt.12783. Epub 2017 May 18. PMID: 28371342
81. Hategeka C, Shoveller J, Tuyisenge L, **Lynd LD**. Assessing process of paediatric care in a resource-limited setting: a cross-sectional audit of district hospitals in Rwanda. *Paediatr Int Child Health*. 2017 Mar 27; 38(2):137-145. doi: 10.1080/20469047.2017.1303017. PMID: 28346109
82. Marra CA, Harvard S, Grubisic M, Galo J, Clarke A, Elliot S, **Lynd LD**. Consumer preferences for food allergen labelling. *Allergy Asthma Clin Immunol*. 2017 Apr 4;13:19. doi: 10.1186/s13223-017-0189-6. eCollection 2017. PMID: 28392808
83. Hategeka C, Shoveller JA, Tuyisenge L, Kenyon C, Cechetto D, **Lynd LD**. Pediatric emergency care capacity in a low-resource setting: an assessment of district hospitals in Rwanda. *PLoS One*. 2017 Mar 3;12(3):e0173233. doi: 10.1371/journal.pone.0173233. eCollection 2017. PMID: 28257500
84. Raymakers AJ, Sadatsafavi M, Sin D, De Vera MA, **Lynd LD**. The impact of statin use on all-cause mortality in patients with COPD: a population based cohort study. *Chest*. 2017 Feb 12. pii: S0012-3692(17)30194-0. doi: 10.1016/j.chest.2017.02.002. [Epub ahead of print]. PMID: 27815152
85. Raymakers AJ, McCormick N, Marra CA, Fitzgerald JM, Sin D, **Lynd LD**. Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review. *Respirology*. 2017 Jan;22(1):61-70. doi: 10.1111/resp.12919. PMID: 27761973
86. Dragojlovic N, **Lynd LD**. What will the crowd fund? Preferences of prospective donors for drug development fundraising campaigns. *Drug Discov Today*. 2016 Dec;21(12):1863-1868. doi: 10.1016/j.drudis.2016.07.002. PMID: 27422268
87. Khakban A, Mohammadi T, **Lynd LD**, Mabbott D, Bouffet E, Gastonguay L, Zafari Z, Malkin D, Taylor M, Marra CA. Societal preferences in the treatment of pediatric medulloblastoma: Balancing risk of death and quality of life. *Pediatr Blood Cancer*. 2016 Dec 4. doi: 10.1002/pbc.26340. [Epub ahead of print]. PMID: 27917595
88. Whitfield KC, Karakochuk CD, Kroeun H, Sokhoing L, Chan BB, Borath M, Sophonneary P, Moore K, Tong JK, McLean J, Talukder A, **Lynd LD**, Li-Chan EC, Kitts DD, Green TJ. Household consumption of thiamin-fortified fish sauce increases erythrocyte thiamin concentrations among rural Cambodian women and their children under 5 years: a randomized controlled efficacy trial. *J Pediatr*. 2016 Dec 6. pii: S0022-3476(16)31200-8. doi: 10.1016/j.jpeds.2016.10.066. [Epub ahead of print]. PMID: 27939124
89. Sadatsafavi M, Tavakoli H, **Lynd LD**, FitzGerald JM. Has asthma medication use caught up with the evidence? A 12-year population-based study of trends. *Chest*. 2016 Nov 1. pii: S0012-3692(16)62294-8. doi: 10.1016/j.chest.2016.10.028. [Epub ahead of print]. PMID: 27815152
90. Whitfield KC, Karakochuk CD, Kroeun H, Hampel D, Sokhoing L, Chan BB, Borath M, Sophonneary P, McLean J, Talukder A, **Lynd LD**, Li-Chan EC, Kitts DD, Allen LH, Green TJ. Perinatal consumption of thiamine-fortified fish

- sauce in rural Cambodia: a randomized clinical trial. *JAMA Pediatr.* 2016 Oct 3;170(10):e162065. doi: 10.1001/jamapediatrics.2016.2065. PMID: 27532780.
91. Tavakoli H, FitzGerald JM, Chen W, **Lynd LD**, Kendzerska T, Aaron S, Gershon A, Marra C, Sadatsafavi M. Ten-year trends in direct costs of asthma: a population-based study. *Allergy.* 2017 Feb;72(2):291-299. doi: 10.1111/all.12993.. PMID: 27455382.
 92. Tsao NW, Khakban A, Gastonguay L, Zafari Z, **Lynd LD**, Marra CA. Opinions and preferences of British Columbia pharmacists and physicians on medication management services. *Can Pharm J.* 2016 Oct 12;150(1):42-51. doi: 10.1177/1715163516671746.PMID: 28286592
 93. Chen W, **Lynd LD**, FitzGerald JM, Marra CA, Balshaw R, To T, Sadatsafavi M. Excess medical costs in patients with asthma and the role of comorbidity. *Eur Respir J.* 2016 Dec;48(6):1584-1592. doi: 10.1183/13993003.01141-2016. PMID: 27824603
 94. Zhang W, Guh D, Sun H, Marra CA, **Lynd LD**, Anis AH. The impact of price-cap regulations on exit by generic pharmaceutical firms. *Med Care.* 2016 Sep;54(9):884-90. doi: 10.1097/MLR.0000000000000577. PMID: 27213540
 95. **Lynd LD**, Traboulsee A, Marra CA, Mittmann N, Evans C, Li KH, Carter M, Hategekimana C. Quantitative analysis of multiple sclerosis patients' preferences for drug treatment: a best-worst scaling study. *Ther Adv Neurol Disord.* 2016 Jul;9(4):287-96. doi: 10.1177/1756285616648060. Epub 2016 May 15. PMID: 27366235
 96. Hategekimana C, Shoveller J, Tuyisenge L, Kenyon C, Cechetto DF, **Lynd LD**. Correlates of performance of healthcare workers in Emergency, Triage, Assessment and Treatment plus Admission Care (ETAT+) course in Rwanda: context matters. *PLoS One.* 2016 Mar 31;11(3):e0152882. doi: 10.1371/journal.pone.0152882. PMID: 27030974.
 97. Chen W, Marra CA, **Lynd LD**, FitzGerald JM, Zafari Z, Sadatsafavi M. The natural history of severe asthma and influences of early risk factors: a population-based cohort study. *Thorax.* 2016 Mar;71(3):267-75. doi: 10.1136/thoraxjnl-2015-207530. PMID: 26732738.
 98. Chen W, **Lynd LD**, FitzGerald JM, Sadatsafavi M. Influences of socioeconomic status on costs of asthma under universal health coverage. *Med Care.* 2016 Aug;54(8):789-95. doi: 10.1097/MLR.0000000000000563. PMID: 27213543
 99. Leung VW, Soon JA, **Lynd LD**, Marra CA, Levine M. Population-based evaluation of the effectiveness of two regimens for emergency contraception. *Int J Gynaecol Obstet.* 2016 Jun;133(3):342-6. doi: 10.1016/j.ijgo.2015.10.017. PMID: 26969148
 100. Harvey-Leeson S, Karakochuk CD, Hawes M, Tugirimana PL, Bahizire E, Akilimali PZ, Michaux KD, **Lynd LD**, Whitfield KC, Moursi M, Boy E, Foley J, McLean J, Houghton LA, Gibson RS, Green TJ. Anemia and micronutrient status of women of childbearing age and children 6-59 Months in the Democratic Republic of the Congo. *Nutrients.* 2016 Feb 17;8(2). pii: E98. doi: 10.3390/nu8020098. PMID: 26901219.
 101. Raymakers AJ, Mayo J, Lam S, FitzGerald JM, Whitehurst DG, **Lynd LD**. Cost-effectiveness analyses of lung cancer screening strategies using low-dose computed tomography: a systematic review. *Appl Health Econ Health Policy.* 2016 Aug;14(4):409-18. doi: 10.1007/s40258-016-0226-5. PMID: 26873091
 102. Tsao NW, **Lynd LD**, Gastonguay L, Li K, Nakagawa B, Marra CA. Factors associated with pharmacists' perceptions of their working conditions and safety and effectiveness of patient care. *Can Pharm J (Ott).* 2016 Jan;149(1):18-27. doi: 10.1177/1715163515617777. PMID: 26798374.
 103. Ungar WJ, Hadioonzadeh A, Najafzadeh M, Tsao NW, Dell S, **Lynd LD**. Parents and adolescents preferences for asthma control: A best-worst scaling choice experiment using an orthogonal main effects design. *BMC Pulm Med.* 2015;15:146. doi: 10.1186/s12890-015-0141-9. PMID: 26577906

104. McDonald CM, McLean J, Kroeun H, Talukder A, **Lynd LD**, Green TJ. Household food insecurity and dietary diversity as correlates of household food insecurity and low dietary diversity in rural Cambodia. *Asia Pac J Clin Nutr*. 2015;24(4):720-30. doi: 10.6133/apjcn.2015.24.4.14. PMID: 26693758.
105. Tsao **NW**, Khakban A, Gastonguay L, Li K, **Lynd LD**, Marra CA. Perceptions of British Columbia residents and their willingness to pay for medication management services provided by pharmacists. *Can Pharm J (Ott)*. 2015;148(5):263-73. doi:10.1177/1715163515597244. PMID:26445585
106. O'Hara NN, **Roy L**, O'Hara LM, Spiegel JM, **Lynd LD**, FitzGerald JM, Yassi A, Nophale LE, Marra CA. Healthcare worker preferences for active tuberculosis case finding programs in South Africa: A best-worst scaling choice experiment. *PLoS One*. 2015 Jul 21;10(7):e0133304. doi: 10.1371/journal.pone.0133304. eCollection 2015. PMID: 26197344
107. **Chen W**, **Lynd LD**, FitzGerald JM, Marra CA, Rousseau R, Sadatsafavi M. The added effect of comorbidity on health-related quality of life in patients with asthma. *Qual Life Res*. 2015 Oct;24(10):2507-17. doi: 10.1007/s11136-015-0995-6. Epub 2015 Jun 3. PMID: 26038225
108. Law MR, Cheng L, Kratzer J, Morgan SG, Marra C, **Lynd LD**, Majumdar SM. Impact of allowing pharmacists to independently renew prescriptions: a population-based study. *J Am Pharm Ass*. 2015;55:e333-e339. doi:10.1331/JAPhA.2015.14262. PMID: 26197344
109. Dionne F, Mitton C, Dempster B, **Lynd LD**. Developing a multi-criteria approach for drug reimbursement decision making: an initial step forward. *J Pop Ther Clin Pharmacol*. 2015 Feb 12;22(1):e68-e77. Epub 2015 Feb 12. PMID: 25715383
110. **Douglas CMW**, **Wilcox E**, Burgess M, **Lynd LD**. Why orphan drug coverage reimbursement decision-making needs patient and public involvement. *Health Policy*. 2015 May;119(5):588-96. doi:org/10.1016/j.healthpol.2015.01.009. Epub 2015 Jan 19 PMID: 25641123
111. **Dragojlovic N**, Rizzardo S, Bansback N, Mitton C, Marra CA, **Lynd LD**. Challenges in measuring the societal value of orphan drugs: insights from a Canadian stated preference survey. *Patient*. 2015;8(1):98-101. doi:10.1007/s40271-014-0109-5. PMID: 25586645
112. Sadatsafavi M, **Lynd LD**, De Vera MA, **Zafari Z**, FitzGerald JM. One-year outcomes of inhaled controller therapies added to systemic corticosteroids after asthma-related hospital discharge. *Respir Med*. 2015 Mar;109(3):320-8. doi: 10.1016/j.rmed.2014.12.014. Epub 2015 Jan 7. PMID: 25596136
113. De Vera MA, Sadatsafavi M, **Tsao NW**, **Lynd LD**, Lester R, Gastonguay L, Galo J, FitzGerald JM, Brasher P, Marra CA. Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): study protocol for a randomized controlled trial. *Trials*. 2014 Dec 13;15:488. doi: 10.1186/1745-6215-15-488. PMID: 25494702
114. Whitfield KC, Karakochuk CD, Liu Y, McCann A, Talukder A, Kroeun H, Ward M, McNulty H, **Lynd LD**, Kitts DD, Li-Chan ECY, McLean J, Green TJ. Poor thiamin and riboflavin status is common among women of childbearing age in rural and urban Cambodia. *Journal of Nutrition*. 2015 Mar;145(3):628-33. doi: 10.3945/jn.114.203604. Epub 2015 Jan 7. PMID: 25733481
115. Brown KM, Fenton NE, **Lynd LD**, Marra CA, FitzGerald MJ, Harvard SS, Rosenthal M, Chow BYL, Clarke AE, Elliott SJ. Canadian policy on food allergen labelling: Consumers' perspectives regarding unmet needs. *Universal Journal of Public Health*. January 2015; 3(1):41-48. DOI: 10.13189/ujph.2015.030106.
116. Trenaman L, Sadatsafavi M, Almeida F, Ayas N, **Lynd LD**, Marra C, Stacey D, Bansback N. Exploring the potential cost-effectiveness of patient decision aids for use in adults with obstructive sleep apnea: a case study. *Med Decis Making*. 2014 Jul; 35(5):671-82. doi: 10.1177/0272989X14556676. Epub 2014 Oct 24. PMID: 25344130
117. **Dragoljovic N**, **Lynd LD**. Crowdfunding drug development: the state of play in oncology and rare diseases. *Drug Discov Today*. 2014 Nov;19(11):1775-1780. doi: 10.1016/j.drudis.2014.06.019. PMID: 24973645

118. [Bansback N](#), Li LC, **Lynd LD**, Bryan S. Development and preliminary user testing of the DCIDA (Dynamic computer interactive decision application) for ‘nudging’ patients towards high quality decisions. *BMC Med Inform Decis Mak*. 2014 Aug 1;14:62. PMID: 25084808
119. McDonald CM, McLean J, Kroeun H, Talukder A, **Lynd LD**, Green TJ. Household food insecurity and dietary diversity as correlates of maternal and child undernutrition in rural Cambodia. *European J of Clin Nutrition*. 2015 Feb;69(2):242-6. doi: 10.1038/ejcn.2014.161 Epub 2014 Aug 13. PMID: 25117993
120. Tsao NW, Marra CA, **Lynd LD**, Thomas JM, Ferreira E. Community pharmacist surveillance of hypertension in pregnancy: Are we ready for prime time? *Canadian Pharmacists Journal (Ott)*. 2014 Sep;147(5):307-15. doi: 10.1177/1715163514543898. PMID: 25364340
121. Zafari Z, **Lynd LD**, FitzGerald JM, Sadatsafavi M. Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: A simulation study. *J Allergy Clin Immunol*. 2014 Oct;134(4):908-915.e3. doi: 10.1016/j.jaci.2014.04.009. Epub 2014 May 27. PMID: 24875619
122. [Bansback N](#), Li L, **Lynd LD**, Bryan S. Exploiting order effects to improve the quality of decisions. *Patient Educ Couns*. 2014 Aug;96(2):197-203. doi: 10.1016/j.pec.2014.05.021 PMID: 24961445
123. Ungar WJ, Hadioonzadeh A, Najafzadeh M, Tsao NW, Dell S, **Lynd LD**. Quantifying preferences for asthma control in parents and adolescents using best-worst scaling. *Resp Med*. 2014 Jun;108(6):842-51. doi.org/10.1016/j.rmed.2014.03.014. Epub 2014 Apr 15. PMID: 24780719
124. Henrich N, Marra CA, Gastonguay L, Mabbott D, Malkin D, Fryer C, Bouffet E, Taylor M, Hukin J, Scantlebury N, **Lynd LD**. De-escalation of therapy for pediatric medulloblastoma: trade-offs between quality of life and survival. *Pediatr Blood Cancer*. 2014 Jul;61(7):1300-4. doi: 10.1002/pbc.24990. PMID: 24616367
125. Marra F, Kaczorowski J, Gastonguay L, Marra CA, **Lynd LD**, Kendall P. Pharmacy-based immunization in rural communities strategy (PhICS): A community cluster randomized trial. *Can Pharm J (Ott)*. 2014 Jan;147(1):33-44. doi: 10.1177/1715163513514020. PMID: 24494014
126. Sadatsafavi M, Rousseau R, [Chen W](#), Zhang W, **Lynd LD**, FitzGerald JM. Economic Burden of Asthma (EBA) study team. The preventable burden of productivity loss due to suboptimal asthma control: a population-based study. *Chest*. 2014; 145(4): 787–93. PMID: 24337140
127. Sadatsafavi M, **Lynd LD**, FitzGerald JM. Post-hospital syndrome in adults with asthma: a case-crossover study. *Allergy Asthma Clin Immunol*. 2013 Dec 23;9(1):49. doi: 10.1186/1710-1492-9-49. PMID: 24364886
128. Najafzadeh M, Johnston MK, Peakcock JS, Connors MJ, Marra MA, **Lynd LD**, Marra CA. Genomic testing to determine drug response: measuring preferences of the public and patients using a discrete choice experiment. *BMC Health Serv Res*. 2013 Oct 31;13(1):454. doi: 10.1186/1472-6963-13-454. PMID: 24176050
129. Davis EM, **Lynd LD**, Grubisic M, Kopec JA, Sayre EC, Cibere J, Esdaile J, Marra CA. Responsiveness of health state utility values in knee osteoarthritis. *J Rheumatol*. 2013 Dec;40(12):2075-82. doi: 10.3899/jrheum.130176. Epub 2013 Nov 1. PMID: 24187098
130. Bashir J, Cowan S, [Raymakers A](#), Yamashita M, Danter M, Krahn A, **Lynd LD**. A cost-effectiveness analysis of a proactive management strategy for the Sprint Fidelis recall: a probabilistic decision analysis model. *Heart Rhythm*. 2013 Dec;10(12):1761-7. doi: 10.1016/j.hrthm.2013.09.067. Epub 2013 Sep 25. PMID: 24076445
131. [Sweeney K](#), Grubisic M, Marra CA, Kendall R, Li L, **Lynd LD**. Comparison of HRQL between unicompartmental knee arthroplasty and total knee arthroplasty for the treatment of osteoarthritis. *J Arthroplasty*. 2013 Oct;28(9 Suppl):187-190. doi: 10.1016/j.arth.2013.05.009. Epub 2013 Jul 11. PMID: 23850408

132. Sadatsafavi M, **Lynd LD**, Marra CA, FitzGerald JM. Dispensation of long-acting β agonists with or without inhaled corticosteroids and risk of asthma-related hospitalisation: a population-based study. *Thorax*. 2014 Apr;69(4):328–34. doi:10.1136/thoraxjnl-2013-203998. Epub 2013 Nov 26. PMID: 24281327
133. Chen W, FitzGerald JM, Rousseau R, **Lynd LD**, Tan WC, Sadatsafavi M. Complementary and alternative asthma treatments and their association with asthma control: a population-based study. *BMJ Open*. 2013 Sep 4;3(9):e003360. doi:10.1136/bmjopen-2013-003360. PMID: 24005131
134. Najafzadeh M, Marra CA, **Lynd LD**, Wiseman S. Authors' response to "comparative effectiveness and personalized medicine" by Dr. J.D. Hornberger. *Value Health*. 2013 Jun;16(4):697. doi:10.1016/j.jval.2013.02.005. PMID: 23796305
135. Cloutier AM, Greenfield B, Lavoie A, **Lynd LD**, Tournier M, Brabant M-J, Moride Y. Effectiveness of risk communication interventions on the medical follow-up of youth treated with antidepressants. *Psychiatry Research*. 2013 Oct 30;209(3):471-8. doi:10.1016/j.psychres.2012.12.029. PMID: 23664663
136. Sadatsafavi M, **Lynd LD**, Marra CA, Bedouch P, FitzGerald M. Comparative outcomes of leukotriene receptor antagonists and long-acting beta-agonists as add-on therapy in asthma: a population-based study. *J Allerg Asthma Clin Immunol*. 2013 Jul;132(1): 63-9. doi:10.1016/j.jaci.2013.02.007. PMID: 23545275
137. Sadatsafavi M, FitzGerald JM, Marra CA, **Lynd LD**. Costs and health outcomes associated with primary versus secondary care after an asthma-related hospitalization, a population-based study. *Chest*. 2013 Aug;144(2):428-35. doi:10.1378/chest.12-2773. PMID: 23519289
138. Koehoorn M, Tamburic L, McLeod CB, Demers PA, **Lynd LD**, Kennedy SM. Population-based surveillance of asthma among workers in British Columbia, Canada. *Chronic Dis Inj Can*. 2013 Mar;33(2):88-94. PMID: 23470174
139. Bedouch P, Marra CA, FitzGerald JM, Sadatsafavi M, **Lynd LD**. Trends in asthma-related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population based-cohort study. *PLoS ONE*. 2012;7(12):e50949. doi:10.1371/journal.pone.0050949. Epub 2012 Dec 5. Erratum in: *PloS One*. 2013;8(6). doi:10.1371/annotation/a3275f00-6d75-4430-a0d6-5b4397ba501a. PMID: 23227222
140. Najafzadeh M, Marra CA, **Lynd LD**, Wiseman SM. Cost-effectiveness of using a molecular diagnostic test to improve pre-operative diagnosis of thyroid cancer. *Value Health*. 2012 Dec;15(8):1005-13. doi:10.1016/j.jval.2012.06.017. PMID: 23244801
141. Sadatsafavi M, Marra CA, Marra F, Moran O, FitzGerald JM, **Lynd LD**. A quantitative benefit risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental net-benefit framework. *Value in Health*. 2013 Jan-Feb;16(1):66-75. PMID: 23337217
142. Najafzadeh M, Marra CA, **Lynd LD**, Sadatsafavi M, FitzGerald JM, McManus B, Sin D. Future impact of various interventions on the burden of COPD in Canada: A dynamic population model. *Plos One*. 2012;7(10):e46746. doi:10.1371/journal.pone.0046746. Epub 2012 Oct 11. PMID: 23071626
143. Almeida FR, Henrich N, Marra C, **Lynd LD**, Lowe AA, Tsuda H, Fleetham JA, Pliska B, Ayas N. Patient preferences and experiences of CPAP and oral appliances for the treatment of obstructive sleep apnea: a qualitative analysis. *Sleep Breath*. 2013 May;17(2):659-66. doi:10.1007/s11325-012-0739-6. Epub 2012 Jul 26. PMID: 22833346
144. Lau M, Colley L, Willett B, **Lynd LD**. Employee's preferences for access to Mindfulness-based Cognitive Therapy to reduce the risk of depressive relapse - a discrete choice experiment. *Mindfulness*. 2012;3(4): 318-26.
145. Marra CA, **Lynd LD**, Colley L, Harvard SS, Lacaille D, Schwenger E, Anis AH, Esdaile JM. Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib. *J Rheumatol*. 2012 May;39(5):910-5. doi:10.3899/jrheum.110604. Epub 2012 Mar 15. PMID: 22422500

146. Marra CA, **Lynd LD**, Grindrod KA, Joshi P, Isakovic A. Evaluating the labour costs associated with pharmacy adaptation services in British Columbia. *Can Pharm J (Ott)*. 2012 Mar;145(2):78-82. doi: 10.3821/145.2.cpj78. PMID: 23509507
147. Najafzadeh M, **Lynd LD**, Davis JC, Bryan S, Anis A, Marra M, Marra CA. Barriers to integrating personalized medicine into clinical practice: a best-worst scaling choice experiment. *Genet Med*. 2012 May;14(5):520-6. doi:10.1038/gim.2011.26. PMID: 22241089
148. Wilby K, Marra CA, da Silva JH, Grubisic M, Harvard S, **Lynd LD**. Randomized Controlled Trial Evaluating Pictogram Augmentation of HIV Medication Information. *Ann Pharmacother*. 2011 Nov;45(11):1378-83. doi:10.1345/aph.1Q091. Epub 2011 Oct 25. PMID: 22028420
149. Marra F, Marra CA, Richardson KJ, **Lynd LD**, Fitzgerald JM. Antibiotic Consumption in Children Prior to Diagnosis of Asthma. *BMC Pulmonary Medicine*. 2011 May 31;11:32. doi:10.1186/1471-2466-11-32. PMID: 21627795
150. Marra CA, **Lynd LD**, Harvard S., Grubisic M. Agreement between aggregate and individual-level measures of income and education: a comparison across three patient groups. *BMC Health Services Research*. 2011 Mar 31;11:69. doi:10.1186/1472-6963-11-69. PMID: 21453534
151. Ogrodniczuk JS, **Lynd LD**, Joyce AS, Grubisic M, Piper WE, Steinberg PI. Predicting response to day treatment for personality disorder. *Can J Psychiatry*. 2011 Feb;56(2):110-7. PMID: 21333038
152. Guimaraes C, Marra CA, Gill S, Simpson S, Meneilly G, Queiroz RH, **Lynd LD**. A discrete choice experiment evaluation of patients' preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management. *Patient Prefer Adherence*. 2010 Dec 8;4:433-40. doi:10.2147/PPA.S14217. PMID: 21301591
153. Grindrod KA, **Lynd LD**, Joshi P, Rosenthal M, Isakovic A, Marra CA. Pharmacy owner and manager perceptions of pharmacy adaptation services in British Columbia. *Can Pharm J*. 2011;144(5):231-5.
154. Henrich N, Joshi P, Grindrod K, **Lynd LD**, Marra CA. Family physicians' perceptions of pharmacy adaptation services in British Columbia. *Can Pharm J*. 2011;144(4):172-8.
155. Oteng B, Marra F, **Lynd LD**, Ogilvie G, Patrick D, Marra CA. Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening program. *Sex Transm Infect*. 2011 Feb;87(1):52-57. doi:10.1136/sti.2009.041392. Epub 2010 Oct 18. PMID: 20956352
156. Grindrod KA, Marra CA, Colley L, Tsuyuki RT, **Lynd LD**. Pharmacists' preferences for providing patient-centred services: a discrete choice experiment to guide health policy. *Ann Pharmacother*. 2010 Oct;44(10):1554-64. doi:10.1345/aph.1P228. Epub 2010 Sep 14. PMID: 20841513
157. Law MR, Morgran SG, Majumdar SR, **Lynd LD**, Marra CA. Effects of prescription adaptation by pharmacists. *BMC Health Serv Res*. 2010 Nov 17;10:313. doi:10.1186/1472-6963-10.313. PMID: 21083922
158. Kliber A, **Lynd LD**, Sin DD. The effects of long acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. *Resp Res*. 2010 May 11;11:56. doi:10.1186/1465-9921-11-56. PMID: 20459831
159. Wilbur K, **Lynd LD**, Sadatsafavi M. Low molecular weight heparin versus Unfractionated Heparin for Prophylaxis of Venous Thromboembolism in Medicine Patients – A Pharmacoeconomic Analysis. *Clin Applied Thromb Hemostasis*. 2011 Oct;17(5):454-465. doi:10.1177/1076029610376935. Epub 2010 Aug 10. PMID: 20699258
160. **Lynd LD**, Marra CA, Najafzadeh M, Sadatsafavi M. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework. *Pharmacoeconom Drug Saf*. 2010 Nov;19(11):1172–80. doi:10.1002/pds.1994. PMID: 20602338
161. Johnson FR, Hauber AB, Ozdemir S, **Lynd LD**. Quantifying Women's Stated Benefit-Risk Trade-Off Preferences for IBS Treatment Outcomes. *Value Health*. 2010 Jun-Jul;13(4):418-23. doi:10.1111/j.1524-4733.2010.00694.x. PMID: 20230550

162. Marra F, **Lynd LD**, Coombes M, Richardson K, Legal M, FitzGerald JM, Marra CA. Does antibiotic exposure during infancy lead to development of asthma? A systematic review and metaanalysis. *Chest*. 2009 Nov;135(5 Suppl):e30. PMID: 20162773
163. **Lynd LD**, Najafzadeh M, Colley L, Byrne MF, Willan AR, Sculpher MA, Johnson RF, Hauber AB. Using the incremental net-benefit framework for quantitative benefit-risk analysis in regulatory decision making – a case study of alosetron in irritable bowel syndrome. *Value Health*. 2010 Jun-Jul;13(4):411-7. doi:10.1111/j.1524-4733.2009.00595.x. Epub 2009 Sep 10. PMID: 19744297
164. **Guimaraes C**, Marra CA, Simpson SH, Meneilly GS, Queiroz RHC, **Lynd LD**, Gill S. Exploring patients' perceptions for insulin therapy in type 2 diabetes: A Brazilian and Canadian qualitative study. *Patient Pref Adherence*. 2010 Jul 21;4:171-9. PMID: 20694179
165. Sadatsafavi M, **Lynd LD**, Marra CA, Carleton B, Tan WC, FitzGerald JM. Direct health care costs associated with asthma in British Columbia. *Can Resp J*. 2010 Mar-Apr;17(2):74-80. PMID: 20422063
166. Simon LS, Strand CV, Boers M, Brooks PM, Tugwell PS, Bombardier C, Fries JF, Henry D, Goldkind L, Guyatt G, Laupacis A, **Lynd LD**, Macdonald T, Mamdani M, Moore A, Saag KG, Silman AJ, Stevens R, Tyndall A. How to ascertain drug safety in the context of benefit. Controversies and concerns. *J Rheumatol*. 2009 Sep;36(9):2114-21. doi: 10.3899/jrheum.090591. PMID: 19738223
167. **Grindrod KA**, Rosenthal M, **Lynd LD**, Marra CA, Bougher D, Wilgosh C, Tsuyuki R. Pharmacist perspectives on providing chronic disease management services in the community (Part 1): Current Practice Environment. *Can Pharm J*. 2009;142(5):234–9.
168. Rosenthal M, **Grindrod KA**, **Lynd LD**, Marra CA, Bougher D, Wilgosh C, Tsuyuki R. Pharmacist perspectives on providing chronic disease management services in the community (Part 2): Development & Implementation. *Can Pharm J*. 2009;142(6):284–9.
169. **Guimaraes C**, Marra CA, Simpson SH, Meneilly GS, Queiroz RHC, **Lynd LD**. A valuation of patients' willingness-to-pay for insulin delivery in diabetes. *Int J Technol Assess Health Care*. 2009 Jul;25(3):359-66. doi:10.1017/S0266462309990055. PMID: 19619355
170. **Guimaraes C**, Marra CA, Colley L, Gill S, Simpson SH, Meneilly GS, Queiroz RHC, **Lynd LD**. Socioeconomic Differences in Preferences and Willingness-to-Pay for Insulin Delivery Systems in Type 1 and Type 2 Diabetes. *Diabetes Technol Ther*. 2009 Sep;11(9):567-73. doi:10.1089/dia.2009.0034. PMID: 19764835
171. Bahadori K, Doyle-Waters MM, Marra C, **Lynd LD**, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. *BMC Pulm Med*. 2009 May 19;9:24. doi:10.1186/1471-2466-9-24. PMID: 19454036
172. Marra F, Marra CA, Richardson K, **Lynd LD**, Kozyrskj A, Patrick DM, Bowie WR, FitzGerald JM. Antibiotic use in children is associated with increased risk of asthma. *Pediatrics*. 2009 Mar;123(3):1003-10. doi:10.1542/peds.2008-1146. PMID: 19255032
173. **Tsang R**, Colley L, **Lynd LD**. Inadequate statistical power to detect clinically significant differences in adverse events rates in randomized controlled trials. *J Clin Epidemiol*. 2009 Jun;62(6):609-16. doi: 10.1016/j.jclinepi.2008.08.005. Epub 2008 Nov 14. PMID: 19013761
174. **McTaggart-Cowan HM**, Shi P, Anis AH, FitzGerald JM, Kopec JA, Bai TR, Currie G, Soon JA, **Lynd LD**. An evaluation of patients' preferences for asthma therapy using a discrete choice experiment. *J Asthma*. 2008 Oct;45(8):630-8. doi: 10.1080/02770900802126990. PMID: 18951253
175. Sadatsafavi M, Najafzadeh M, **Lynd LD**, Marra CA. Reliability studies are not using enough observers for robust estimation of observer agreement: a simulation study. *J Clin Epidemiol*. 2008;61(7):722-7.
176. **Lynd LD**, Richardson KJ, Pursell RA, Abu-Laban RB, Brubacher JR, Lepik KJ, Sivilotti ML. An evaluation of the osmole gap as a screening test for toxic alcohol poisoning. *BMC Emerg Med*. 2008 Apr 28;8:5. doi: 10.1186/1471-227X-8-5. PMID: 18442409

177. McTaggart-Cowan HM, Marra CA, Yang Y, Brazier JE, Kopec JA, Fitzgerald JM, Anis AH, **Lynd LD**. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. *Qual Life Res*. 2008 Apr;17(3):453-62. doi: 10.1007/s11136-008-9309-6. Epub 2008 Feb 15. PMID: 18274882
178. Ogrodniczuk JS, Joyce AS, **Lynd LD**, Piper WE, Steinberg PI, Richardson K. Predictors of premature termination of day treatment for personality disorder. *Psychother Psychosom*. 2008;77:365-71. doi: 10.1159/000151390. Epub 2008 Aug 14. PMID: 18701833
179. Regier D, Marra CA, **Lynd LD**. Economic evaluations of anticoagulants for the prophylaxis of venous thromboembolism following major trauma. *Expert Rev Pharmacoecon Outcomes Res*. 2007;7(4):403-13.
180. Shalansky S, **Lynd LD**, Richardson K, Ignaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. *Pharmacotherapy*. 2007;27(9):1237-47.
181. **Lynd LD**, Goeree R, Crowther M, O'Brien BJ. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep vein thrombosis following major trauma. *Can J Clin Pharmacol*. 2007 Summer;14(2):e215-26. Epub 2007 Jun 6. PMID: 18000316
182. Tan MC, Regier DA, Esdaile JM, **Lynd LD**, Anis AH, Marra CA. Health economic evaluation: a primer for the practicing rheumatologist. *Arth Care Res*. 2006 Aug 15;55(4):648-56. Review. PMID: 16874788
183. Regier DA, Sunderji R, **Lynd LD**, Marra CA. Cost-effectiveness analysis of self-managed versus physician-managed oral anticoagulation therapy. *CMAJ*. 2006 Jun 20;174(13):1847-52. PMID: 16785459
184. Marra F, **Lynd LD**, Coombes M, Richardson K, Legal M, Fitzgerald JM, Marra CA. Does antibiotic exposure during infancy lead to development of asthma? A systematic review and meta-analysis. *Chest* 2006; 129: 610-18.
185. Marra CA, **Lynd LD**, Anis AH, Esdaile JM. Approval process and access to prescription drugs in Canada. *Arthritis Rheum*. 2006 Feb 15;55(1):9-11. PMID: 16463404
186. **Lynd LD**, Goeree R, O'Brien BJ. Antiviral agents for influenza: a comparison of cost-effectiveness data. *Pharmacoeconomics*. 2005;23(11):1083 – 1106. Review. PMID: 16277546
187. **Lynd LD**, Taylor J, Dobson R, Willison DJ. Prescription to over-the-counter deregulation in Canada: Are we ready for it, or do we need to be? *CMAJ*. 2005 Sep 27;173(7):775-7. Epub 2005 Sep 12. PMID: 16157708
188. Willan AR, Pinto EM, O'Brien BJ, Kaul P, **Lynd LD**, Goeree R, Armstrong PW. Country-specific cost comparisons from multinational clinical trials: using empirical Bayesian shrinkage estimation. *Health Econ*. 2005;14:327-38.
189. Purssell RA, **Lynd LD**, Koga Y. The use of the osmole gap as a screening test for the presence of exogenous substances: a review of the literature. *Toxicol Rev*. 2004;23(3):189-202. Review. PMID: 15862085
190. Koga Y, **Lynd LD**, Purssell RA. A review of osmolality and molarity, applicable physical chemistry principles and recommendations to improve current practices. *Toxicol Rev*. 2004;23(3):203-211. Review. PMID: 15862086
191. **Lynd LD**, Sandford AJ, Kelly EM, Pare PD, Bai TR, FitzGerald JM, Anis AH. Reconcilable differences - a cross-sectional study of the relationship between socioeconomic status and the magnitude of short-acting beta-agonist use in asthma. *Chest*. 2004 Oct;164(4):1161-8. PMID: 15486378
192. Dobson R, Taylor J, **Lynd LD**. Are we ready for prescriptive authority? Lessons from the self-care example. *Can Pharm J* 2004; 137 (9):38-9.
193. Marra CA, **Lynd LD**, Esdaile JM, Kopec J, Anis AH. The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment. *Rheumatology (Oxford)*. 2004 Nov;43(11):1390-7. Epub 2004 Aug 3. PMID: 15292531
194. **Lynd LD**, O'Brien BJ. Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. *J Clin Epidemiol*. 2004 Aug;57(8):795-803. PMID: 15485731
195. **Lynd LD**, Warren L, Maclure M, Paré PD, Anis AH. Using administrative healthcare data to recruit study subjects: experience with "camouflaged sampling". *Eur J Epidemiol*. 2004;19(6):517-25. PMID: 15330123

196. **Lynd LD**, O'Brien BJ. Cost-effectiveness of the implantable cardioverter-defibrillator: a review of the current evidence. *J Cardiovasc Electrophysiol*. 2003;14(Suppl. 9):S99-S103.
197. **Lynd LD**, Guh DP, Paré PD, Anis AH. Patterns of inhaled asthma medication use: a 3 year longitudinal analysis of prescription claims data from British Columbia, Canada. *Chest*. 2002;122(6):1973-1981.
198. **Lynd LD**. Use of inhaled anti-inflammatory medications for asthma: are they worth the cost? *J Inform Pharmacother*. 2001;5:216-218.
199. Anis AH, **Lynd LD**, Wang XH, King G, Spinelli JJ, Fitzgerald M, Bai T, Paré PD. Double trouble: inappropriate asthma medication use linked to increased use of health care resources. *CMAJ*. 2001; 164(5):625-31.
200. **Gerber P**, **Lynd LD**. Selective serotonin re-uptake inhibitor-induced movement disorders. *Ann Pharmacother* 1998; 32:692-698.
201. **Gardner DM**, **Lynd LD**. Sumatriptan and the serotonin syndrome. *Ann Pharmacother* 1998; 32(1): 33-38.
202. **Lynd LD**. Serotonin syndrome - a review of the drug-induced disease of the 90's. *Can Pharm J* 1997;130(6):31-4.
203. Marra CA, Carleton BC, **Lynd LD**, Marra F, McDougal AR, Chow D, McKerrow R. Drug and poison information resources on the internet, part 2: identification and evaluation. *Pharmacotherapy*. 1996;16(5):806 - 818.
204. Marra CA, **Lynd LD**, McKerrow R, Carleton BC. Drug and poison resources on the internet, part 1: an introduction. *Pharmacotherapy*. 1996;16(4):537-546.
205. **Lynd LD**. Isotretinoin - are concerns with its long-term toxicity legitimate? *Can Pharm J*. 1995;128(9):23-4.
206. McCormack JP, **Lynd LD**, Pfeifer NM. Vancomycin cost containment through a therapeutic and pharmacokinetic drug monitoring service. *Can J Hosp Pharm*. 1989;42(1):3-9.

(a) *Conference Proceedings*

1. Dragojlovic N, Nagase F, Meng FY, Akinsoji T, Lynd LD. Facilitating academic life science innovation with early health technology assessment: A survey of potential user needs and perceptions. Poster presented at the *Health Technology Assessment international (HTAi) 2024 Meeting*, Seville, Spain, June 18, 2024.
2. Akinsoji T, Dragojlovic N, Darviot C, Meunier M, Lynd LD. Potential cost-effectiveness and innovation headroom of a more accurate companion diagnostic for PD-L1 in non-small cell lung cancer. Poster presented at the *Health Technology Assessment international (HTAi) 2024 Meeting*, Seville, Spain, June 18, 2024.
3. Dragojlovic N, Kopac N, Rodriguez Llorian E, Lehman A, Lynd LD. The health system impact of returning rare disease variants as secondary findings from genomic sequencing. Poster presented at the *Health Technology Assessment international (HTAi) 2024 Meeting*, Seville, Spain, June 17, 2024.
4. **Borle, K.**, Kopac, N., Dragojlovic, N., Rodriguez Llorian, E., GenCOUNSEL Study, Elliott, A.M., **Lynd, LD**. Challenges and opportunities for the clinical genetics workforce. Canadian Association of Genetic Counsellors Annual Conference (Virtual). Oral presentation. Oct 2022.
5. Rodriguez Llorian E, Waliji L, Dragojlovic N, Michaux K, Nagase F, Lynd LD. Application of early health technology assessments to nanomedicine: a review of conceptual frameworks. *Liposomes Research Days 2022*. Poster. Vancouver, B.C. June 2022.
6. Borle K, Kopac N, Dragojlovic N, Rodriguez-Llorian E, Friedman J, Elliot AM, Lynd LD. Future trends in clinical genetics services: exploring the perspectives of Canadian genetics professionals using the Delphi method," Poster presented at the *American College of Medical Genetics* annual conference (virtual). April 2021.
www.sciencedirect.com/science/article/pii/S1096719221006338

7. Dragojlovic N, Borle N, Kopac N, Khakban A, Shechter S, Friedman JM, the GenCOUNSEL study, Elliot AM, Lynd LD. Projecting the utilization of clinical genetics services in Canada: a demand model. *2020 Virtual CADTH Symposium*, Nov 2020.
8. Dragojlovic N, Borle K, Kopac N, Khakban A, Nuk J, Jevon M, Kelley S, Nisselle A, Shechter S, Friedman JM, GenCOUNSEL study, Elliot AM, Lynd LD. Projecting the future demand for hereditary cancer genetic services in North America and its workforce implications. 42nd Annual Meeting of the *Society for Medical Decision Making*. Oral Presentation - Virtual meeting; October 2020.
9. Dragojlovic N, Johnson D, Kopac N, Chen Y, Lenzen M, le Huray S, Borle K, Pollard S, George A, Regier D, Harrison M, Carenini G, Ng R, Lynd LD. Estimating patient preferences for drug therapies from online text using aspect-based sentiment analysis," 42nd Annual Meeting of the *Society for Medical Decision Making*. Oral Presentation - Virtual meeting. October 2020. **Selected as one of the "Top 20" abstracts out of 262 abstracts in the program.**
10. Rodriguez Llorian E, Zhang W, Khakban A, Patten S, Trabousee A, Oh J, Kolind K, Prat A, Tam R, Lynd LD. "Productivity loss among people with multiple sclerosis: A Canadian study." Canadian Economics Association Conference 2021. Simon Fraser University, BC. June 3, 2021.
11. Dragojlovic N, Kopac N, Borle K, Tandun R, Salmasi S, Ellis U, Birch P, Adam S, Friedman JM, Elliott AM, **Lynd LD**. Utilization of clinical genetic services in high-income countries: A scoping review. Accepted for a poster presentation at the joint meeting of 8th annual Canadian Human and Statistical Genetics Meeting and CIHR Institute of Genetics Canadian GE3LS* and Health Services Policy Meeting. Montreal, QC, June 16-19 2019.
12. Dragojlovic N, Van Karnebeek CDM, Ghani A, Genereaux D, Kim E, Birch P, Elliott AM, Friedman JM, **Lynd LD**. Mapping the cost trajectory of the diagnostic odyssey for children with undiagnosed but suspected genetic conditions. Accepted for a poster presentation at the joint meeting of 8th annual Canadian Human and Statistical Genetics Meeting and CIHR Institute of Genetics Canadian GE3LS* and Health Services Policy Meeting. Montreal, QC, June 16-19 2019.
13. Dragojlovic N., Elliott AM, Friedman JM, **Lynd LD**. Family effects of receiving a diagnosis from Genome-Wide Sequencing. Health Technology Assessment international (HTAi) 2018 Meeting, Vancouver, BC, June 1-5, 2018.
14. Dragojlovic N, Elliott AM, Friedman JM, **Lynd LD**. Cost-effectiveness of exome sequencing for intellectual disability. Health Technology Assessment international (HTAi) 2018 Meeting, Vancouver, BC, June 1-5, 2018.
15. Douglas C, Dragojlovic N, Panagiotoglou D, Blanis L, **Lynd LD**. Using scenario studies to inform orphan drug coverage. Health Technology Assessment international (HTAi) 2018 Meeting, Vancouver, BC, June 1-5, 2018.
16. Hong J*, Conklin AI, Dragojlovic N, Elliott AM, Friedman JM, **Lynd LD**. Caregiver perceptions and experiences of diagnostic GWS. Health Technology Assessment international (HTAi) 2018 Meeting, Vancouver, BC, June 1-5, 2018.
17. Dragojlovic N, Li K, Wu H, Tan J, **Lynd LD**. Predictors of public payer reimbursement for orphan drugs in Canada, Europe, and Australia. 2018 CADTH Symposium, Halifax, NS, April 2018.
18. Dragojlovic N, Elliott AM, Friedman JM, **Lynd LD**. Family spillover effects of the quest for a causal diagnosis for children with suspected genetic disorders on caregiver mental health. 2018 CADTH Symposium, Halifax, NS, April 2018.
19. Elliott A, du Souich C, Lehman A, Guella I, Evans D, Candido T, Tooman L, Young A, Dragojlovic N, **Lynd LD**, Farrer M, Friedman J, Osiovich H. RAPIDOMICS: A study of rapid genome-wide sequencing in the neonatal intensive care unit at BC Women's Hospital – successes and challenges with implementation. 2018 ACMG Annual Clinical Genetics Meeting, Charlotte, NC, April 10-14, 2018.

20. Lehman A, Guella I, Armstrong L, Candido T, Clarke L, Dragojlovic N, Evans D, Gibson W, Gill H, Lewis MES, McKinnon M, Nikkel S, Patel M, du Souich C, Tooman L, **Lynd LD**, Farrer M, Friedman J, Osiovich H, Elliott AM. First-line rapid genomic diagnosis for newborns affects medical decision-making. 2018 ACMG Annual Clinical Genetics Meeting, Charlotte, NC, April 10-14, 2018.
21. Tsao NW, **Lynd LD**, De Vera MA. Maternal and neonatal outcomes in women with autoimmune disease using biologics in pregnancy: A systematic review and meta-analysis of observational studies. The 62nd Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology, Tokyo, Japan. April 27 2018.
22. Tsao NW, Hanley G, Sadatsafavi M, **Lynd LD**, Marra C, De Vera MA. Risk of Major Congenital Malformations Associated with Exposure to Biologics Before or During Pregnancy: A Population-based Cohort Study. 2018 Canadian Rheumatology Association Annual Scientific Meeting, February 23 2018. Vancouver, Canada.
23. Loewen P, Bansback N, Adrade J, Bonet B, Deymell M, Hicklin J, Kapanen A, Kwan, L, **Lynd LD**, McClean A, McGillvray J, Salmasi S. Patient preferences for atrial fibrillation stroke prevention therapy using an individualized risks and preferences-based decision aid. CSHP Professional Practice Conference. February 3-7, 2017. Toronto, Ontario.
24. Loewen P, Bansback N, Adrade J, Bonet B, Deymell M, Hicklin J, Kapanen A, Kwan, L, **Lynd LD**, McClean A, McGillvray J, Salmasi S. Performance of an innovative patient decision aid for atrial fibrillation stroke prevention therapy. CSHP Professional Practice Conference. February 3-7, 2017. Toronto, Ontario.
25. Raymakers AJN, Sadatsafavi M, Sin DD, FitzGerald JM, Marra CA, **Lynd LD**. An evaluation of the association between statin use and lung cancer risk in chronic obstructive pulmonary disease patients. Canadian Centre for Applied Research in Cancer Control Conference, May 25-26, 2017. Toronto, Ontario.
26. Hategeka C, Traboulsee A, McMullen K, **Lynd LD**. Stigma in multiple sclerosis: association with work productivity loss, health-related quality of life and caregivers' burden. American Academy of Neurology 69th Annual Conference. Boston, US. April 22-28, 2017.
27. Dragojlovic N, Kim E, Elliott AM, Friedman JM, **Lynd LD**. Mapping the cost trajectory of the diagnostic odyssey for children with undiagnosed but suspected genetic conditions. 2017 CADTH Symposium. Ottawa, ON. April 24, 2017.
28. Ghani A, Dragojlovic N, Birch P, Salvarinova R, Horvath G, Generaux D, Sayson B, Lafek M, Blydt-Hansen T, Connolly M, Demos M, Lehman A, Patel M, Armstrong L, Van Allen M, McKinnon M, Nelson T, Eydoux P, Matthews A, Tarailo-Graovac M, Vallance H, Sinclair G, **Lynd LD**, Stockler S, van Karnebeek C. Screening for treatable inborn errors of metabolism in 498 intellectual developmental disorder patients. Poster presented at the 2016 American Society of Human Genetics Meeting, Vancouver, B.C., October 19, 2016.
29. Dragojlovic, N., Kim, E., Elliott, AM, Friedman, JM, **Lynd, LD**. Evaluating the validity of parental reports of healthcare utilization for children with suspected genetic disorders of unknown cause. Poster presentation, 38th Annual Meeting of the Society for Medical Decision-Making, Vancouver, B.C., October 2016.
30. Dragojlovic N, Elliott AM, Friedman JM, **Lynd LD**. Predictors of anxiety and depression in caregivers of children with chronic conditions of unknown but suspected genetic origin. Poster presentation, 2016 American Society of Human Genetics Meeting, Vancouver, B.C., October 2016.
31. Dragojlovic, N, **Lynd LD**. Preferences for Donating Money to Support Drug Development Research Projects in a Sample of Canadian and U.S. Adults. Podium presentation at the Canadian Society for Pharmaceutical Sciences Annual Symposium, Richmond, British Columbia, June 3, 2016.
32. Rayamkers AJN, Sadatsafavi M, **Lynd LD**. One-year survival among statin users in a population-based cohort of COPD patients. Canadian Association for Population Therapeutics (CAPT). Toronto, Ontario (2015, 2 November).

33. Raymakers AJN, **Lynd LD**, Bashir J. Management of the Riata Implantable Cardioverter Defibrillator (ICD) Lead Failure - A Cost-Effectiveness Analysis. Canadian Agency for Drugs and Technologies in Health (CADTH). Saskatoon, Saskatchewan (2015, 13 April).
34. Ungar WJ, Hadioonzadeh A, Najafzadeh M, Tsao NW, Dell S, **Lynd LD**. Parents and adolescents with asthma express disparate preferences for parameters of asthma control: A best-worst scaling choice experiment. Oral presentation at 6th Biennial Conference of the American Society of Health Economists, Philadelphia, June 2016.
35. Hategekimana, C. Tuyisenge, L. **Lynd, LD**. The impact of an intervention to improve emergency triage, assessment and admission care on pediatric hospital mortality in Rwanda: an interrupted time series analysis. The 28th Annual CHSPR Health Policy Conference, Vancouver, Canada, April 5 – 6, 2016.
36. Raymakers AJ, Whitehurst DG, FitzGerald JM, Lam S, Mayo J, **Lynd LD**. Cost-effectiveness analyses of Lung Cancer screening strategies using low dose computed tomography: A systematic review. Poster Presentation at ISPOR 20th Annual International Meeting. Philadelphia, PA, May 16-20, 2015. Value in Health. 2015 May; 18(3): A46.
37. Tsao NW, **Lynd LD**, Marra CA, Sayre EC, De Vera MA. Patterns of biologics use among women with autoimmune disease before, during, and after pregnancy: A Population-based Study. American College of Rheumatology Conference 2015. San Francisco, CA, November 6-11, 2015.
38. Chen W, **Lynd LD**, FitzGerald JM, Sadatsafavi M. Influences of socioeconomic Status on Costs of Asthma under Universal Health Coverage. Canadian Respiratory Conference 2015. Ottawa, ON, April 23-25, 2015. (poster)
39. Chen W, **Lynd LD**, FitzGerald JM, Sadatsafavi M. Influences of Socioeconomic Status on Costs of Asthma under Universal Health Coverage. Heart and Lung FEST. Vancouver, BC, March 26-27, 2015. (poster)
40. Raymakers AJN, **Lynd LD**, Bashir J. Management of the Riata Implantable Cardioverter Defibrillator (ICD) Lead Failure - A Cost-Effectiveness Analysis. Abstract accepted to the CADTH 2015 Symposium, Saskatoon, SK, April 12-14, 2015.
41. Rosenthal MM, Marra CA, Nakagawa B, Tsao NW, **Lynd LD**, Tsuyuki RT. Understanding pharmacy culture using the organizational culture profile. Poster presentation at the Canadian Pharmacists Association Conference, Saskatoon, SK, May 31-June 3, 2014.
42. Rosenthal MM, Marra CA, Nakagawa B, Tsao NW, **Lynd LD**, Tsuyuki RT. Understanding pharmacy culture using the big five inventory. Poster presentation at the Canadian Pharmacists Association Conference, Saskatoon, SK, May 31-June 3, 2014.
43. Tsao NW, Marra CA, **Lynd LD**, Gastonguay L, Nakagawa B. Impact of expanded pharmacy services on pharmacists' working conditions in British Columbia. Poster presentation at the Canadian Pharmacists Association Conference, Saskatoon, SK, May 31-June 3, 2014.
44. Sadatsafavi M, FitzGerald M, Marra C, De Vera M, Zafari Z, **Lynd LD**. Comparative costs and effectiveness of asthma controller therapies after discharge from an asthma-related hospitalization. Poster Presentation at ISPOR 19th Annual International Meeting, Montreal, Quebec, May 31 - June 4, 2014. Value in Health; Volume 17 (3): A169.
45. Raymakers AJN, Marra CA, Sadatsafavi M, FitzGerald JM, Sin DD, **Lynd LD**. A population-based cohort study evaluating the association between inhaled corticosteroid use and lung cancer development in patients with COPD. CIHR Institute of Circulatory and Respiratory Health (ICRH) Young Investigators' Forum, Edmonton, Alberta, May 26-29, 2014. Won "Outstanding Poster Award" .
46. FitzGerald JM, Marra CA, **Lynd LD**, Sadatsafavi M. Comparative costs and effectiveness of asthma controller therapies after discharge from an asthma-related hospitalization. Abstract accepted for poster presentation American Thoracic Society Conference. San Diego, US. May 19, 2014. Am J Respir Crit Care Med 189;2014:A3707.
47. Trenaman L, Almeida F, Ayas N, **Lynd LD**, Marra CA, Stacey D, Sadatsafavi M, Bansback N. Evaluating the potential cost-effectiveness of patient decision aids: A case study in obstructive sleep apnea. CADTH Symposium 2014. Ottawa, ON, April 6-8, 2014.
48. Zhang W, Guh D, Sun H, Marra CA, **Lynd LD**, Anis AH. The impact of price-cap regulations on exit by generic firms in Canada. iHEA/ECHE Congress 2014. Dublin, Ireland, July 13-16, 2014.

49. Mohammadi T, Guo N, Marra F, Khakban A, Campbell J, FitzGerald JM, **Lynd LD**, Marra CA. Comparing stated preferences and actual choices at individual level using Bayesian estimation: an application to latent tuberculosis infection treatment. iHEA/ECHE Congress 2014. Dublin, Ireland, July 13-16, 2014.
50. Lakzadeh P, Green TJ, McLean J, Talukder Z, Li K, **Lynd LD**. Factors Associated with Household Income in Rural Cambodia. Food Security Dialogue 2014. Edmonton, Alberta, April 30 - May 2, 2014.
51. Raymakers AJN, Marra CA, Sadatsafavi M, FitzGerald JM, Sin DD, **Lynd LD**. Inhaled corticosteroid (ICS) use in Chronic Obstructive Pulmonary Disease and Lung Cancer Diagnosis. Institute for Heart and Lung Health FEST 2014, Vancouver, BC, February 2014.
52. Rizzardo S, Bansback N, Mitton C, Marra C, **Lynd LD**. Canadian Societal Views and Trade-Offs for Rare Disease Treatment. Oral presentation. 2014 CADTH Symposium, Hilton Lac-Leamy in the National Capital Region, Gatineau, Quebec, April 6-8, 2014.
53. Rizzardo S, Bansback N, Mitton C, Marra C, **Lynd LD**. Rare Diseases Equity and Funding; A Canadian Perspective. Poster presentation. 2014 CADTH Symposium, Hilton Lac-Leamy in the National Capital Region, Gatineau, Quebec, April 6-8, 2014.
54. Wilcox E, Mitton C, **Lynd LD**. Incorporating societal values into healthcare decision-making: Engaging publics in reimbursement decision-making for drugs for rare diseases. Oral presentation at 2014 CADTH Symposium, National Capital Region, ON, Canada, April 6-7, 2014.
55. Wilcox E, Mitton C, **Lynd LD**. Engaging publics in reimbursement decision-making for drugs for rare diseases. Poster presentation. 25th Annual Canadian Bioethics Society conference, Vancouver, BC, Canada, May 29-31, 2014.
56. Rizzardo S, Bansback N, Mitton C, **Lynd LD**. Values of the Canadian public towards pharmaceutical reimbursement decisions. Poster Presentation at ISPOR 19th Annual International Meeting. Montreal, Quebec, May 31 - June 4, 2014. Value in Health; 17(3): A234.
57. Rizzardo S, Bansback N, Mitton C, Marra C, **Lynd LD**. How Canadians value rare diseases given their opportunity cost. Podium presentation at ISPOR 19th Annual International Meeting, Montreal, Quebec, May 31 - June 4, 2014. Value in Health; 17(3): A4.
58. Zafari Z, Sadatsafavi M, FitzGerald JM, **Lynd LD**, Marra C. The humanistic and economic impact of following evidence-based asthma controller therapy: a simulation study. Poster Presentation at ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013. Value in Health 2013; 16(3): A235.
59. Zafar Z, Thorlund K, FitzGerald M, **Lynd LD**, Marra C, Sadatsafavi M. Impact of multiple treatment comparison meta-analysis on value of information evaluations: A case study of pharmacotherapies for chronic obstructive pulmonary disease. Poster Presentation at ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013. Value in Health 2013; 16(3): A26-A27.
60. Patel A, Lester R, Ritvo P, Marra C, **Lynd LD**, Karanja S, Van der Kop M. Discriminative ability of the SF-12 in Kiswahili by HIV stage in Kenya. Poster Presentation at ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013. Value in Health; 16(3): A95.
61. Rizzardo S, **Lynd LD**. Canadian values, attitudes and willingness to pay for expensive medications for rare diseases. Poster presentation. International Rare Diseases Research Consortium (IRDiRC), Dublin, Ireland, April 16-17, 2013.
62. Zafari Z, Thorlund K, FitzGerald M, Marra C, **Lynd LD**, Sadatsafavi M. Multiple-treatment comparison versus pairwise meta-analysis: Impact on the expected value of information results. iHEA 2013, Australia, July 7-10, 2013.
63. Rizzardo S, **Lynd LD**. Canadian values, attitudes and willingness to pay for expensive medications for rare diseases. Poster presentation. 16th Canadian Society for Pharmaceutical Sciences (CSPS) Annual Symposium, Vancouver, BC, Canada, June 11-14, 2013. Journal of Pharmacy & Pharmaceutical Sciences; 16(3).
64. Wilcox E, Mitton C, **Lynd LD**. Public engagement: Understanding and accounting for public values and perspectives in reimbursement decision-making to expensive drugs for rare diseases. Poster presentation. 2013 Vancouver Health Economics Methodology Meeting, Vancouver, BC, Canada, June 7, 2013.
65. Raymakers AJN, **Lynd LD**. A critical review of cost-effectiveness analyses of lung cancer screening with computed tomography. Institute for Heart and Lung Health (IHLH) Fest 2013. Vancouver, BC, February 21, 2013

66. Raymakers AJN, Marra CA, FitzGerald JM, Sadatsafavi M, Sin DD, **Lynd LD**. A population-based cohort study evaluating the association between inhaled corticosteroid use and lung cancer development in patients with COPD. Canadian Institutes of Health Research, Institute of Circulatory and Respiratory Health. May 2013.
67. Raymakers AJN, Sadatsafavi M, **Lynd LD**, FitzGerald JM. The Economic Burden of COPD: A Systematic Review. Canadian Agency for Drugs and Technologies in Health (CADTH), St. John's, NL, May 5-7, 2013.
68. Raymakers AJN, Bashir J, Cowan S, Yamashita M, **Lynd LD**. A Cost-Effectiveness Analysis of Alternative Management Strategies for the Sprint Fidelis Implantable Cardioverter-Defibrillator Recall: A Probabilistic Decision Analysis Model. Canadian Agency for Drugs and Technologies in Health (CADTH), St. John's, NL, May 5-7, 2013.
69. Talukder Z, McLean J, **Lynd LD**, Kroeun H, Green TJ. Household food security, dietary diversity, anemia, and anthropometric status of poor women farmers in Prey Veng Province, Cambodia: A cross-sectional study. Accepted. IUNS 20th International Congress of Nutrition. Granada, Spain, September 15-20, 2013.
70. McLean J, **Lynd LD**, Talukder Z, Kroeun H, Lakzadeh P, Ly S, Green TJ. Nutrition knowledge, attitudes and cultural practices of rural women farmers in Prey Veng Province, Cambodia. Accepted. IUNS 20th International Congress of Nutrition. Granada, Spain, September 15-20, 2013.
71. Sweeney K, Grubisic M, Marra CA, Kendall R, Li L, **Lynd LD**. Comparison in HRQOL between unicompartmental knee arthroplasty and total knee arthroplasty for the treatment of osteoarthritis. Global Oxford Masters Symposium. Oxford, UK, September 24-25, 2012.
72. Leung VWY, Soon JA, **Lynd LD**, Marra CA, Levine M. The effect of the timing of oral hormonal emergency contraceptives on pregnancy rate. The 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (Poster Walk presentation). Barcelona, August 25-26, 2012.
73. Tsao NW, Rosenthal M, Thomas JM, Marra CA, **Lynd LD**, Tsuyuki R. Factors affecting community pharmacists' participation in pharmacy practice research. Poster presentation at Canadian Pharmacists Association National Conference June 2012.
74. **Lynd LD**, Marra C, Sadatsafavi M. Safety of long-acting beta agonists (LABA) with or without inhaled corticosteroids in asthma. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Barcelona, Spain, August 23-26, 2012.
75. Bashir J, Cowan S, Yamashita M, Raymakers A, **Lynd LD**. Impact of Cost on the Management of the Spring Fidelis Recall. Heart Rhythm Society, St. Paul's Hospital, Vancouver, BC, 2012.
76. Raymakers AJN, McCormick N, FitzGerald JM, Marra CA, Sin D, **Lynd LD**. The Use of Inhaled Corticosteroids (ICS) in Chronic Obstructive Pulmonary Disease (COPD) Patients and Risk of Lung Cancer: A Systematic Review. 2012 American Thoracic Society (ATS) International Conference, San Francisco, CA. May 18-23, 2012.
77. Leung VWY, Soon JA, **Lynd LD**, Marra CA, Levine M. Comparison of pregnancy rates after two hormonal emergency contraceptives. North American Forum on Family Planning. Washington, DC, October 22-24, 2011. (Contraception 2011; 84:333-4.)
78. Leung VWY, Soon JA, **Lynd LD**, Marra CA, Levine M. A population-based comparison of the effectiveness of two emergency contraceptives. The 6th Asian Conference on Pharmacoepidemiology 2011. Beijing, October 30, 2011.
79. Leung VWY, Soon JA, Marra CA, **Lynd LD**, Levine M. Adjudication of pregnancy-related health outcomes using administrative data. The 6th Asian Conference on Pharmacoepidemiology. Beijing, October 28-30, 2011.
80. Leung VWY, Soon JA, **Lynd LD**, Marra CA, Levine M. The levonorgestrel and Yuzpe regimens of emergency contraceptives: a comparative effectiveness study. (Presentation) EC Jamboree 2011: Annual Meeting of the International Consortium for Emergency Contraception and the American Society for Emergency Contraception, New York City, October 4, 2011.
81. Sadatsafavi M, Bedouch P, FitzGerald JM, Marra CA, **Lynd LD**. Impact on direct health care costs associated with asthma of various controller medications: results from a population based cohort study. Submitted, 8th World iHEA Congress in Health Economics/International AllerGen Symposium on Asthma and Economics. Toronto, July 2011.

82. Bedouch P, Sadatsafavi M, FitzGerald JM, Marra CA, **Lynd LD**. Trends in asthma-related direct medical costs in British Columbia, Canada. Submitted, 8th World iHEA Congress in Health Economics/International AllerGen Symposium on Asthma and Economics. Toronto, July 2011.
83. Leung VWY, Soon JA, Marra CA, **Lynd LD**, Levine M. History of regular hormonal contraceptive use among emergency contraceptive users in British Columbia. Canadian Association for Population Therapeutics Annual Conference. Ottawa, Ontario, April 17-19, 2011.
84. Leung VWY, Soon JA, **Lynd LD**, Marra CA, Levine M. Comparison of pregnancy rates after two hormonal emergency contraceptives. North American Forum on Family Planning. Washington, DC, October 22-24, 2011.
85. Bedouch P, Sadatsafavi M, FitzGerald JM, Marra C, **Lynd LD**. Initiation of controller medication in newly diagnosed asthma patients: impact on economic resource utilization. European Respiratory Society Annual Congress, Amsterdam, September 2011. Oral communication.
86. Sadatsafavi M, Bedouch P, FitzGerald JM, Marra C, **Lynd LD**. Stepping up the controller medication in asthma patients: impact of various treatment options on costs. European Respiratory Society Annual Congress, Amsterdam, September 2011. Oral communication.
87. Najafzadeh M, **Lynd LD**, Davis JC, Bryan S, Anis A, Marra M, Marra CA. Barriers for integrating personalized medicine into clinical practice: a best worst scaling choice experiment. CADTH 2011 symposium April 3-5, 2011, Vancouver, BC. Oral presentation in the "Evidence to Practice: Maximizing Our Investment in Health Care" section, session C6, April 4th.
88. Bedouch P, Sadatsafavi M, FitzGerald JM, Marra C, **Lynd LD**. Health care costs of uncontrolled asthma: a population-based cohort study in British Columbia. Canadian Association for Population Therapeutics Annual Conference, Ottawa, ON, April 2011. Oral communication.
89. Sadatsafavi M, Bedouch P, FitzGerald JM, Marra C, **Lynd LD**. Asthma-related direct medical costs in British Columbia from 2002 to 2007: a population-based cohort study. Canadian Association for Population Therapeutics Annual Conference, Ottawa, ON, April 2011. Oral communication.
90. Bedouch P, Sadatsafavi M, FitzGerald JM, Marra C, **Lynd LD**. Evolution of asthma-related direct medical costs in British Columbia from 2002 to 2007: a population-based cohort study. Heart + Lung Health Fest 2011, Vancouver (BC), March 8-12. (Awarded best poster)
91. Bedouch P, Sadatsafavi M, FitzGerald JM, Marra CA, **Lynd LD**. Calculating direct health care costs associated with asthma in British Columbia, 2002-2007. Allergen's 6th Annual Research Conference, Vancouver, British Columbia, February 6-8, 2011.
92. Marra CA, Harvard SS, Wilby K, De Silva J, **Lynd LD**. A randomized controlled trial evaluating pharmaclymph augmentation of patient information for HIV drugs. International Pharmaceutical Federation (FIP). Lisbon, Portugal, September 2010. (podium)
93. Najafzadeh M, Marra CA, **Lynd LD**, Sadatsafavi M, Sin DD. The economic value of a potential biomarker for chronic obstructive pulmonary disease. Canadian Association for Population Therapeutics Annual Conference, Toronto, ON. March 28-30, 2010.
94. Wong-Regier D, **Lynd LD**, Drummond M, Menon D. The value of patients' preferences in Health Economics. 15th Annual Meeting – International Society of Pharmacoeconomics and Outcomes Research. May 15 – 19, 2010. Issues Panel.
95. Marra C, **Lynd LD**, Grindrod K, Joshi P, Isakovic A. An Overview of Pharmacy Adaption Services in British Columbia. Canadian Pharmacists Association Annual General Meeting in Calgary, AB (May 15-May 18, 2010) podium.
96. Marra C, **Lynd LD**, Henrich N, Joshi P. Pharmacy Adaption Services in BC: The Physician Perspective. Canadian Pharmacists Association Annual General Meeting in Calgary, AB (May 15 - May 18, 2010) podium.

97. Sadatsafavi M, Marra CA, **Lynd LD**, Marra F, Liu J, Mendoza O, Tan M, Elwood KR, Fitzgerald JM. Benefit-risk analysis of isoniazid (INH) for treatment in latent tuberculosis infection (LTBI). Canadian Association for Population Therapeutics Annual Conference, Toronto, ON. March 28-30, 2010.
98. **Lynd LD**, Marra CA, Harvard S, Liu J, Najafzadeh M, FitzGerald JM, Sin D. Risk benefit analysis of LABA + ICS versus ICS alone for the treatment of asthma. Canadian Association for Population Therapeutics Annual Conference, Toronto, ON. March 28-30, 2010.
99. Marra C, Marra F, Richardson K, **Lynd LD**, FitzGerald JM. Are we treating wheeze with bug killer? Canadian Association for Population Therapeutics Annual Conference, Toronto, ON. March 28-30, 2010. (podium)
100. Najafzadeh M, Marra CA, **Lynd LD**, Sadatsafavi M, Sin DD. Economic value of potential biomarker for chronic obstructive pulmonary disease. Society for Medical Decision Making 31st Annual Meeting. Hollywood, CA. Oct 18 – 21, 2009.
101. **Lynd LD**, Marra CA, Grubisic M, Colley L. Using density plots to illustrate preference heterogeneity derived using a mixed logit model of discrete choice data. Society for Medical Decision Making 31st Annual Meeting. Hollywood, CA. Oct 18 – 21, 2009.
102. Sadatsafavi M, Marra CA, **Lynd LD**, Marra F, Liu J, Mendoza O, Tan M, Elwood K, FitzGerald JM. Benefit-risk analysis of isoniazid (INH) for treatment of latent class tuberculosis. Society for Medical Decision Making 31st Annual Meeting. Hollywood, CA. Oct 18 – 21, 2009.
103. Oteng B, Marra F, **Lynd LD**, Marra CA. Societal preferences for the quadrivalent versus bivalent human papillomavirus vaccine. Health Technology Assessment International 6th Annual Meeting. Singapore, June 21-24, 2009.
104. Oteng B, Marra CA, **Lynd LD**, Marra F. Societal preferences for the Human Papillomavirus vaccine. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual International Meeting, Orlando, Florida, May 16-20, 2009.
105. Marra F, Marra CA, Richardson K, **Lynd LD**, Fitzgerald JM. What is the magnitude and pattern of antibiotic consumption in asthmatic children? American Thoracic Society, San Diego, California, May 18 - 24, 2009.
106. Grindrod K, Colley L, Marra CA, **Lynd LD**, Koehoorn M. Factors associated with taking antihypertensives: A population-based cross-sectional study of hypertensive individuals in the Canadian Community Health Survey. Canadian Association for Population Therapeutics Annual Conference, Montreal, QC. April 19-21, 2009.
107. Sweeney K, **Lynd LD**, Marra CA, Kendall R, Li L. Differences in health related quality of life following total and unicompartmental knee arthroplasty. Canadian Agency for Drugs and Technologies in Health 2009 Symposium. Ottawa, April 5-7, 2009. (Awarded best poster)
108. Oteng B, Marra CA, **Lynd LD**, Ogilvie G, Patrick DM, Marra F. Evaluating societal preferences for the Human Papillomavirus vaccines using discrete choice experiment. Canadian Agency for Drugs and Technologies in Health 2009 Symposium. Ottawa, April 5-7, 2009.
109. **Lynd LD**, FitzGerald JM, Colley L, Soon JA. Establishing patients' preference weights for GINA criteria of asthma control using a discrete choice experiment. The Second Conjoint Analysis in Healthcare Conference, Delray Beach FL, March 24-26, 2009.
110. Oteng B, Marra CA, **Lynd LD**, Ogilvie G, Patrick D, Marra F. Evaluating Societal Preferences for the Human Papillomavirus Vaccines Using Discrete Choice Experiment. The Second Conjoint Analysis in Healthcare Conference, Delray Beach FL, March 24-26, 2009.
111. Grindrod K, Marra CA, Tsuyuki R, **Lynd LD**. Expanded scope of practice: What do pharmacists want? Vancouver Coastal Health Research Institute, Celebrate Research Week. March 2009.
112. Grindrod K, Colley L, Marra CA, **Lynd LD**, Koehoorn M. Factors associated with taking antihypertensives: A population-based cross-sectional study of hypertensive individuals in the Canadian Community Health Survey. Vancouver Coastal Health Research Institute, Celebrate Research Week. March 2009.
113. Woolcott JC, **Lynd LD**, Koehoorn M, Marra CA. An assessment of the construct validity of the Health Utilities Index Mark 3 in asthmatics using the population based Canadian Community Health Survey Cycle 3.1. Vancouver Coastal Health Research Institute, Celebrate Research, February 2009.
114. Marra F, Kaczorowski J, Marra CA, **Lynd LD**, Tsuyuki R, Kendall P, Brunham RC. Pharmacy based immunization in rural communities' strategies. Pandemic Influenza Preparedness Strategic Planning Meeting, Winnipeg, Manitoba, November 6-8, 2008.

115. **Lynd LD**, Fitzgerald M, Colley L, Soon J. Establishing Patients' Preference Weights for GINA Criteria of Asthma Control: A Discrete Choice Experiment. ISOQOL, October 22nd – 25th, 2008, Montevideo, Uruguay.
116. Maxwell CJ, Jantzi M, Poss J, Wodchis W, Hogan D, Supina A, **Lynd LD**, Marra C, Hirdes JP. Construct validity of an observed health-related quality of life (HRQL) measure in Alzheimer's disease. (Oral Presentation) presented at the 15th Annual Conference of the International Society for Quality of Life Research, Montevideo Uruguay, Oct 22-25, 2008. Abstract published in *Quality of Life Research* 2008;A-13, Abstract #1504.
117. **Lynd LD**. Did the removal of rofecoxib from the market result in increased gastrointestinal risk for rheumatoid arthritis patients? A population based analysis. Annual European Congress of Rheumatology EULAR, Paris, France, June 11-14, 2008.
118. Rosenthal M, Grindrod K, **Lynd LD**, Marra CA, Wilgosh C, Bougher D, Tsuyuki RT. Study of Understanding Pharmacists' Perspectives on Remuneration and Transition towards Chronic Disease Management (SUPPORT-CDM): Qualitative Methods (Part 1 of 3). Presented at: Canadian Pharmacists Association Annual General Meeting in Victoria (May 31-June 3, 2008).
119. Grindrod K, Rosenthal M, **Lynd LD**, Marra CA, Wilgosh C, Bougher D, Tsuyuki RT. Study of Understanding Pharmacists' Perspectives on Remuneration and Transition towards Chronic Disease Management (SUPPORT-CDM): Challenges & Enablers (Part 2 of 3). Presented at: Canadian Pharmacists Association Annual General Meeting in Victoria (May 31-June 3, 2008).
120. Rosenthal M, Grindrod K, **Lynd LD**, Marra CA, Wilgosh C, Bougher D, Tsuyuki RT. Study of Understanding Pharmacists' Perspectives on Remuneration and Transition towards Chronic Disease Management (SUPPORT-CDM): Remuneration (Part 3 of 3). Presented at: Canadian Pharmacists Association Annual General Meeting in Victoria (May 31-June 3, 2008).
121. **Lynd, LD**, Lee A, FitzGerald JM, Soon J. The impact of socioeconomic status on self-reported quality of life in asthma. American Thoracic Society 2008 International Conference, Toronto, ON, May 18, 2008. (poster)
122. **Lynd, LD**, FitzGerald JM, Colley L, Soon J. Establishing patients' preference weights for GINA criteria of asthma control: A discrete choice experiment. American Thoracic Society 2008 International Conference, Toronto, ON, May 18, 2008. (presentation)
123. **Lynd LD**, Colley L, Najafzadeh M, Sculpher MJ, Willan AR, Johnson RF, Ozdemir S. Quantitative risk-benefit analysis of alosetron in irritable bowel syndrome: a patient-level meta-cohort analysis. *Pharmacoepi Drug Safety* 2007; 16: S183.
124. Hobbiger S, **Lynd LD**, Salek S. ISSUES PANEL: Benefit risk-modeling as an important component of good risk management. 43rd Annual Meeting, Drug Information Association. Atlanta, GA, USA. June 17-20, 2007.
125. Marra CA, **Lynd LD**, Bansback N, Guh D, Anis AH. Predicting preference-based measures from the HAQ-DI and the RAQoL. European League Against Rheumatism Annual European Congress of Rheumatology. Barcelona, Spain, June 13-16, 2007.
126. Marra CA, Marra F, Richardson K, **Lynd LD**, Kozyrskyj A, Patrick D, Bowie W, FitzGerald JM. Does antibiotic exposure during infancy lead to development of asthma? A population based analysis. [Accepted]. 4th Canadian Therapeutics Congress. May 27 – 30. Halifax, NS.
127. Woolcott JC, **Lynd LD**, Koehoorn M, Marra CA. An assessment of the construct validity of the Health Utilities Index Mark 3 in asthmatics using the population based Canadian Community Health Survey Cycle 3.1. 4th Annual Canadian Therapeutics Congress. May 27 – 30. Halifax, NS.
128. **Lynd LD**, Marra CA. Development of an undergraduate course and 1-day workshop on Health Technology Assessment [accepted]. 2007 Canadian Agency for Drugs and Technologies in Health Symposium. April 23 – 24, 2007. Ottawa, ON.
129. Moride Y, **Lynd LD**, Abenheim L, Moore N, Kurz X, Hartford C. Methods for therapeutic risk benefit analysis. 22nd International Conference in Pharmacoepidemiology and Therapeutic Risk Assessment. August 25, 2006. Lisbon, Portugal. *Pharmacoepi and Drug Safety* 2006;15(suppl. 1): S1.
130. **Lynd LD**, Marra CA, Najafzadeh M, Sadatsafavi M. Risk benefit analysis of rofecoxib versus naproxen for the treatment of rheumatoid arthritis patients: a discrete event simulation. *Pharmacoepidemiology and Drug Safety* 2006; 15(Suppl. 1): S225.

131. McTaggart-Cowan HM, **Lynd LD**. Patients' preferences in the treatment of asthma: a review of the current evidence. American Thoracic Society Meeting, May 23, 2006. San Diego, CA.
132. **Lynd LD**, Marra CA, Najafzadeh M, Sadatsafavi M. Harm-benefit analysis of rofecoxib versus naproxen for the treatment of rheumatoid arthritis patients: a discrete event simulation. *Can J Clin Pharmacol* 2006; 13(1): e133.
133. McTaggart-Cowan HM, **Lynd LD**, Shi P, Marra CA, Anis AH, Soon JA, FitzGerald JM, Bai TR, Currie G. Evaluating treatment preferences in asthma using a discrete choice experiment. *Can J Clin Pharmacol* 2006; 13(1): e132.
134. McTaggart-Cowan HM, **Lynd LD**, Shi P, Marra CA, Ssozi V, Anis AH, Soon JA, FitzGerald JM, Bai TR, Currie G. A comparison of generic, indirect utility measures and disease-specific instruments in Asthma. *Can J Clin Pharmacol* 2006; 13(1): e136.
135. McTaggart-Cowan HM, Shi P, **Lynd LD**. Quantifying benefits and harms for treatment in asthma. *Canadian Respiratory Journal* 2006; 13(3): 158.
136. Johnson-Masotti AP, Fishman DN, **Lynd LD**, Sheehan D. A new decision-making framework for the prioritization of health technologies. Health Services Restructuring: New Evidence and New Direction. Queen's University, Kingston, ON, November 17-18, 2005.
137. **Lynd LD**, Sculpher MJ, Willan AR, Coombes ME, Rashidi AA. A systematic review and critical evaluation of risk-benefit analysis methods for therapeutic interventions. Society of Medical Decision Making Annual Meeting. October 2005. San Francisco, CA.
138. **Lynd LD**, Sculpher MJ, Willan AR, Coombes ME, Rashidi AA. A systematic review and critical evaluation of risk-benefit analysis methods for therapeutic interventions. International Conference on Pharmacoepidemiology. August 2005. Nashville, TN. *Pharmacoepi and Drug Safety*; 14 (Supp 2): S12.
139. **Lynd LD**, Willan A, Sculpher M, Coombes M. A systematic review of risk-benefit analytic methods applied in health care. Canadian Association of Population Therapeutics Annual Conference. April 17-19, 2005. Vancouver, BC. *Can J Clin Pharmacol* 2005; 12(1): 46.
140. **Lynd LD**, Richardson K, Abu-Labban R, Brubacher J, Lepik K, Pursell R. An evaluation of diagnostic accuracy of the osmole gap for screening for toxic alcohol poisoning. Canadian Association of Population Therapeutics Annual Conference. April 17-19, 2005. Vancouver, BC. *Can J Clin Pharmacol* 2005; 12(1): 45.
141. Marra C, **Lynd LD**, Richardson K, Coombes M, Marra F. Antibiotic exposure in infants and the development of asthma: a systematic review and meta-analysis. Canadian Association of Population Therapeutics Annual Conference. April 17-19, 2005. Vancouver, BC. *Can J Clin Pharmacol* 2005; 12(1): 15.
142. Regier DA, Sunderji R, Gin K, **Lynd LD**, Marra CA. The cost-effectiveness of patient self-managed versus physician-managed oral anticoagulation: a Bayesian approach. Canadian Association of Population Therapeutics Annual Conference. April 17-19, 2005. Vancouver, BC. *Can J Clin Pharmacol* 2005; 12(1): 10.
143. **Lynd LD**, Goeree R, Crowther M, O'Brien BJ. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for DVT prophylaxis following major trauma. *Med Dec Making* 2004; 24 (5): 154.
144. **Lynd LD**, O'Brien BJ. Advances in risk-benefit evaluation using probabilistic simulation modeling. *Pharmacoepi and Drug Safety* 2004; 13 (Supp 1): S35.
145. Fisman DN, Johnson-Masotti A, **Lynd LD**, Sheehan D. Anonymous HIV testing in Canada: a cost-effective health intervention. American Public Health Association 132nd Annual Meeting and Exposition. Washington, DC. November 6-10, 2004.
146. **Lynd LD**, Cook D, O'Brien BJ. A risk-benefit analysis of enoxaparin versus unfractionated heparin for DVT prophylaxis post-trauma – a Bayesian perspective. *Exp Clin Cardiol* 2004; 9 (1): 65.
147. **Lynd LD**, Johnson-Masotti A, Sheehan D, Fisman DN. Anonymous HIV testing in Canada: a cost-effective health intervention. CDC STD Prevention Meeting, Philadelphia PA, March 8-11, 2004.
148. Marra CA, **Lynd LD**, Esdaile JM, Anis AH. The negative impact of low family income on health-related quality of life and physical function in patient with rheumatoid arthritis in a publicly funded health care environment.

International Society of Quality of Life Research, 10th International Conference, Prague, Czech Republic, November 2003.

149. **Lynd LD**, O'Brien BJ. Taking calculated risks: advances in advances in risk-benefit evaluation using probabilistic simulation methods. Canadian Institutes for Health Research. Strengthening the Foundations: Health Services and Policy Research Symposium. Montreal, QC. Nov. 22 – 24, 2003.
150. **Lynd LD**, O'Brien BJ. Taking calculated risks: advances in advances in risk-benefit evaluation using probabilistic simulation methods. *Med Decis Making* 2003; 23 (6):560.
151. Shalansky SJ, **Lynd LD**, Ignaszewski A, Kerr C, Vickars L, Abd-Elmessih E. The effect of complementary and alternative medicine usage patterns on warfarin-related adverse events. *Can J Cardiol* 2003; 19 (Suppl A):164A.
152. Shalansky SJ, **Lynd LD**, Ignaszewski A, Kerr C, Vickars L. The risk of adverse events associated with complementary and alternative medicine amongst a cohort of patients taking warfarin. *Can J Cardiol* 2003; 19 (Suppl A): 163A.
153. **Lynd LD**, Paré PD, FitzGerald JM, Anis AH. Beyond drug therapy – an evaluation of the etiologic factors of the socioeconomic gradient in asthma control. *Can J Clin Pharmacol* 2003; 10(1):25.
154. Marra CA, **Lynd LD**, Esdaile JM, Anis AH. The relationship between socioeconomic status and quality of life/functional status in patients with rheumatoid arthritis. *Can J Clin Pharmacol* 2003; 10(1): 50.
155. Shalansky S, Neall E, Lo M, Abd-Elmessig T, Vickars L, **Lynd LD**. The impact of complementary an alternative medicine use on warfarin-related adverse outcomes. *Pharmacotherapy* 2002; 10:1245.
156. Pursell RA, **Lynd LD**, Brubacher J, Sivilotti M, Pudek M, Lepik K, Abu-Laban R, Koga Y. The osmolal gap as a screening test for toxic alcohol poisoning. The North American Congress of Clinical Toxicology 2002. Palm Springs, CA. Sept. 24 – 29, 2002.
157. **Lynd LD**, Paré PD, Fitzgerald JM, Anis AH. The association between proximate and contextual measures of socioeconomic status and magnitude of short-acting β -agonist use in asthma. *Can J Clin Pharmacol* 2002; 9(1): 79.
158. **Lynd LD**, Paré PD, Fitzgerald JM, Anis AH. Socioeconomic status and asthma control: a cross-sectional assessment of the association between social class and excessive short-acting β -agonist use in British Columbia, Canada. Drug Information Association 38th Annual meeting. Chicago, IL, USA. June 16 – 20, 2002.
159. **Lynd LD**, Paré PD, Fitzgerald JM, Anis AH. The association between proximate and contextual measures of socioeconomic status and magnitude of short-acting β -agonist use in asthma. Canadian Association for Population Therapeutics Annual Conference Year 2002. Toronto, ON, Canada. April 12 – 14, 2002.
160. **Lynd LD**, Guh D, Anis AH. Using administrative prescription data to enroll patients into clinical studies. International Society of Health Technology Assessment Annual Meeting. Philadelphia, PA, USA. June 3 – 6, 2001.
161. **Lynd LD**, Guh D, Paré PD, Anis AH. The standardized asthma-related quality of life questionnaire (AQLQ-S): does socioeconomic status affect measurements? *Value in Health* 2001; 4(2):75.
162. **Lynd LD**, Paré PD, Anis AH. Asthma-related quality of life: is there a social gradient in how asthmatics feel. *Can J Clin Pharmacol* 2001; 8(1):17.
163. **Lynd LD**, Paré PD, Anis AH. The social gradient of asthma-related morbidity: is disease severity the lone culprit? *Can J Clin Pharmacol* 2001; 8(1):38.
164. Warren L, Maclure M, Cassels A, Russwurm S, Carleton B, **Lynd LD**, Anis A. Finding study participants from administrative data without violating privacy: applications of camouflage sampling. The Wealth of Nations: Growth, Ideas and Technology. Western Economic Association International 75th Annual Conference. Vancouver, BC. June 29 – July 3, 2000.
165. Maclure M, **Lynd LD**, Warren LD, Paré P, Anis AH. 'Camouflaged sampling' using BC Ministry of Health data – recruiting while maintaining confidentiality. *Value in Health* 2000; 3(2):109.
166. **Lynd LD**, Rabout J, Guh D, Paré P, Anis AH. Trends in the use of β -agonist medications in British Columbia: an analysis of BC Pharmacare data. *Value in Health* 2000; 3(2):143.

167. Maclure M, **Lynd LD**, Warren LD, Paré P, Anis AH. ‘Camouflaged sampling’ using BC Ministry of Health data: a method of recruiting while preserving data privacy. *Can J Clin Pharmacol* 2000; 7(1):65.
168. **Lynd LD**, Raboud J, Guh D, Paré P, Anis AH. The use of β -agonist medications in British Columbia: an analysis of trends using BC Pharmacare data. *Can J Clin Pharmacol* 2000; 7(1):65.
169. **Lynd LD**. Drug-related mortality rates in British Columbia and Canada: an assessment of reported trends and data validity. 3rd International Conference on the Scientific Basis of Health Services. Toronto, Canada. Oct 1 – 3, 1999.

(c) *Peer- Reviewed Letters*

1. Raymakers AJN, **Lynd LD**. Inclusion criteria may significantly bias study results. *Am J Cardiol*. 2016 Jul 28. pii: S0002-9149(16)31160-2. doi: 10.1016/j.amjcard.2016.07.001. [Epub ahead of print]

(d) *Other*

1. Sirrs S, **Lynd LD**. When zebras run with horses – inherited metabolic diseases come mainstream [Editorial]. *Rev Endocr Metab Disord*. 19(1):1-3, 2018 Mar . <https://doi.org/10.1007/s11154-018-9456-1>. PMID: 30101364
2. Cechetto D, Kenyon C, **Lynd LD**, Bishagara T, Ntahobakulira I, Rulisa S, Uwimana C, Silcox J, Davemport P, Haase P, Orchard C, Semanyenzi S, Tuyisenge G. An Evaluation of Health Care Quality in Rwanda 2010. Submitted to: Rwanda Ministry of Health, July 2011.
3. **Lynd LD**, Marra CA. Evaluating the Cost-Effectiveness and Economic Impact of Cognitive Behavioural Therapy (CBT) vs. Pharmacotherapy for the Treatment of Depression in British Columbia. For: British Columbia Mental Health Society. April, 2009.
4. **Lynd LD**. Guidelines for schedule status submission for review by the National Drug Scheduling Advisory Committee (NDSAC) For: National Association of Regulatory Authorities. June 06, 2007.
5. **Lynd LD**, Marra CA. Expert review of benefit-risk assessment data submitted for Singulair® (montelukast sodium). For: Health Canada Therapeutic Products Directorate. March 31, 2006.
6. **Lynd LD**, Marra CA. Expert review of benefit-risk assessment data submitted for Accolate® (zafirlukast). For: Health Canada Therapeutic Products Directorate. March 31, 2006.
7. **Lynd LD**, Willan A, Sculpher M, Coombes M, Rashidi AA. Identification and evaluation of harm-benefit assessment methods. For: GlaxoSmithKline. August 8, 2005.
8. **Lynd LD**, Marra CA. A review of immunosuppressant strategies currently funded by the British Columbia Transplant Society. For: The British Columbia Transplant Society. April 8, 2002.

2. NON-REFEREED PUBLICATIONS

(a) *Journals*

(b) *Conference Proceedings*

1. “EXPECT-NLP: An Integrated Pipeline and User Interface for Exploring Patient Preferences Directly from Patient-Generated Text.” https://link.springer.com/chapter/10.1007/978-3-031-14771-5_6

(c) *Other - Text Interviews*

“Plan sponsors bracing for onset of new orphan drugs” *Benefits Canada*. <http://www.benefitscanada.com/news/plan-sponsors-bracing-for-onset-of-new-orphan-drugs-97379>

2. "Steroids can reduce lung cancer risk in COPD patients" UBC Faculty of Medicine.
<https://www.med.ubc.ca/news/steroids-can-reduce-lung-cancer-risk-in-chronic-obstructive-pulmonary-disease-copd-patients/>
3. "Steroids can reduce lung cancer risk in COPD patients" UBC News.
<https://news.ubc.ca/2019/05/28/steroids-can-reduce-lung-cancer-risk-in-copd-patients/>
4. *Inhaled steroids reduce risk of lung cancer in COPD patients: UBC study.*
<https://vancouversun.com/news/local-news/inhaled-steroids-reduce-risk-of-lung-cancer-in-copd-patients-ubc-study>
5. "Steroids can lower risk of lung cancer in COPD patients up to 30 pc" Business Standard.
https://www.business-standard.com/article/news-ani/steroids-can-lower-risk-of-lung-cancer-in-copd-patients-up-to-30-pc-119052801199_1.html
6. "Steroids can reduce lung cancer risk in COPD patients" CCCEP e-connect.
<http://multibriefs.com/briefs/CCCEP/CCCEP060619.php>

(d) *Video Interviews*

1. Fairchild TV. *Funding for orphan drugs for rare diseases.* March 21, 2019.

3. BOOKS

- (a) *Authored*
- (b) *Edited*
- (c) *Chapters*

4. PATENTS

5. SPECIAL COPYRIGHTS

6. ARTISTIC WORKS, PERFORMANCES, DESIGNS

7. OTHER WORKS

Public Town Hall to discuss funding and reimbursement for Drugs for Rare Diseases – Oct 23, 2018
Role: PI on grant, organizer, and co-producer (with CBC Ideas)

CBC Ideas Documentary. All the Drugs that are Fit to Take. Aired Jan 22, 2019. CBC Radio 1
Role: Co-Producer (with CBC Ideas)

SNOWCAP 2019 – UBC International Summit on Orphan Drug Pricing and Policy. March 14-15, 2019.
Role: PI of UBC VP Research and International Cluster Grant - \$100,000, and organizer and host of the Summit.

8. WORK SUBMITTED (including publisher and date of submission)

9. **WORK IN PROGRESS** (including degree of completion)